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GENERAL INTRODUCTION
We are not alone; our bodies are in constant contact with an entire ecosystem of 
microorganisms. In the human intestine, the number of microorganisms exceeds 
10-times that of the cells of our own bodies 1. Most microorganisms colonizing our 
bodies are commensals, however, sometimes these or other microorganisms can 
invade tissues and cause disease. In order to cope with these infections, the human 
body is equipped with an advanced network of defense mechanisms, called the 
immune system. 
 The first line of immune defense is the innate immune system. Innate cells 
can recognize intruders like bacteria, fungi, viruses and protozoa through their pattern 
recognition receptors (PRRs). On the one hand this leads to the phagocytosis and killing 
of invading pathogens, and on the other hand this activates a second line of defense, 
the adaptive immune system, through cytokine production and antigen presentation 
to B- and T-cells. The adaptive immune system distinguishes itself from the innate 
immune system in that it manifests specificity for a particular target and because it 
builds strong specific memory to the pathogens (Figure 1).
Figure 1. Schematic overview of immune response
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C. albicans is a commensal microorganism present on the mucosa of humans, 
predominantly in the gastro-intestinal tract. Thirty to 50% of individuals are colonized 
by C. albicans at any given time 2, without any sign of disease 3. At the same time 
however, C. albicans is an opportunistic fungal pathogen that can cause mucosal as 
well as systemic infections. Mucosal infections are common and can occur in otherwise 
healthy individuals. Systemic infections, i.e. C. albicans disseminating into the blood 
stream, are life threatening with mortality rates reaching up to 40% 4.
 There are several factors that can drive the switch between commensalism and 
invasion, some of which concern C. albicans itself. C. albicans is a polymorphic fungus: 
it can grow in multiple morphological forms ranging from yeast to hyphae. It has been 
suggested that this feature is central to the pathogenicity of C. albicans 5. Furthermore, 
the fungal load can influence the growth and amount of hyphae formation of the 
fungus itself 6. Disturbances in the regular flora of commensal microorganisms, e.g. 
by the use of antibiotics, gives an increased risk for systemic infections 7. Also damage 
to epithelial barriers, protecting the body from the outside world, increases the risk 
for C. albicans infections 7. Other factors increasing the risk for C. albicans infections 
are related to the genetic make-up of the host, which is believed to have a significant 
influence on disease susceptibility 8. Furthermore, when the immune system of the 
host is weakened, there is an increased risk for mucosal and even systemic infections 9. 
 Since the 1980’s there has been a significant increase in the number 
of immunocompromised patients. In the United Sates, over 28,000 solid organ 
transplantations were performed in 2011, more than twice the amount in comparison 
with 1988 10. Furthermore, there has been an increase in the number of patients 
undergoing hematopoietic stem cell transplantation 11, especially in the eastern 
Mediterranean region 12. This illustrates that there is a large at-risk population that is 
still increasing in size. Despite current anti-fungal medication, systemic infections are 
associated with high morbidity and mortality rates. In order to improve the outcome of 
infections, the understanding of the host immune response against C. albicans should 
be improved.
OUTLINE OF THE THESIS
The general aim of this thesis is to investigate the immune response against Candida 
albicans and understand the factors leading to an increased susceptibility to infection. 
Chapter 2 gives an overview of the current knowledge on the host defense against C. 
albicans, and the general and genetic factors contributing to the risk of infection.
The first section of the thesis focuses on “Candida-induced immune responses” and 
comprises chapters 3 to 5. In the first set of studies we addressed the question how 
the anti-Candida immune response is modulated, including the role of different types 
of monocytes, of processes such as autophagy, and of Candida cell-wall components in 
shifting cytokine responses.
 Upon infection, innate immune cells such as neutrophils and monocytes can 
readily phagocytose invading pathogens. The engulfed microorganism will consequently 
be destroyed, and small parts will be presented to cells from the adaptive immune 
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system. In Chapter 3, the two main types of monocytes described in the literature, 
CD14++CD16- and CD14lowCD16+, are compared with respect to the anti-Candida immune 
response, and in particular their ability to induce protective T helper (Th)17 responses. 
Th17 cells, and interleukin (IL)-17 production are important in fighting mucosal Candida 
infections 13. IL-6 and transforming growth factor (TGF)-β are crucial cytokines in the 
development of Th17 cells 14, while IL-23 is required for the functioning of Th17 cells 15. 
Prostaglandin (ΡG) E2 and IL-23 can synergistically favor the expansion of Th17 cells 
16. 
In Chapter 4, the Candida albicans-induced PGE2 production, and its effect on the Th17 
response are studied.
 The role of autophagy, a basic process recently described to participate in host 
defense 17, in the immune response against Candida albicans will be investigated in 
Chapter 5. Reduced autophagy leads to increased endotoxin-induced IL-1β responses 
18,19, another important cytokine driving anti-fungal Th17 cell differentiation 20.
 
The second part of the thesis “Genetic variation and the anti-Candida host response” 
includes chapters 6 to 10. Chapter 6 describes a functional genomics study in which the 
C. albicans–induced immune response was investigated in a systematic way. This has 
been done by a complementary systems biology approach combining transcriptome 
data, genomics studies, and immunological validation experiments. Although type I 
interferons (IFNs) had thus far only been implicated in the immune response against 
viral infections 21, an unexpected role for type I IFNs in anti-C. albicans host response 
was identified.
 Chronic mucocutaneous candidiasis (CMC) is a disorder characterized by 
chronic fungal infections of the skin, nails and oropharynx 22. We have recently reported 
defects in the signal transducer and activation of transcription (STAT) 1 gene in patients 
with autosomal-dominant (AD) CMC 23. Chapter 7 describes the study that was 
performed in order to unravel the molecular mechanism underlying the immunologic 
defects seen in AD-CMC patients.
 Similarly to CMC, hyper IgE syndrome (HIES) is a primary immunodeficiency 
characterized by mucocutaneous candidiasis. In addition, HIES patients also suffer 
from recurrent skin and pulmonary infections caused by S. aureus 24. The disease is 
caused by mutations in STAT3 25. What links both CMC and HIES is the severe defect 
in protective anti-fungal Th17 responses in both diseases. However, in addition to the 
direct effect of the genetic defect on the immune response, we hypothesized that an 
indirect effect on the host defense of these patients may be exerted through a modified 
microbiome. There are several studies showing that genetic defects can alter the gut 
microbiome 26, and it has been also demonstrated that the susceptibility to cutaneous 
infections can be influenced by the skin microbiome 27. Therefore, in Chapter 8, we 
investigated the skin and mucosal microbiome of patients with AD-CMC and HIES, and 
assessed whether the composition has the potential to influence the immune system 
of the host.
 IL-1β needs to be cleaved by the inflammasome before it can be secreted as 
an active cytokine 28. It has been suggested that reactive oxygen species (ROS) are 
necessary for the activation of the inflammasome 29. In Chapter 9, we investigate the 
C. albicans-induced IL-1β production in cells from chronic granulomatous disease (CGD) 
patients, which are deficient in NADPH-dependent ROS 30. ROS have a wide variety 
13
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of different functions, including the activation of indoleamine 2,3-dioxygenase 31, the 
rate-limiting enzyme from the tryptophan metabolism, which converts tryptophan 
to L-kynurenin 32. It has been demonstrated that L-kynurenin can suppress the Th17 
response 33,34 and that CGD mice have increased Th17 responses 35. Therefore we 
investigated the tryptophan metabolism and Th17 response in cells from human CGD 
patients in Chapter 10.
A summary of the new findings and conclusions of this thesis are presented in Chapter 
11.
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INFECTIONS wITH Candida SPECIES
Candida spp, especially Candida albicans, are commensal fungi that reside on the skin, 
mucosa and gastrointestinal tract of 30 to 50% of healthy individuals at any given time, 
with everyone being colonized at a certain moment of his/her lifetime 1. Although C. 
albicans is not pathogenic under normal host conditions, it can cause severe mucosal 
or systemic infections when host defense is compromised.
Mucosal infections
Mucosal infections affect the skin and mucous membranes. Common sites for these 
superficial infections are the mouth, vagina, external ear, skin and nails, of which oral 
candidiasis is the most common 2. Mucosal infections are usually sporadic, but some 
patients experience severe and recurrent infections of the skin and oropharyngeal 
cavities termed chronic mucocutaneous candidiasis (CMC). In addition, most women 
suffer at least once in their lifetime from vulvovaginal candidiasis, while up to 8% of 
them have recurrent infections 3.
Systemic infections
In contrast to mucosal candidiasis which is highly prevalent but does not cause high 
mortality, systemic infections are life threatening, with mortality rates reaching up to 
26-60% 4. When the organisms enter the blood stream they can reach vital organs 
such as the brain, heart and kidneys. Considering the number of patients diagnosed 
each year, Candida has emerged in the recent decades as one of the most important 
pathogens in sepsis, causing significant morbidity and mortality. Moreover, mortality 
due to these severe infections has not been significantly changed in the last decade, 
despite the introduction of potent antifungals such as azoles and echinocandins 1,5. It 
is currently believed that only a combination of standard antimycotic treatment with 
adjuvant immunotherapy may significantly improve the outcome of fungal infections, 
and both immunological and genetic studies are needed to accomplish the necessary 
understanding of the pathogenesis of these infections.
Candida albiCans HOST-DEFENSE
The C. albicans cell wall can be divided into two distinct layers: the inner layer consisting 
mainly of polysaccharides like chitin, 1,3 β-glucans and 1,6 β-glucans, and the outer 
layer consisting mainly of proteins that are heavily mannosylated with mannan side-
chains. These pathogen-associated molecular patterns (PAMPs) can be recognized by 
several pattern recognition receptors (PRRs), such as the Toll-like receptors (TLRs) and 
C-type lectins (CLRs) on the surface of antigen presenting cells (APCs). TLR2 recognizes 
phospholipomannans 2,6, and TLR4 recognizes O-linked mannans 3,7. N-linked mannans 
are recognized by the macrophage mannose receptor (MMR) 4,7, with other C-type 
lectins which can recognize mannose residues being Dectin-2 8, Mincle 9, DC-specific 
ICAM-grapping non-integrin (DC-SIGN) 10 and the soluble receptor mannose-binding 
lectin (MBL) 11. The C-type lectin Dectin-1 recognizes β-glucan 12 (Figure 1).
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Figure 1. Schematic overview of anti-Candida albicans immune response
When Candida is recognized by Toll-like receptors (TLRs) and C-type lectin receptors, the 
production of cytokines is initiated through activation of transcription factors like NF-κB. IL-1β 
and IL-18 first need to be cleaved by the NALP3 inflammasome before they can be secreted. IL-2 
is involved in the differentiation of all effector T-cells. The IL-2 receptor is highly expressed on 
regulatory T-cells (Treg). IL-12, IL-18 and IFN-γ promote the differentiation of T helper 1 (Th1) 
cells. IL-4 and IL-10 promote the differentiation of Th2 cells. IL-10 can also suppress Th1 cells. 
IL-1β, IL-6 and IL-12 drive the development of Th17 cells. DOCK8 is involved in the maintenance 
of Th17 cells. IL-17 can promote the recruitment of neutrophils, which have tissue protective 
effects by the production of beta-defensins. Cytokines are recognized by cytokine receptors, 
which use several adaptor molecules like STAT1, STAT3 and TYK2. PTPN22 is involved in B- and 
T-cell receptor signaling. Components with mutations and/or genetic variation known to be 
associated with Candida infection are shown in color. APC: antigen presenting cell, BCR: B-cell 
receptor, CARD9: caspase recruitment domain 9, DC-SIGN: dendritic cell-specific ICAM-grapping 
non-integrin, MBL: mannose binding lectin, MMR: macrophage mannose receptor, NALP3: 
NACHT, LRR and PYD domains-containing protein 3, TCR: T-cell receptor, TLR: Toll-like receptor.
20
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When a PRR recognizes its corresponding ligand, adaptor molecules engage with the 
receptor. Different types of receptors use different adaptor molecules. The adaptor 
molecules transduce a signal to the nucleus of the cell, by activating a kinase cascade, 
in order to induce the transcription of proinflammatory cytokines.  Dectin-1 signals 
through Syk 13 and caspase recruitment domain 9 (CARD9) 14. Dectin-1 can induce 
cytokine production independently of other receptors, as well as synergize with TLRs 
for an optimal stimulation of the cell. When ligands are recognized by TLRs, signals 
are transduced intracellular through adaptor proteins like myeloid differentiation 
factor (MYD)88. Subsequently, a mitogen-activated protein kinase (MAPK) response 
is activated leading to the nuclear translocation of transcription factors like NF-κβ 
and c-jun, inducing the transcription of cytokines and chemokines 1,15. Interestingly, 
depending on the fungal burden and amount of hyphae formation a second MAPK 
phase, consisting of MKP1 and c-Fos activation, can be initiated, further promoting 
proinflammatory responses 2,16.
 The recognition of C. albicans by cells of the innate immune system will lead to 
phagocytosis 3,17 and killing of the invading pathogen. At the same time, the production 
of cytokines is induced that on the one hand activate inflammation, and on the other 
hand engage and direct the adaptive immune response. Activation of the inflammasome 
component caspase-1, mediated by the intracellular activation of the nucleotide-
binding oligomerization domain-like receptor NALP3, is a central event leading to 
the processing of pro-interleukin (IL)-1β and pro-IL-18 into their respective bioactive 
cytokines, directing the induction of T helper (Th)17 and Th1 responses, respectively 
4,18,19. Interferon (IFN)-γ production by Th1 cells, and IL-17 production by Th17 cells are 
important characteristics of the Candida-induced immune response 5,20. Inflammasome 
and Th17 activation is considered to be a central event for the discrimination of 
colonization versus invasion with C. albicans at the level of the mucosa 6,21.
GENERAL RISk FACTORS FOR Candida INFECTIONS
Candida albicans is an opportunistic fungal pathogen. In healthy individuals, the immune 
response will usually clear infections, but an immunocompromised immune system 
causes a significant increase in the risk for Candida infections. Das et al. demonstrated 
that 92% of Candida bloodstream infections are preceded by a course of broad-spectrum 
antibiotics 4,7, which suppress the growth of the normal bacterial flora and eliminates 
natural antagonism of fungal colonization of the mucosa. There are numerous other 
examples in which Candida acts as an opportunistic pathogen. For example, almost all 
acquired immunodeficiency syndrome (AIDS) and oncologic patients with neutropenia 
suffer from oropharyngeal candidiasis 7,22,23. Furthermore, 41% of patients undergoing 
hematopoietic stem cell transplantation, for which the immune system is destroyed 
beforehand, suffer from one or more bloodstream infections within the first ten years 
after transplantation, 4% of which are caused by Candida spp. The crude mortality rate 
associated with these Candida-infections is 42% 8,24. Also patients with systemic lupus 
erythematosus, which are treated with glucocorticoids and other immunosuppressive 
agents, have an increased risk for invasive fungal infections, which are predominantly 
caused by Candida spp. 9,25.
21
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Not only a weakened immune system increases the risk for Candida infections, also 
the extent to which individuals are colonized with pathogens plays a significant role in 
the development of candidiasis. Candidiasis typically affects patients with prolonged 
hospitalization. 51% of Candida blood-stream infections is associated with being 
admitted to the intensive care unit (ICU) 4,10. The mean time of onset of systemic 
Candida infections is 22 days after hospitalization 11,26. Furthermore, when barriers to 
the outside world are damaged or breached by medical devices or surgery, this creates 
a portal of entry for pathogens like Candida albicans. For instance, major abdominal 
surgery poses an increased risk for systemic Candida infections, which is underlined 
by the observation that in a cohort of 107 patients with candidemia, 50% underwent 
recent surgery 4,12. Another factor contributing to the amount of Candida infections 
is the fact that Candida spp. can form biofilms on many medical devices like central 
venous catheters, contact lenses, intrauterine devices 13,27 and pacemakers 14,28. 
Candida can even cause prosthetic joint infections, although they are considered to 
be rare 29. Indeed, neonates on the ICU with a central line often suffer from infections, 
with the third most causative pathogen being Candida spp. Fortunately this incidence 
is decreasing due to the use of anti-fungal prophylaxis 30. 
GENETIC RISk FACTORS FOR CANDIDA INFECTIONS
In spite of the important role played by these risk factors, they do not explain all 
Candida infections, and only a minority of individuals at risk will eventually develop a 
fungal infection. It is therefore believed that also genetic factors must play an important 
role in determining the susceptibility to Candida infections. Indeed, mutations in 
single genes were found to be responsible for severe Candida infections in several 
primary immunodeficiencies that display the clinical picture of monogenetic disorders. 
However, these disorders are rare, and in the majority of patients no sole causative 
genetic factor can be found. In most patients a combination of gene polymorphisms 
and/or environmental factors will determine whether a patient will develop a Candida 
infection. The genetic susceptibility to more common Candida infections such as 
recurrent vulvo-vaginal candidiasis (RVVC) or candidemia is likely polygenic, but the 
understanding of the genetic factors that determine it is nevertheless crucial for future 
immunotherapeutic approaches in these patients.
Monogenetic disorders
Several monogenetic disorders have been described in the literature to be associated 
with an increased susceptibility to fungal infections. Glocker et al. described that a 
homozygous mutation in the CARD9 gene, coding for a protein downstream of Dectin-1, 
results in an increased susceptibility to both mucosal and invasive Candida infections 
31,32. Disease severity in these patients is likely explained by the fact that CARD9 is also 
involved in the downstream signaling of several other C-type lectin receptors, such as 
Dectin-2 and Mincle 33-36, implying that CARD9 is a central mediator of anti-Candida 
host defense.
 Another monogenetic disorder that results in an important primary 
immunodeficiency associated with Candida infections is CMC. Both autosomal recessive 
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and autosomal dominant variants of the disease have been described. Mutations in 
the CC-domain of signal transducer and activator of stranscription (STAT)1, a signaling 
molecule downstream of the IFN receptor 37, have recently been demonstrated to be 
the main cause of autosomal-dominant CMC 38, and these findings were confirmed 
by several other research groups 39-45. In addition to STAT1 mutations, Puel et al. 
demonstrated the presence of mutations in IL-17 receptor (R)A and IL-17F in some 
unexplained CMC cases 46. In contrast, patients with autosomal recessive autoimmune 
polyendocrinopathy candidiasis ectodermal dystrophy (APECED) not only suffer from 
CMC, but also experience autoimmune phenomena 47. APECED has been linked to 
mutations in the autoimmune regulator (AIRE) gene 48 that result in a loss-of-function 
phenotype, causing the production of neutralizing autoantibodies against important 
cytokines with antifungal properties such as IL-17E, IL-17F and IL-22 49.
 Another monogenetic defect resulting in a primary immunodeficiency 
syndrome associated with Candida infections of the skin is hyper-IgE syndrome (HIES). 
HIES was first described as Job’s syndrome and is characterized by high serum IgE levels, 
eczema, recurrent mucosal infections with Candida albicans, and skin and pulmonary 
infections with Staphylococcus aureus 50. There are a number of mutations known to 
be associated with HIES. Several mutations have been found in STAT3 51,52, a signaling 
molecule downstream of the IL-23 receptor, resulting in absent IL-17 production 53-56. 
Other genes which also have been associated with HIES include dedicator of cytokinesis 
(DOCK) 8, coding for a protein involved in Th17 polarization 57 and tyrosine kinase (TYK)2 
58, coding for a Janus kinase (JAK) downstream of the IL-12 receptor 59. All in all, defective 
Th17 responses underlie both CMC and HIES, two immunodeficiencies associated with 
severe, chronic, mucosal Candida infections. This emphasizes the importance of the 
Th17 response in mucosal Candida immunity.
 Also mutations in genes coding for cytokines and their receptors have been 
described to be associated with Candida infections. For example, IL-12Rb1 deficiency 
has been linked to mucocutaneous Candida infections, and these patients also have 
increased susceptibility for invasive candidiasis 60. Sharfe et al. described a patient 
Table 1. Monogenetic disorders (Continuation Table 1)
Gene Mutation Mode of inheritance Phenotype Disease Reference
AIRE R257X Autosomal-dominant Autoantibodies against IL-17 and IL-22 CMC 80,81
CARD9 Q295X Autosomal-recessive Reduced TNF-α production and Th17 cells CMC 31
Q289X R101C Autosomal-recessive Reduced Th17 responses Invasive dermamtophytic disease 32
CD25 Deletion (60-64) Autosomal recessive Reduced number of CD4+ cells Candida esophagitis 53
DOCK8 Multiple deletions and point mutations Autosomal-recessive Reduced Th17 cells Hyper IgE syndrome 57
IL-12Rb1 Multiple point mutations Autosomal-recessive Low levels of IFN-γ Mucosal candidiasis 60
IL-17RA Q284X Autosomal-recessive Absent IL-6 and GRO-a production CMC 82
IL-17F S65L Autosomal-dominant Reduced IL-6 and GRO-a production CMC 82
STAT1 R274W A267V Autosomal-dominant Reduced IL-17, IL-22 and IFN-γ production CMC 38
STAT3 Multiple point mutations Autosomal-dominant Reduced IL-17 production HIES 51
TYK2 Deletion (550-553) Autosomal-recessive Reduced Th1 and Type I IFN responses HIES 58
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with a deletion in the CD25 gene, suffering from esophageal candidiasis. CD25 is the 
α-subunit of the IL-2 receptor, which is constitutively expressed on T regulatory cells 61. 
Furthermore, IL-2 is involved in the differentiation of effector T cells. Although Sharfe 
et al. only described a single patient, this again emphasizes the importance of T-cells 
in the anti-Candida host response. A complete overview of monogenetic disorders 
causing fungal infections is depicted in Table 1 and Figure 1.
Common genetic variants and susceptibility to Candida infections
Despite the presence of primary immunodeficiency syndromes with fungal infections, 
the vast majority of fungal infections is not present in these individuals, but are common 
diseases with a polygenic pattern of increased susceptibility. Several studies have been 
published showing a link between genetic variation and an increased risk for Candida 
infections, with different genetic pattern being discerned between mucosal and systemic 
candidiasis. An example of this dichotomy is the role of a Dectin-1 polymorphism for 
susceptibility to mucosal, but not systemic, candidiasis. We have recently described a 
family in which its members suffered from RVVC and onychomycosis. Their symptoms 
could be explained by an early stop codon in Dectin-1 (Y238X) that resulted in defective 
β-glucan recognition and Th17 responses. Interestingly, this polymorphism is present 
in up to 8% of the Europeans and up to 40% of some sub-Saharan African populations 
62, being associated with mucosal Candida colonization and treatment in hematopoetic 
patients 63, but not with systemic candidiasis 64.
 Genetic variation localized in other PRRs, such as the TLRs, has also been 
associated with an increased susceptibility to fungal infections. Three single-nucleotide 
polymorphisms (SNPs) in the TLR1 gene have been shown to influence susceptibility to 
candidemia, presumably mediated by decreased levels of IL-8 and IFN-γ 65. However, 
these findings need to be replicated in independent studies, and it is unclear which 
component of Candida is recognized by TLR1. A similar observation has been made 
for TLR2 and TLR4, which recognize phospholipomannans and O-linked mannans, 
respectively. The R753Q TLR2 polymorphism increased the risk for candidemia in one 
Table 1. Monogenetic disorders (Continuation Table 1)
Gene Mutation Mode of inheritance Phenotype Disease Reference
AIRE R257X Autosomal-dominant Autoantibodies against IL-17 and IL-22 CMC 80,81
CARD9 Q295X Autosomal-recessive Reduced TNF-α production and Th17 cells CMC 31
Q289X R101C Autosomal-recessive Reduced Th17 responses Invasive dermamtophytic disease 32
CD25 Deletion (60-64) Autosomal recessive Reduced number of CD4+ cells Candida esophagitis 53
DOCK8 Multiple deletions and point mutations Autosomal-recessive Reduced Th17 cells Hyper IgE syndrome 57
IL-12Rb1 Multiple point mutations Autosomal-recessive Low levels of IFN-γ Mucosal candidiasis 60
IL-17RA Q284X Autosomal-recessive Absent IL-6 and GRO-a production CMC 82
IL-17F S65L Autosomal-dominant Reduced IL-6 and GRO-a production CMC 82
STAT1 R274W A267V Autosomal-dominant Reduced IL-17, IL-22 and IFN-γ production CMC 38
STAT3 Multiple point mutations Autosomal-dominant Reduced IL-17 production HIES 51
TYK2 Deletion (550-553) Autosomal-recessive Reduced Th1 and Type I IFN responses HIES 58
24
Chapter 2
small study through decreased IFN-γ and IL-8 levels 66, and two SNPs in the TLR4 gene 
were shown to be a risk factor for candidemia through increased IL-10 production 67, but 
these observations were not replicated in a larger study of patients with candidemia 
65. Nahum et al. suggested that the L412F TLR3 polymorphism increases the risk for 
CMC, an effect mediated by decreased IFN-γ production 68. Furthermore, variable 
number of tandem repeats in the mannose-binding lectin (MBL)2 gene that codes 
for the soluble PRR MBL has been linked to RVVC in two separate studies 69,70. Finally, 
length polymorphisms in the NLPR3 gene, coding for the receptor subunit of the NALP3 
inflammasome, can increase the risk for RVVC 71.
 In addition to the first step of pathogen recognition, genetic variation in 
several cytokines has been linked to an increased risk for Candida infections. Choi et 
al. demonstrated that the -1089T/G, -589C/T and the -33C/T polymorphisms in IL-4 
are associated with chronic disseminated candidiasis 72. Interestingly, the -589T/C SNP 
has also been demonstrated to pose a risk for RVVC 73. The -1082A/G polymorphism 
in IL-10 coding for the anti-inflammatory cytokine IL-10 and the 274insertion/deletion 
polymorphism in IL-12b, are associated with persisting candidemia 74. These data 
strongly suggest that the balance between pro- and anti-inflammatory cytokines 
represent an important component of host defense against both mucosal and systemic 
candidiasis.
 The -44C/G polymorphism in DEFB1, coding for beta-defensin 1, is correlated 
with increased Candida carriage 75. The exact underlying mechanism is unclear, but in 
general beta-defensins are secreted by neutrophils and epithelial cells and contribute 
to epithelial immunity. The R620W polymorphism in the gene coding for PTPN22, a 
protein involved in T-cell and B-cell receptor signaling, was suggested to be associated 
Table 2. Common genetic variants (Continuation Table 2)
Gene SNP (rs-number) Phenotype Disease Reference
Dectin-1 Y238X (rs16910526) Decreased IL-1β and Th17 responses Candida colonization 63
DEFB1 -44C/G (rs1800972) Unknown Candida carriage 75
IL-4 -589T/C (rs2243250) Increased vaginal IL-4, reduced NO and 
MBL levels
RVVC 73
-1098T/G (rs2243248), -589C/T (rs2243250), -33C/T (rs2070874) Unknown Chronic disseminated candidiasis 72
IL-10 -1082A/G (rs1800896) Higher Candida-induced IL-10 
production
Persisting candidemia 74
IL-12B 2724INS/DEL (rs17860508) Lower Candida-induced IFNg production Persisting candidemia 74
MBL2 Variable number of tandem repeats in intron 4 Reduced vaginal MBL levels RVVC 69,70
NLPR3 Length polymorphism Impaired IL-1β production RVVC 71
PTPN22 R620W (rs2476601) Unknown Increased risk for CMC 76
TLR1 R80T (rs5743611), S248N (rs4833095), I602S (rs5743618) Decreased production of IL-1β, IL-6 and 
IL-8 after TLR1-TLR2 stimulation
Increased susceptibility to candidemia 65
TLR2 R753Q (rs5743708) Decreased levels of IFN-γ and IL-8 Increased susceptibility to candidemia 66
TLR3 L412F (rs3775291) Decreased IFN-γ levels Increased risk for CMC 68,83
TLR4 D299G (rs4986790), Y399I (rs4986791) Increased IL-10 production Increased susceptibility to candidemia 67
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with an increased risk for CMC, although the potential mechanism of this association 
is unclear 76. A complete overview of common genetic variants associated with fungal 
infection is depicted in Table 2 and Figure 1.
FUTURE DEvELOPMENTS
The current body of evidence has provided many new insights into the working 
mechanism of the anti-Candida immune response. These new insights can pinpoint 
novel potential targets for immunotherapy. For example, several studies have 
demonstrated a correlation between decreased IFN-γ levels and an increased risk for 
systemic candidiasis 66,74. In a double blind, randomized, placebo-controlled study, 
subcutaneous injections of IFN-γ could partially reverse LPS-induced immune paralysis 
in vivo 77. This suggested that IFN-γ is a promising treatment option in sepsis-induced 
immune paralysis. We are currently investigating the efficacy of recombinant IFN-γ in 
patients with Candida sepsis.
 Despite the significant progress of the last few years for uncovering susceptibility 
to fungal infections, there are still a significant number of Candida infections for which 
the environmental and/or genetic risk factors are not yet deciphered. Even more 
importantly, in spite of current treatment regimens, mortality rates associated with 
systemic infections are still very high, and in order to improve diagnostic- and treatment 
options, future efforts should be directed towards gaining more insight into the anti-
Candida host immune response. This can be achieved in several ways. Discovering novel 
mutations that underlie monogenetic disorders associated with Candida infections can 
Table 2. Common genetic variants (Continuation Table 2)
Gene SNP (rs-number) Phenotype Disease Reference
Dectin-1 Y238X (rs16910526) Decreased IL-1β and Th17 responses Candida colonization 63
DEFB1 -44C/G (rs1800972) Unknown Candida carriage 75
IL-4 -589T/C (rs2243250) Increased vaginal IL-4, reduced NO and 
MBL levels
RVVC 73
-1098T/G (rs2243248), -589C/T (rs2243250), -33C/T (rs2070874) Unknown Chronic disseminated candidiasis 72
IL-10 -1082A/G (rs1800896) Higher Candida-induced IL-10 
production
Persisting candidemia 74
IL-12B 2724INS/DEL (rs17860508) Lower Candida-induced IFNg production Persisting candidemia 74
MBL2 Variable number of tandem repeats in intron 4 Reduced vaginal MBL levels RVVC 69,70
NLPR3 Length polymorphism Impaired IL-1β production RVVC 71
PTPN22 R620W (rs2476601) Unknown Increased risk for CMC 76
TLR1 R80T (rs5743611), S248N (rs4833095), I602S (rs5743618) Decreased production of IL-1β, IL-6 and 
IL-8 after TLR1-TLR2 stimulation
Increased susceptibility to candidemia 65
TLR2 R753Q (rs5743708) Decreased levels of IFN-γ and IL-8 Increased susceptibility to candidemia 66
TLR3 L412F (rs3775291) Decreased IFN-γ levels Increased risk for CMC 68,83
TLR4 D299G (rs4986790), Y399I (rs4986791) Increased IL-10 production Increased susceptibility to candidemia 67
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generate crucial information about a particular gene or protein, and the pathway in 
which this protein is involved. For example, the use of next generation sequencing and 
whole exome sequencing to discover STAT1 mutations as a cause of CMC 38, has also 
led in the understanding of its role for the generation of Th1 and Th17 responses and 
the anti-Candida host defense 45. This discovery can lead to novel approaches to the 
therapy of CMC, some of them being currently tested.
 Of course, the list of existing monogenetic disorders is relatively small, as 
the majority of Candida cases are likely polygenic and/or multifactorial. In order to 
investigate this type of disorders other methods will have to be employed such as 
genome-wide association studies, deep sequencing, and systems biology. We have 
recently used a combination of transcriptional analysis and functional genomics to 
demonstrate that type I IFNs play an important role in the anti-Candida host defense 78. 
Stimulation of circulating leukocytes with C. albicans led to a transcription profile with 
overrepresentation of genes from the type I IFN pathway. Subsequently, we showed 
that polymorphisms in these genes modify Candida-induced cytokine production 
and influence susceptibility to systemic Candida infections. Furthermore, validation 
studies showed that type I IFNs skew Candida-induced cytokine responses from Th17 
toward Th1, while STAT1-deficient CMC patients display defective expression of genes 
in the type I IFN pathway. This “systems approach”, that integrates the information 
on anti-Candida host defense from several types of studies, provides information 
with respect to potential novel anti-Candida immune responses that may represent 
targets for immunotherapy. It is to be expected that an integration of efforts from 
immunology, genetics, microbiology, and systems biology will represent the novel level 
of understanding of host defense against fungal (and other) pathogens, improving the 
outcome of these severe infections.
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SUMMARy
In the present study we investigated the functional differences between cluster of 
differentiation (CD)14++CD16- and CD14+CD16+ monocytes during anti-Candida host 
defense. CD14++CD16- are the “classical” monocytes and represent the majority of 
circulating monocytes in humans, while CD14+CD16+ monocytes patrol the vasculature 
for maintenance of tissue integrity and repair. Both monocyte subsets inhibited 
the germination of live C. albicans, and there was no difference in their capacity to 
phagocytose and kill Candida. Although production of interleukin (IL)-6 and IL-10 
induced by Candida albicans was found to be similar between monocyte subsets, 
IL-1β and prostaglandin E2 (PGE2) production was higher in CD14
++CD16- compared 
with CD14+CD16+ monocytes. In line with the increased production of IL-1β and PGE2, 
central mediators for inducing T helper (Th)17 responses, CD14++CD16- monocytes 
induced greater Th17 responses upon stimulation with heat-killed (HK) C. albicans 
yeast. The percentage of cells that expressed mannose receptor (MR) was higher in 
the CD14++CD16- monocyte subset, and MR-specific stimulation induced higher Th17 
responses only in co-cultures of CD14++CD16- monocytes and CD4 lymphocytes. In 
conclusion, both monocyte subsets have potent innate antifungal properties, but only 
CD14++CD16- monocytes are capable of inducing a potent Th17 response to C. albicans, 
an important component of antifungal host defense.
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INTRODUCTION
Human blood monocytes are divided into two major subsets based on their expression 
of CD14 and CD16. The “classical” CD14++CD16- monocytes comprise 90-95% of total 
monocytes 1, while CD14+CD16+ monocytes, identified by Passlick et al.2, are proposed 
to have a more mature and proinflammatory phenotype. This is based on a series 
of observations: CD14+CD16+ monocytes produce very little to no IL-10 (messenger 
ribonucleic acid (mRNA)) upon stimulation with LPS 3,4 and produce more tumor 
necrosis factor (TNF)-α after stimulation of whole blood with lipopolysaccharides (LPS) 
and Pam3cys 5. Furthermore, CD14+CD16+ monocytes express more human leukocyte 
antigen-DR, which could predict a higher antigen-presenting cell activity 2. Also, their 
dendritic cell progeny are superior in terms of antigen-presenting capacity 6-9. Another 
indication for the fact that CD14+CD16+ are more proinflammatory than CD14++CD16- 
monocytes is that the number of CD14+CD16+ appears to increase during exercise 10,11 
and inflammatory conditions 12.    
 It has been therefore suggested that CD14+CD16+ monocytes are superior to 
the classical CD14++CD16- monocytes in terms of inflammatory response. However, 
until recently, little research had been done to compare the defense mechanisms of 
CD14++CD16- and CD14+CD16+ monocytes against live microorganisms, and especially 
fungal pathogens. Serbina et al. were the first to show that, although CD14++CD16- 
monocytes produced lower levels of TNF-α compared to CD16+ monocytes upon 
stimulation with live Aspergillus fumigatus, CD14++CD16- monocytes, unlike CD14+CD16+ 
monocytes, were able to restrict germination of A. fumigatus yeast 13. Apparently, 
both monocyte subtypes play important but different roles in host defense against A. 
fumigatus.
 Candida albicans is a major causative pathogen of fungal infections 14. In 
healthy subjects, C. albicans is present as a commensal yeast, with 30% of individuals 
being colonized at any given moment in time 14. When host defense mechanisms 
are impaired, Candida can cause mucocutaneous infections, or disseminate into the 
bloodstream and infect multiple organs 14. Mucocutaneous candidiasis occurs when 
T-lymphocyte defenses are impaired, as is the case in human immunodeficiency virus 
infection or congenital immunodeficiency disorders such as chronic mucocutaneous 
candidiasis and hyper IgE syndrome 15. Risk factors for disseminated Candida infections 
are mainly a consequence of neutropenia and neutrophil dysfunction, with major 
abdominal surgery, total parenteral nutrition, antibiotic treatment, and the presence 
of indwelling medical devices as additional risk factors 16.
 Recent studies have demonstrated that the Th17 lymphocyte differentiation 
pathway and the neutrophil-activating cytokine IL-17 are responsible for the mucosal 
defense to Candida species. In previous studies, we have demonstrated that C. albicans 
is an extremely potent inducer of the Th17 differentiation pathway 15,17,18.
 In this study, we investigated the role of CD14++CD16- and CD14+CD16+ 
monocytes in the host defense against C. albicans. We demonstrate that, while both 
monocyte subpopulations display potent antifungal properties such as inhibition 
of germination, phagocytosis, and killing, only CD14++CD16- monocytes can induce a 
protective Th17 response upon recognition of C. albicans.
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MATERIALS AND METHODS
Healthy volunteers
Peripheral blood mononuclear cells (PBMCs) were isolated from buffycoats isolated 
from healthy volunteers (Sanquin Bloodbank, Nijmegen, the Netherlands).
Reagents
The following reagents were used: Ficoll-Paque (GE Healthcare, Diegem, Belgium), 
RPMI 1640 Dutch modifications culture medium (Sigma-Aldrich, Zwijndrecht, the 
Netherlands). The RPMI 1640 medium was supplemented with 1% gentamicin, 1% 
L-glutamine and 1% pyruvate (Life Technologies, Nieuwerkerk, the Netherlands). 
For isolation of monocyte subsets and CD4 positive lymphocytes: CD16 isolation kit 
(130-091-765, Miltenyi Biotec, Utrecht, the Netherlands), CD14 beads (130-050-201, 
Miltenyi Biotec), CD4 beads (130-045-101, Miltenyi Biotec), BSA (Sigma-Aldrich), EDTA 
(Merck, Darmstadt, Germany). For cell stimulations: Candida mannans and particulate 
β-glucan were kindly provided by Prof. David Williams; Pam3Cys (EMC microcollections, 
Tuebingen, Germany); LPS (E. Coli serotype 055:B5) was purchased from Sigma-
Aldrich, and an additional purification step was performed as described previously 54; 
mannoprotein (MP) 65 of C. albicans was kindly provided by Prof. Antonio Cassone 
(Rome University, Italy) 25; IL-1RA was a kind gift of Prof. Charles Dinarello (University 
of Colorado, Denver); mannan from saccharomyces cerevisiae was purchased from 
Sigma; diclofenac was obtained from the local pharmacy (Novartis Pharma, Arnhem, 
the Netherlands). For germination, phagocytosis and killing: Modified eagle’s medium5 
(21935-028, Invitrogen, Breda, the Netherlands). Antibodies used for FACS analysis: 
α-Dectin-1-APC (FAB1859A, R&D, Abindon, United Kingdom), α-Toll-like receptor 
(TLR)2-PerCP (FAB2616C, R&D), α-TLR4-Pacific Blue (57-9917-73, eBioscience, Frankfurt, 
Germany), α-mannose receptor (MR)-PE (321106, Biolegend, San Diego, USA), IgG1κ 
isotype control (55749, BD Bioscience).
Microorganisms
Candida yeast (American type culture collection MYA-3573 (UC820)), a strain well 
described elsewhere 55, were grown overnight in Sabouraud broth at 37°C. Cells were 
harvested by centrifugation, washed twice, and resuspended in culture medium. 
C. albicans yeasts or hyphae were heat-killed for one hour at 100 °C. HK Aspergillus 
fumigatus (V05-27) was prepared ad described previously 56; Staphylococcus aureus 
(American type culture collection) 25923 was heat-killed for 30 minutes at 100 °C.
Isolation of CD14++CD16- and CD14+CD16+ monocytes
PBMC were isolated by density gradient centrifugation of PBS-diluted blood (1:1) over 
Ficoll-Paque. PBMCs were washed three times in PBS and resuspended in RPMI culture 
medium. Cells were counted in a Coulter counter (Beckman Coulter, Woerden, the 
Netherlands).
 Monocyte subsets were purified from freshly isolated PBMC using MACS 
microbeads, according to the instructions of the manufacturer (Miltenyi Biotec). 
In short, PBMC were depleted of granulocytes and NK cells using CD15 and CD56 
microbeads. CD14+CD16+ monocytes were positively selected using CD16 microbeads. 
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Subsequently, CD14++CD16- monocytes were positively selected from the CD16- 
population, using CD14 microbeads. Finally, T cells were positively selected using CD4 
microbeads.
Stimulation experiments
Monocytes were diluted to a concentration of 1×106 cells per mL; 100 μL of this 
suspension was put into a round bottom plate. When cells were cultured for 2 or 7 days, 
50 μL of monocyte suspension was stimulated in the presence of CD4 positive cells 
(4×106/mL). For the induction of Th17 responses, 7 day cultures were performed with 
10% human pool serum. Monocytes were primed with several stimuli, as indicated in 
the figure legends, in a volume of 200 μL. When cells were stimulated with heat-killed 
C. albicans this was done in a concentration of 1×106/mL. When cells were stimulated 
with live C. albicans this was done in a concentration of 1×104/mL, in order to prevent 
the live Candida to completely overgrow to cell culture in seven days. Experiments 
were performed in duplicate. After 1, 2 or 7 days, duplicate supernatants were pooled 
and stored at –20°C until assayed.
Cytokine assay
The concentration of IFN-γ, IL-1β, IL-6, IL-10, IL-17A, prostaglandin E2 (PGE2) and TNF-α 
were measured in cell culture supernatants using ELISA, according to instructions of the 
manufacturer (IL-6, IL-10 and IFN-γ: Sanquin, Amsterdam, the Netherlands; and IL-1β, 
IL-17A, PGE2 and TNF-α: R&D, Abingdon, UK). IL-1β, IL-6, PGE2 and TNF-α were measured 
after one day of incubation, IL-10 and IFN-γ were measured after two days incubation, 
and IL-17A was measured after seven days of incubation, according to the incubation 
times to achieve maximal cytokine production, as we determined previously 17.
Phagocytosis and killing
Phagocytosis and killing was performed as described previously 55,57. In short, 5×105 
monocytes (in a volume of 100 μL) were put in a flat-bottom well. The plate was 
incubated at 37 °C for two hours, to allow the cells to adhere to the plastic surface. 
Thereafter, the supernatant was removed, and the monolayer was rinsed with MEM. 
200 μL of live C. albicans (5×104/mL) in modified eagle’s medium, 2.5% serum was 
added, and the plate was incubated for 15 minutes to allow phagocytosis of the yeast. 
The supernatant was removed, and the monolayer was rinsed with modified eagle’s 
medium. 200 μL of modified eagle’s medium /sabouraud was added to the monolayer 
after which the plate was put in the incubator for 2 hours and 45 minutes to allow 
intracellular killing of the yeast. After this incubation period, the monocytes were 
lysed. Both the supernatants with non-phagocytosed Candida and the lysed monocyte 
suspension with non-killed Candida were directly plated in duplicate in two different 
dilutions on agar plates. These plates were cultured for 24 hours, after which the 
number of colonies was counted. The percentage of phagocytosed and killed Candida 
was calculated.
FACS analysis
50 μL (5×106/mL) freshly isolated, unstimulated monocytes were stained with the 
different antibodies for 30 minutes on ice, according to instructions of the manufacturer. 
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After incubation, the cells were washed twice with 1% BSA. The cells were resuspended 
in 200 μL 1% BSA, and fluorescence was measured on a CyAn FACS machine (Dako, 
Enschede, the Netherlands).
Germination
Live C. albicans (1×105/mL) was incubated in the lower compartment of a Trans-well 
culture system (Costar 3413, Corning Life Sciences, Amsterdam, the Netherlands) 
at 37 °C, in the absence or presence of freshly isolated CD14++CD16- or CD14+CD16+ 
monocytes (2.5×105/mL) in the upper chamber of the system. After 24 hours, germination 
was inspected under an inverted microscope (Leica EC3 with, x20 objective).
Statistical analysis
The differences between groups were analyzed using the Wilcoxon signed rank test 
(cytokine data) or the paired t-test (flow cytometry data). Differences were considered 
statistically significant if p≤ 0.05 (*) or p ≤0.01 (**).
RESULTS
Cytokine production by CD14++CD16- and CD14+CD16+ monocyte subsets upon 
stimulation with C. albicans
To determine the early cytokine response produced by both CD14++CD16- and 
CD14+CD16+ monocytes upon Candida stimulation, both subtypes were stimulated for 
24 h with RPMI, HK C. albicans yeasts, A. fumigatus or S. aureus. CD14++CD16- monocytes 
released more TNF-α and IL-1β compared to CD14+CD16- monocytes (Figure 1). 
Stimulation with HK Aspergillus resulted in low to undetectable production of IL-β, IL-6 
and TNF-α in both monocyte subsets. Furthermore, CD14++CD16- monocytes produced 
more IL-6 upon stimulation with S. aureus (Figure 1C).
No differences of C. albicans phagocytosis and killing, or inhibition of germination, 
between CD14++CD16- and CD14+CD16+ monocytes
To establish whether these differences in the early cytokine response would result in 
differences in the phagocytic and/or killing capacity of CD14++CD16- and CD14+CD16+ 
monocytes, the phagocytosis and killing of C. albicans by the two cell populations 
was assessed. CD14++CD16- and CD14+CD16+ monocytes phagocytosed and killed live 
Candida at a similar rate (Figure 2A).
 An important component of the virulence of C. albicans is its ability to grow in 
a variety of morphological forms 19. At a temperature of 37°C or at a CO2 concentration 
of 5.5%, especially in the presence of human serum, Candida changes its morphology 
from an unicellular yeast cell to filamentous forms such as hyphae and pseudohyphae 
20,21. It has been previously shown that soluble factors such as NO can inhibit yeast-to-
hyphae transition in vitro 22, and IFN-γ release can also inhibit germ-tube formation 
in vitro 23. To investigate whether the two monocyte subpopulations could inhibit 
this process equally, live Candida yeasts were cultured in the lower half of a transwell 
system, in the absence or presence of CD14++CD16- or CD14+CD16+ monocytes in the 
upper half of a transwell system. When Candida was cultured alone for 24 h, Candida 
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hyphae could be observed (Figure 2B). When Candida was cultured in the presence of 
unstimulated CD14++CD16- or CD14+CD16+ monocytes, hyphal formation was almost 
absent (Figure 2B). Prestimulation of monocytes with HK C. albicans yeast, as described 
above, also led to inhibition of hyphal formation, similar to unstimulated cells (not 
shown). No differences between the capacities of the two monocyte subpopulations 
to inhibit germination were apparent.
CD14++CD16- monocytes have a higher expression of mannose receptor
The distribution of several pathogen recognition receptors (PRRs) was determined using 
FACS analysis, to evaluate whether this could explain the different cytokine responses 
between CD14++CD16- and CD14+CD16+ monocytes upon stimulation with Candida. 
TLR4 and dectin-1 were slightly more often expressed in CD14++CD16- monocytes, and 
TLR2 was slightly more expressed in CD14+CD16+ monocytes, but these differences 
were not significant (Figure 2C). However, the expression of MR differed substantially 
between the two monocyte populations: 91% versus 66 % of the CD14++CD16- and 
CD14+CD16+ monocytes expressed MR respectively (Figure 2D).
Figure 1. Proinflammatory cytokine production by CD14++CD16- and CD14+CD16+ monocytes
Human monocytes were stimulated for 24 hours with RPMI, heat-killed C. albicans yeast 
(1×106/mL), heat-killed Aspergillus fumigates (1×106/mL), or heat-killed Staphylococcus 
aureus (1×107/mL). The concentration of (A) TNF-α (B) IL-β and (C) IL-6 was determined 
in cell culture supernatants using ELISA. Data were analyzed using the Wilcoxon 
signed rank test. Graphs depict mean + SEM from at least five healthy volunteers.
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Figure 2. CD14++CD16- monocytes express more mannose receptor than CD14+CD16+ monocytes
(A) The percentage of C. albicans yeasts phagocytosed and killed by monocytes was determined 
after 15 minutes and 3 hours respectively. Data were analyzed using the Wilcoxon signed 
rank test (* = p ≤ 0.05). Graph depicts mean ± SEM from four healthy volunteers. (B) After 
24 hours of incubation, inhibition of C. albicans germination by monocytes was examined 
visually under an inverted microscope (Leica EC3 with 200× magnification). Images were 
saved using Las ez 1.5.0 software. Images are representative of experiments performed 
with cells isolated from six volunteers. (C) Freshly isolated monocytes were directly stained 
with fluorescent labels for different cell membrane receptors. The percentage of positive cells 
was determined by flow cytometric analysis. Data were analyzed using the paired t-test 
(* = p ≤ 0.05). Graph depicts mean + SEM from four healthy volunteers. (D) Difference in 
fluorescence between isotype control (grey) and MR antibody (black line) in CD14++CD16- 
and CD14+CD16+ monocytes. Data are representative for cells isolated from two volunteers.
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CD14++CD16- monocytes induce a stronger Th17 response
IL-1β production was higher when CD14++CD16- monocytes were stimulated (Figure 
1B), and IL-1β is known to be crucial for the antifungal Th17 responses. In order to 
assess whether CD14++CD16- and CD14+CD16+ were equally capable of inducing Th17-
responses, CD14++CD16- and CD14+CD16+ monocytes were stimulated for 2 or 7 days in 
the presence of CD4+ cells and 10% human pooled serum, with RPMI, HK C. albicans yeast, 
or S. aureus. CD14+CD16+ monocytes tended to induce more IFN-γ upon stimulation 
with Candida and S. aureus, but the differences were not statistically significant (Figure 
3A). Neither monocytes subset induced a substantial IL-10 release upon stimulation 
with Candida, although CD14++CD16- monocytes produced more IL-10 upon stimulation 
with S. aureus (Figure 3B). After stimulation with C. albicans, CD14++CD16- monocytes 
induced more IL-17A when co-incubated with T-cells compared with CD14+CD16+ 
monocytes (Figure 3C). Since C. albicans is a dimorphic fungus which is able to actively 
suppress IL-17 production 24, IL-17 production was measured after stimulation with live 
C. albicans, with HK Candida hyphae, or with Candida yeasts. Live Candida induced little 
IL-17 production, and there was no difference in IL-17 production induced by C. albicans 
hyphae in CD14++CD16- or CD14+CD16+ monocytes. However, HK C. albicans yeasts 
induced a higher IL-17A response in T-cells coincubated with CD14++CD16- monocytes 
compared with those coincubated with CD14+CD16+ monocytes (p=0.002) (Figure 3D).
Figure 3. CD14++CD16- monocytes induce stronger IL-17A responses upon C. albicans stimulation
Human monocytes (5x104) were stimulated in the presence of 2x105 CD4+ cells and 10% serum, 
for two (for IFN and IL-10 measurements) and seven (for IL-17A measurements) days. The 
concentration of (A) IFN-γ, (B) IL-10 or (C)  IL-17 was determined in cell culture supernatants using 
ELISA, after stimulation with RPMI, HK C. albicans yeast (1·106/mL) or HK S. aureus (1×107/mL). Data 
represent mean + SEM from at least four healthy volunteers. (D) The concentration of IL-17 was 
determined after stimulation with RPMI, live Candida (1×104/mL), HK C. albicans yeast (1×106/mL) 
or HK C. albicans hyphae (1×106/mL). Data represent mean + SEM from at least six healthy 
volunteers. Data were analyzed using the Wilcoxon signed rank test (* = p ≤ 0.05, ** = p ≤ 0.01).
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CD14++CD16- monocytes induce higher Th17 responses via the mannose receptor and 
PGE
2
 production
Next, we investigated whether the differences in receptor expression were also 
reflected in the cytokine production upon stimulation with receptor-specific stimuli. 
Production of IL-17A was undetectable upon stimulation with Pam3Cys (TLR2 ligand), 
LPS (TLR4 ligand), mannan (MR ligand) and β-glucan (dectin-1 ligand) alone, in both 
monocyte subsets coincubated with CD4+ lymphocytes (data not shown). However, 
when cells were stimulated with serotype A mannan in the presence of MP65, a potent 
inducer of lymphoproliferation 25,26, IL-17A production was detectable and higher in 
CD14++CD16- monocytes than in CD14+CD16+ monocytes (Figure 4A). Furthermore, 
stimulating CD14++CD16- monocytes with MP65 and serotype A mannan together, 
had a synergistic effect on IL-17 production (p=0.0313) (Figure 4A). When the MR 
was blocked with mannan from saccharomyces cerevisiae, C. albicans induced IL-17 
production decreased in CD4+ cells co-incubated with CD14++CD16- monocytes, but 
not in those co-incubated with CD14+CD16+ monocytes (Figure 4B). Since CD14++CD16- 
monocytes show increased expression of the MR compared to CD14+CD16+ monocytes, 
and stimulation of the MR results in PGE2 production 
27, which in turn can induce IL-17 
production in T-lymphocytes 28,29, we decided to measure PGE2 production in cell 
culture supernatants. It appeared that CD14++CD16- monocytes produced more PGE2 
than CD14+CD16+ monocytes upon stimulation with HK C. albicans yeasts (Figure 
4C). When PGE2 production was blocked using diclofenac, Candida-induced IL-17 
production in CD4+ cells co-incubated with CD14++CD16- monocytes decreased, but not 
in CD4+ cells co-incubated with CD14+CD16+ monocytes (Figure 4D). Next, we wanted 
to investigate the relative importance of IL-1β in inducing the Th17 response. IL-RA 
decreased Candida-induced IL-17 production substantially, especially in CD14++CD16- 
monocytes (Figure 4E).
DISCUSSION
In the present study we demonstrate that CD14++CD16- monocytes produce more IL-
1β and PGE2 upon stimulation with HK C. albicans yeast, compared with CD14
+CD16+ 
monocytes. IL-1β is a central cytokine involved in the induction of Th17 responses, 
and CD14++CD16- monocytes induce a greater IL-17A production in CD4 lymphocytes. 
These differences in cytokine production were associated with an increased expression 
of MR on the cell membrane of CD14++CD16- compared to CD14+CD16+ monocytes. 
Regarding the innate host defense, there was no large difference in Candida-induced 
IL-6 production, and both monocyte subpopulations are able to phagocytose and kill 
C. albicans, and inhibit at similar rates the germination of yeasts into hyphae. Thus, 
while both CD14++CD16- and CD14+CD16+ monocytes play a role in host defense against 
C. albicans, it is only CD14++CD16- monocytes that are able to induce protective Th17 
responses.
 Host defense against Candida species is a dynamic interplay between innate 
immunity and adaptive immune mechanisms, with cellular T-helper responses playing 
a central role. The first step in the activation of host defense is represented by fungal 
recognition by various pattern recognition receptors such as TLRs and C-type lectin 
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Figure 4. Stimulation of monocytes with PRR-specific stimuli
(A,B,D,E) Monocytes were stimulated in the presence of CD4+ lymphocytes and 10% serum for 
seven days. IL-17A production was determined in cell culture supernatants using ELISA. (A) IL-17A 
production upon stimulation with RPMI, serotype A mannan (MR ligand) (100 μg/mL), MP65 
(antigen) (1 μg/mL) or a combination of MP65 and serotype A mannan. Data represent mean + 
SEM from six healthy volunteers. (B) IL-17A production upon stimulation with RPMI, heat-killed 
C. albicans yeast (1×105/mL) in the absence or presence of S. cerevisiae mannan. Experiments 
were performed with cells isolated from four healthy volunteers. Data for each volunteer are 
presented. (C) Monocytes were stimulated for 24 hours with RPMI or heat-killed C. albicans 
yeast (1×106/mL). The concentration of PGE
2
 was determined in cell culture supernatants using 
ELISA. Data represent mean + SEM from six healthy volunteers. (D) IL-17A production upon 
stimulation with RPMI, heat-killed C. albicans yeast (1×105/mL) in the absence or presence of 
diclofenac. Experiments were performed with cells isolated from four healthy volunteers. 
Data for each volunteer are presented. (E) IL-17A production upon stimulation with RPMI, or 
heat-killed C. albicans yeast (1×106/mL) in the absence or presence of IL-1RA (10 µg/mL) was 
determined in cell culture supernatants using ELISA. Data represent mean + SEM from four 
healthy volunteers. (A,C,E) Data were analyzed using the Wilcoxon signed rank test (* = p ≤ 0.05).
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receptors (e.g. dectin-1 and MR), followed by the release of proinflammatory cytokines. 
This is followed by phagocytosis and killing of the fungus by tissue macrophages, as 
well as by inflammatory neutrophils and monocytes migrating into the tissues 30. These 
activated monocytes are also responsible for the induction of a Th17 response, both 
through the production of IL-β and IL-6 31, as well as through cell contact with recruited 
CD4 T cells 32,33.
 If initial innate immune mechanisms are not able to eliminate the infection, 
adaptive cellular immune mechanisms, represented by Th1 (IFN-γ production) and 
Th17 (IL-17A production) responses, will contribute to elimination of infection at later 
stages 34. In the present study we assessed the differential antifungal properties of 
CD14++CD16- and CD14+CD16+ monocytes in initiating both the innate and adaptive 
cellular immune response to the fungal pathogen C. albicans.
 The proinflammatory cytokine response showed an important difference 
between the two monocyte subsets: CD14++CD16- monocytes released more IL-1β 
than CD14+CD16+ monocytes. In addition to its direct proinflammatory effects, IL-1β 
also has an important role in the induction of Th17 responses 35. Part of this effect is 
due to the potent induction by IL-1β of PGE2, a pivotal factor in the induction of Th17 
differentiation 36,37. The PGE2 response was indeed strongly enhanced in CD14
++CD16+ 
monocytes and not in CD14+CD16+ monocytes, which is in line with our recent data 
showing a crucial role of PGE2 for Candida-induced IL-17 
29. Indeed, blocking PGE2 
production reduced IL-17 synthesis induced by CD14++CD16- monocytes. IL-17A is the 
most important effector cytokine of the Th17 response 38, and plays an important role 
in Candida host-defense 39. Mice deficient in IL-17R have an increased susceptibility to 
both systemic 40 and mucosal 41 candidiasis, and patients with defective Th17 responses 
suffer from chronic mucocutaneous candidiasis 15,42. In line with their induction of IL-1β 
and PGE2, it was mainly CD14
++CD16-, but not CD14+CD16+ monocytes, that induced 
IL-17A production from CD4+ lymphocytes after stimulation with C. albicans. We have 
previously demonstrated that C. albicans only induces IL-17 production in CD4+ memory 
T cells 17, and here we demonstrate that CD14++CD16- monocytes are the main blood 
monocyte subpopulation to initiate this response 43.
 How can the difference in the capacity to induce IL-17A responses between 
the two monocyte populations be explained? In a recent study, we have identified the 
PRRs responsible for the induction of a Th17 response after stimulation with C. albicans 
17. We identified that, in addition to antigen presentation, the engagement of MR by 
Candida mannans is a central event in the induction of an antifungal Th17 response. This 
pathway was amplified by recognition of β–glucans by dectin-1, and of an unidentified 
fungal component by TLR2 17. We therefore analyzed the distribution of several PRRs 
on the monocyte subpopulations using flow cytometric analysis. While expression 
of TLR2, TLR4 and dectin-1 was similar between the two monocyte subpopulations, 
a striking difference was found in the distribution of the MR, which was present on 
only 66% of CD14+CD16+ monocytes, versus on 91% of CD14++C16- monocytes. To 
assess whether this may explain the differences in the induction of IL-17A, cells were 
stimulated with various specific receptor ligands. While specific stimulation of dectin-1, 
TLR2 or TLR4 with purified ligands did not induce IL-17A production, stimulation of 
CD14++CD16- (but not CD14+CD16+) monocytes with mannans and MPs isolated from 
C. albicans, which are known to be MR ligands 30, induced a high Th17 response in 
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CD4-lymphocytes co-cultured with CD14++CD16- monocytes. Interestingly, MP65 alone 
only induced little IL-17 production, but together with mannan, IL-17 production was 
significantly increased in CD14++CD16- monocytes, indicating that both mannoproteins 
and mannans are necessary for an effective anti-fungal immune response. Since it is 
known that Candida stimulation of the MR results in a Th17 response, either directly 
17 or via the production of PGE2 
27,29, the difference in MR expression might explain 
the difference in the IL-17 inducing capacity between both monocyte subsets. Indeed, 
blocking the MR decreased IL-17 production induced by CD14++CD16- monocytes. While 
these data support a role of MR in the differences between the two monocyte subsets, 
a role for other PRRs such as dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin 44, dectin-2 45,46, galectin-3 47-49, or macrophage-inducible C-type 
lectin 50,51 cannot be completely ruled out, although their expression on monocytes is 
known to be very low or absent. 
 In addition to Th17 cells, other cellular responses such as Th1-IFN-γ also play an 
important role for host defense to Candida 30. No significant differences in the induction 
of Th1 responses were seen between CD14++CD16- and CD14+CD16+ monocytes, 
although the latter tended to induce higher IFN-γ production from the lymphocytes 
after stimulation with HK C. albicans yeast. Monocyte derived IL-18 is an important 
inducer of IFN-γ production 52, unfortunately in our experiments IL-18 production was 
undetectable (data not shown). Both monocyte subpopulations released very low 
amounts of IL-10 after challenge with C. albicans. However, CD14+CD16+ monocytes 
produced less IL-10 in response to S. aureus than CD14++CD16- monocytes. This is 
in agreement with previous studies which found that the CD14+CD16+ monocytes 
produced less IL-10 mRNA upon LPS stimulation 3,4.
 Another observation in this study is that both CD14++CD16- and CD14+CD16+ 
monocytes displayed vigorous innate antifungal mechanisms, and no large differences 
in terms of IL-6 production, phagocytosis and killing, or inhibition of yeast-hyphal 
germination were observed. Some earlier studies have proposed that CD14+CD16+ 
monocytes have a more pronounced proinflammatory profile based on higher 
production of TNF-α upon stimulation with TLR4 stimuli such as LPS 5 or dormant 
Aspergillus conidia 13. In this study, CD14++CD16- monocytes produced more TNF-α upon 
Candida compared with CD14+CD16+ monocytes. However, CD14+CD16+ monocytes are 
not the major source of TNF-α in all infections: in patients with erysipelas infected with 
group A streptococci, the increase in the CD14+CD16+ cells is associated with diminished 
TNF-α production 53, and germinated Aspergillus induce similar TNF-α production in 
CD14++CD16+ and CD14+CD16- monocytes 13.
 In conclusion, in the present study we report an assessment of the anti-
Candida host defense properties of the two monocyte subpopulations of human blood, 
the CD14++CD16- and CD14+CD16+ monocytes. While both monocyte subpopulations 
displayed equally effective phagocytosis and killing of Candida, only CD14++CD16- 
monocytes were able to initiate effective antifungal Th17 responses in human CD4 
cells. This effect was mediated by a pathway involving enhanced expression of the MR, 
followed by higher production of IL-1β and PGE2 by CD14
++CD16- monocytes. These 
findings may have important consequences in the design of future immunotherapeutic 
strategies aimed to enhance host defense against Candida infections.
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AbSTRACT
The fungus Candida albicans is a potent inducer of the T helper (Th)17 response. 
Prostaglandin E2 (PGE2) is a strong proinflammatory mediator, which has proven to be 
essential for the Th17 response. In this study, we have investigated the role of PGE2 in 
the Th17 response induced by C. albicans in humans.
 Peripheral blood mononuclear cells (PBMCs) were stimulated with Candida 
albicans in the absence or presence of a non-steroidal anti-inflammatory drug (NSAID). 
In separate experiments, PGE2 or the prostlaglandin receptors agonists butaprost 
or misoprostol were added to the cells. PBMCs were also stimulated with fungal 
components and silencing ribonucleic acid (siRNA) for mannose receptor (MR) was 
performed. PGE2 and cytokines were measured by enzyme-linked immunosorbent assay 
(ELISA) or luminex, and the source of interleukin (IL)-17 production was determined 
using fluorescence-activated cell sorting (FACS) analysis.
 Blocking Candida-induced PGE2 production by an NSAID resulted in decreased 
IL-17 and IL-22 production, and inhibited expression of RORγT mRNA. Furthermore 
when PGE2 production was blocked, IL-6, IL-23 and IL-10 were decreased, while TNF-α 
increased. Stimulation with PGE2 or EP2/EP4 agonists restored IL-17 production. 
C. albicans mannan was the only fungal component that was able to directly induce 
PGE2 and silencing of the MR resulted in a reduction of Candida induced PGE2. β-glucan 
engagement of dectin-1 synergistically increased Toll-like receptor (TLR)2-induced 
PGE2 production.
 These data provide evidence that PGE2 pathway is important for the Th17 
response induced by C. albicans, and that PGE2 is induced by the fungal components 
mannan and β-glucan that are recognized by the MR and the dectin-1/TLR2 pathway, 
respectively.
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INTRODUCTION
PGE2 is the most widely produced prostanoid in the body in response to proinflammatory 
cytokines 1, and plays an important role in the regulation of inflammatory responses. 
It is primarily involved in the induction of the classical signs of inflammation, namely: 
erythema, increased vascular permeability, edema, pain and fever 2-4. Furthermore, 
PGE2 alters the capacity of antigen presenting cells (APCs) and T cells to produce certain 
cytokines, and may therefore influence the functional phenotype of T cells during 
priming 5. PGE2 favors a Th2 response, by inhibiting the production of the Th1 cytokine 
interferon (IFN)-γ, and by up regulating the production of the Th2-associated cytokines 
IL-4 and IL-5 6.
 The recently discovered T helper subset called Th17 cells plays an important role 
in the protection against extracellular bacteria and fungi 7. Th17 cells are characterized 
by the production of IL-17A (IL-17), IL-17F, IL-21 and IL-22 7. IL-17 is capable of initiating 
and maintaining inflammation, and plays an important role in auto-immune diseases 
like rheumatoid arthritis, multiple sclerosis and psoriasis 8. The early differentiation 
of Th17 cells is initially regulated by IL-1β signaling 9, while IL-23 plays an important 
in role in the amplification and late stage of  Th17 development 10. Interestingly, PGE2 
induces IL-23 production 11-13, and together with IL-23 synergistically favors human Th17 
expansion 1,14. PGE2 has also been reported to be necessary for the production of the 
Th17 effector cytokine IL-17 15. Furthermore, it has been shown that human memory T 
cells induce a robust Th17 response in reaction to the fungus Candida albicans 16,17.
 In the present study, we investigated the mechanisms through which 
C. albicans induces PGE2 production, and whether this influences the Candida-induced 
Th17 response. It is shown that C. albicans is a potent inducer of PGE2, and that the 
Candida induced Th17 response is dependent on the induction of prostaglandins. 
C. albicans mannan was the only fungal component that was able to directly induce PGE2 
production, while β-glucan exerted synergistic effects on TLR2-induced prostaglandins.
MATERIALS AND METHODS
volunteers
Blood was collected from healthy volunteers who were free of infectious or inflammatory 
disease, after informed consent was given. Blood was collected by venipuncture into 10 
ml EDTA syringes (Monoject, s-Hertogenbosch, The Netherlands). 
Reagents
The following study materials were used: anti-CD3 and anti-CD28 coated (αCD3αCD28) 
beads prepared from a T cell activation/expansion kit (MACS milteny biotec, Bergisch 
Gladbach, Germany); Pam3Cys (EMC microcollections, Tuebingen, Germany). Chitin was 
kindly provided by Prof. Neil A.R. Gow (School of Medical Scienses, Aberdeen, UK) and 
prepared according to previous protocols 18. Candida mannan and particulated β-glucan 
were are a kindly provided by Prof. David Wiliams and were prepared as previously 
described 19,20. Curdlan was purchased from (WAKO, Richmond, USA) and diclofenac 
from Novartis Pharma (Arnhem, the Netherlands). PGE2, butaprost and misoprostol 
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were commercially purchased (Sigma-Aldrich, Zwijndracht, the Netherlands). Culture 
medium used in the experiments was RPMI 1640 Dutch modifications (Sigma-Aldrich) 
supplemented with 1% gentamicin, 1% l-glutamine and 1% pyruvate (Life Technologies, 
Nieuwekerk, the Netherlands).
Microorganism
C. albicans ATCC MYA-3573 (UC 820) 21 was grown overnight in Sabouraud broth at 
37°C, cells were harvested by centrifugation, washed twice, and resuspended in culture 
medium. C. albicans was heat-killed for one hour at 100°C.
In vitro cytokine production
Separation and stimulation of PBMCs was performed as described previously 22. Briefly, 
the PBMCs fraction was obtained by density centrifugation of diluted blood (1 part 
blood to 1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech, Uppsala, 
Sweden). PBMCs were washed twice in saline and suspended in culture. The cells 
were counted in a hemocytometer, and their number was adjusted to 5x106 cells/ml. 
5x105 PBMCs in a volume of 100 μl per well were incubated at 37°C in round-bottom 
96-wells plates (Greiner, Nurnberg, Germany), in the presence of 10% human pooled 
serum, with C. albicans or culture medium alone. After 1,2 or 7 days of incubation, 
supernatants were collected and stored at –20°C until assayed.
Cytokine assays
The concentration of IL-1β, IL-17, IL-22, IL-23 and TNF-α (R&D Systems, Abingdon, UK) 
and IL-6, IL-10 and IFN-γ (Sanquin, Amsterdam, the Netherlands) were measured in cell 
culture supernatants using enzyme-linked immuno sorbent assay (ELISA), according 
to the instructions of the manufacturer. IL-2, IL-4 and IL-12p70 were measured by 
using Luminex technology, according to instructions of the manufacturer (BioRad, 
Veenendaal, the Netherlands).
RT-PCR
Two million freshly isolated PBMC were incubated with the various stimuli. After 
24 hours of incubation at 37°C, total RNA was extracted in 800 μl of TRIzol reagent 
(Invitrogen, Breda, the Netherlands). Isolated RNA was being reverse transcribed into 
complementary DNA using oligo(dT) primers and MMLV reverse transcriptase. PCR was 
performed using a 7300 realtime PCR system (Applied biosystems, Lennik, Belgium). 
Primer sequences for human RORγT: sense: 5’- TGA-GAA-GGA-CAG-GGA-GCC-AA-3’ 
and antisense: 5’- CCA-CAG-ATT-TTG-CAA-GGG-ATC-A-3’. B2M was used as a reference 
gene, for which the primers were: 5- ATG-AGT-ATG-CCT-GCC-GTG-TG-3 (forward) and 
5-CCA-AAT-GCG-GCA-TCT-TCA-AAC-3 (reverse). PCR conditions were as follows: 2 
minutes at 50°C and 10 minutes at 95°C, followed by 40 cycles of PCR reaction at 95°C 
for 15, and 60°C for 1 minute.
FACS
One million freshly isolated PBMC were stimulated for 7 days with heat-killed 
Candida albicans, in the presence of 10% human pool serum, and in the absence of 
presence of NSAIDs. After 7 days the supernatant was removed and replaced with 
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RPMI with Golgiplug (555029, BD Biosciences, Breda, the Netherlands), PMA (50 ng/
mL) (P8139, Sigma-Aldrich) and ionomycin (1 μg/mL) (I0634, Sigma Aldrich) for 4 
hours. After that, the cells were labeled with anti-CD4-APC (555349, BD Biosciences) 
according to instructions of the manufacturer. Accordingly, Fix & Perm (GAS001S-100 
and GAS002S-100, Invitrogen) were used so the cells could be stained intracellularly 
with anti-IL17-FITC (11-7179-82, Ebioscience, Frankfurt, Germany). The cells were 
resuspended in 200 μL 1% BSA and fluorescence was measured on a Cytomics FC500 
FACS machine (Beckmann Coulter, Woerden, the Netherlands). Gates were drawn to 
determine the percentage of IL-17 producing CD4+ lymphocytes.
siRNA transfection
PBMCs were transfected by electroporation with the Amaxa Human Monocyte 
Nucleofector kit (Lonza, Cologne, Germany) in accordance with the manufacturer’s 
instructions. In brief, PBMCs (2x107) were harvested and resuspended in 100 µl of 
nucleofector solution. After addition of mannose receptor (MR) siRNA (Dharmacon, 
Epson, UK, 011730) or control GFP siRNA (VSC-1001, Lonza) at final concentration 
of 125 nM, cells were electroporated with Amaxa program Y-001 and recovered for 
24 hours before further stimulation. Both MR expression on the cell surface and mRNA 
expression for MR were decreased after MR siRNA transfection compared to GFP siRNA 
transfection (data not shown).
Statistical analysis
Experiments were performed in duplicate, and supernatants were pooled. The 
differences between groups were analyzed using the Wilcoxon signed rank test. The 
level of significance between groups was set on p < 0.05. Data are presented as mean 
± SEM, unless stated otherwise.
RESULTS 
Candida albicans-induced IL-17 and IL-22 is dependent on PGE
2
To determine whether C. albicans could induce PGE2 production, PBMCs from 8 healthy 
volunteers were stimulated for 48 hours with C. albicans blastoconidia. Stimulation 
of C. albicans resulted in PGE2 production by PBMCs (Figure 1A). In addition, when 
PBMCs were stimulated with C. albicans in the presence of the prostaglandin inhibitor 
diclofenac, the PGE2 production was completely blocked (Figure 1A). To investigate if 
the Th17 reponse induced by C.albicans is PGE2 dependent, PBMCs were stimulated for 
7 days with C. albicans or beads coated with αCD3αCD28, in the absence or presence 
of diclofenac. Both IL-17 and IL-22 were produced upon stimulation with C. albicans, 
and both cytokines were lower when PCMCs were cultured in the presence of 
diclofenac (Figure 1B). Mitogenic T cell stimulation with αCD3αCD28 beads resulted 
in IL-17 production, but not IL-22 production. The IL-17 induced production by beads 
was not influenced by PGE2 inhibition (Figure 1B). In addition, RORγT mRNA expression 
was decreased in the presence of an NSAID in the system (Figure 1C). To indicate the 
source of IL-17 production, FACS analysis was performed on CD4 and intracellular 
IL-17. It appeared that IL-17 was exclusively produced by CD4+ cells. Furthermore, the 
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Figure 1. Candida albicans-induced IL-17 and IL-22 is dependent on PGE
2
(A) Human PBMCs were stimulated for 48 hours, in the presence of human serum, with RPMI or 
C. albicans (1x106/mL) and in the absence or presence of NSAIDs (n=11). (B) Human PBMCs were 
cultured with human serum for 7 days with RPMI, C. albicans or αCD3αCD28 beads (2.5*105/
mL), in the presence or absence of NSAIDs. Production of IL-17 (n=20) and IL-22 (n=7) in the 
supernatants was measured by ELISA. (C) qPCR of RORgt mRNA expression in human PBMCs that 
were stimulated for 24 hours, in the presence of human serum, with RPMI or C. albicans and in 
the absence or presence of NSAIDs (n=5). (D) Human PBMC were stimulated for 7 days with C. 
albicans, in the presence of human serum, in the absence or presence of NSAIDs. Expression of 
CD4 and intracellular IL-17 were determined with FACS analysis. Figure is representative for 4 
healthy volunteers from 2 different experiments. (E) Human PBMCs were stimulated for 7 days, in 
the presence of human serum, with C. albicans (grey bars) in the absence or presence of NSAIDs 
and in the absence or presence of PGE2 (10 mM), butaprost (10 μM) or misoprostol (35 μM) (n=3). 
Cytokines and PGE2 were measured by ELISA. (A-C) Data are pooled and expressed as mean ± SEM. 
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percentage of IL-17 producing CD4+ cells decreased when cells were cultured in the 
presence of NSAID’s (Figure 1D). To assess whether the decrease in IL-17 production 
caused by the NSAIDs was due to the absence of PGE2, we added exogenous PGE2 to 
assess whether this could restore IL-17 production. Adding PGE2 to the cell culture 
partially restored IL-17 production (Figure 1E). Also butaprost, which is a selective EP2 
receptor agonist, and misoprostol, a non selective-agonist with the highest affinity for 
the EP4 and EP3 receptor, restored the NSAID-inhibited IL-17 production (Figure 1E). 
PBMCs in the presence of PGE2, butaprost or misoprostol alone did not produce IL-17 
(data not shown).
C. albicans mannan is the only fungal component that directly induces PGE
2
 production
To elucidate which fungal components were responsible for the PGE2 production 
induced by C. albicans, PBMCs were cultured with RPMI, mannan, β-glucan or curdlan, 
or chitin and PGE2 production was measured in cell culture supernatants. Interestingly, 
C. albicans mannan was the only component able to induce PGE2 production (Figure 
2A). In line with this, when the transcription of the MR was inhibited using siRNA, PGE2 
production decreased (Figure 2B). β-glucan and curdlan alone were not able to induce 
PGE2.  Also, the TLR2 ligand Pam3Cys alone was not able to induce PGE2 production. 
However, β-glucan and curdlan were able to synergize with the TLR2 ligand Pam3Cys 
and induce PGE2 production (Figure 2C).
Figure 2. C. albicans mannan is the only fungal component that directly induces PGE
2
 production
(A) Human PBMCs were stimulated for 48 hours in presence of human serum with RPMI, mannan 
(10 μg/mL), β-glucan (10 μg/mL), chitin (20 μg/mL), curdlan (10 μg/mL). (n=4) (B) PGE
2
 production in 
cells from two healthy volunteers transfected with control siRNA (GFP) or MR siRNA and stimulated 
with RPMI or C. albicans. (C) Human PBMCs were stimulated for 48 hours in presence of human serum 
with RPMI, mannan, β-glucan or curdlan, in the absence or presence of Pam3Cys (n=6). Production of 
PGE
2
 in the supernatants was measured using ELISA. Data are pooled and expressed as mean ± SEM.
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Prostaglandin E
2
 skewes the cytokine profile favoring a Th17 response
To determine the effects of prostaglandins on the cytokine profile induced by C. 
albicans, we stimulated human PBMCs with C. albicans in the presence or absence 
of the prostaglandin inhibitor diclofenac. Strikingly,  IL-6 and IL-23 decreased when 
PBMCs were preincubated with diclofenac. In addition, IL-10 decreased when PGE2 was 
blocked, while TNF-α increased (Figure 3). IL-1β was not affected by inhibition of PGE2 
production.
Figure 3. Prostaglandin E
2
 skewes the cytokine profile favoring Th17 response
Human PBMCs were stimulated for 24 or 48 hours with RPMI or C. albicans, in the 
presence or absence of diclofenac. IL-1β, IL-6, IL-23, TNF-α, IL2, IL4 and IL-12p70 (24 
hours stimulations), IL-10 and IFN-γ (48 hours stimulations) were measured in the 
supernatants by ELISA or Luminex (n=6). Data are pooled and expressed as mean ± SEM.
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DISCUSSION
In the present study we provide evidence for an important role of PGE2 in the Candida 
induced Th17 response. PGE2 contributes to the Candida-induced Th17 response 
by inducing the Th17 polarizing cytokines IL-6 and IL-23. Furthermore, the fungal 
components mannan and β-glucan were shown to be responsible for the induction of 
PGE2 production. 
 In line with previous studies, we show that C. albicans is capable of inducing 
a strong PGE2 production in human PBMCs 
23. A notable difference is that most studies 
used viable C. albicans. It has been reported that live C. albicans can produce PGE2 
24,25, 
this is why we used heat-killed C. albicans to investigate the induction and functional 
role of PGE2 produced by the host. Boniface et.al. found that PGE2 is necessary for 
the production of IL-17 in the presence of APCs, and that PGE2 directly promotes 
differentiation and proinflammatory functions of Th17 cells, while differentially 
regulating IFN-γ production 15. In line with this, we found that blocking PGE2 production 
resulted in reduced RORγT mRNA expression, IL-17 and IL-22 production, and increased 
TNF-α production. This indicates that PGE2 favours a Th17 response. In line with these 
findings, the addition of PGE2 partially restored the IL-17 production. Furthermore, 
PGE2 signals through the EP2 and EP4 receptors and both receptors are important 
for mediating Th17 responses 15,26,27. Our observations suggest that PGE2 induced by 
Candida also signals through the EP2 and EP4 receptor, since stimulation of these 
receptors in the absence of PGE2 partially, and sometimes completely, restored the 
Candida-induced Th17 response. These data further support the concept that the Th17 
response induced by C. albicans is dependent on the PGE2 signaling pathway. 
 However, although in certain conditions the PGE2 release is completely 
blocked, the production of IL-17 and IL-22 is not completely inhibited. This indicates 
that other mechanisms contribute to the fungal-induced Th17 responses. Importantly, 
blocking PGE2 did not effect IL-1β, and there was still IL-6 and IL-23 production. Since 
IL-1β is essential for the early development of the Th17 response, the IL-1 pathway is 
most likely responsible for the IL-17 production present in the absennce of PGE2. In 
addition, NSAIDs are not associated with mucosal candidiasis, while a defect in the 
Th17 response has been linked to mucosal candidiasis 28,29. The residual production 
of IL-17 is thus most likely to be sufficient to maintain adequate host defense against 
mucosal candidiasis when NSAIDs are used.
 In a subsequent set of experiments, we tried to elucidate which pathogen 
recognition receptors were involved and which components of C. albicans were 
responsible for the induction of PGE2. Mannans were the only fungal components 
that were able to directly induce PGE2 production. We have previously reported 
that mannan from C. albicans was also the only component capable of inducing IL-17 
production 17. Furthermore, blocking of the MR with siRNA lead to inhibition of PGE2 
production, suggesting that the MR receptor plays an important role in the induction 
of PGE2 production by PBMCs. This is supported by the previous observation that 
overexpression of the MR in HeLa cells which are challenged with mannan results 
in a significant induction of COX-2 expression 30. Another C-type lectin, the β-glucan 
receptor dectin-1, also plays an important role in anti-Candida host defense, and 
prostaglandin production can be enhanced by overexpressing dectin-1 in a mouse 
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macrophage cell line 31. However, β-glucans alone did not stimulate PGE2 production 
31. In line with the known and previously reported synergism of dectin-1 and TLR2 32,33, 
β-glucans strongly increased the production of PGE2 induced by TLR2. Furthermore, 
dectin-1 and TLR2 have also been linked to the induction of the Th17 response 17. In 
contrast, we previously found that β-glucans or curdlan did not augment the mannan 
induced IL-17 response 17. Therefore, β-glucans contribute through the dectin-1/TLR2 
pathway to the Candida specific Th17 response by inducing the production of PGE2 by 
the host.
 To understand how PGE2 polarizes the immune response towards a Th17 
profile, we investigated the changes in cytokine profiles when PGE2 production was 
inhibited. PGE2 is known to have a potent IL-6 inducing effect on monocytes 
34. We 
observed that blocking of PGE2 by diclofenac reduced the production of IL-6 induced by 
Candida. IL-6 has been reported to be essential for the induction of Th17 memory cells 
in humans 35. This suggests that skewing of PGE2 towards a Th17 response is dependent 
on IL-6. When PGE2 production was blocked, the induction of IL-23 by Candida was 
also lower. The role of IL-23 in the Th17 response has been well established and it 
is now generally accepted that it IL-23 is needed to maintain the Th17 response 10,36. 
Furthermore, it has been suggested in an experimental inflammatory bowel disease 
model that the proinflammatory effects of PGE2 are due to the induction of dendritic 
cells derived IL-23 that subsequently supports the Th17 response 13. Interestingly, we 
found no effect on IL-1β when we blocked PGE2 production. Since IL-1β is one of the 
most important cytokines in the induction of an early Th17 response 9, it is therefore 
notable that PGE2 does not induce the Th17 response directly through IL-1β. We found 
an increase of TNF-α when PGE2 was inhibited, which is in line with the literature, 
which has reported that PGE2 inhibits TNF-α 
37. However, the exact role of TNF-α in the 
Th17 response is not clear and still has to be elucidated 38. Finally, we found that IL-10 
production was also lower in the presence of a PGE2 inhibitor. Veldhoen et al. already 
speculated that IL-10 production, that suppresses IL-12, might aid the development of 
IL-17 producing T cells, and subsequently reported that anti-IL-10 caused a reduction 
in the proportion of T-cells that were able to produce IL-17 39. Therefore, the loss of 
the suppressive effects of IL-10 could be a possible explanation for the observed lower 
IL-17 production when PGE2 production was blocked. This would ultimately result in a 
stronger Th1 response that is able to subvert the Th17 response.
 In conclusion, prostaglandins were shown to play an important role in the 
Candida albicans induced Th17 response. PGE2 production induced by C. albicans 
skewes the cytokine profile towards a Th17 response, by decreasing IL-6, IL-23, IL-17 
and IL-22. Interestingly, C. albicans mannan, which is the main inducer of the Th17 
response in C. albicans, was also the only fungal component that was able to directly 
induce PGE2. Furthermore, dectin-1, the other major pathway important for the the 
induction of  a Th17 response, was shown to act synergistically on the TLR2 induced 
PGE2 production. These data provide evidence that the Th17 response induced by the 
MR and dectin-1/TLR2 is enhanced by prostaglandins, which in turn skew the cytokine 
profile favoring Th17 polarization.
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AbSTRACT
 
Autophagy has been demonstrated to play an important role in the immunity against 
intracellular pathogens, but very little is known about its role in the host defense 
against fungal pathogens such as Candida albicans. Therefore, the role of autophagy 
for the host defense against C. albicans was assessed by complementary approaches 
using mice defective in autophagy, as well as immunological and genetic studies in 
humans. Although C. albicans induced microtubule-associated protein 1 light chain 3 
(LC3)-II formation in macrophages, myeloid-cell specific ATG7-/- mice with defects in 
autophagy did not display an increased susceptibility to disseminated candidiasis. In 
in vitro experiments in human peripheral blood mononuclear cells (PBMCs), blocking 
autophagy modulated cytokine production induced by lipopolysaccharide, but not by 
C. albicans. Furthermore, autophagy modulation in human monocytes did not influence 
the phagocytosis and killing of C. albicans. Finally, 18 single-nucleotide polymorphisms 
(SNPs) in 13 autophagy genes were not associated with susceptibility to candidemia, or 
clinical outcome of disease in a large cohort of patients, and there was no correlation 
between these genetic variants and cytokine production in either candidemia patients 
or healthy controls. Based on these complementary in vitro and in vivo studies, it can 
be concluded that autophagy is redundant for the host response against systemic 
infections with C. albicans.
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INTRODUCTION
Candida albicans is a commensal fungus that colonizes the gastrointestinal tract, skin, 
and mucosa of more than 50% of healthy individuals. Candida colonization does not 
cause disease in healthy individuals, but in patients in whom the immune system is 
compromised Candida can cause both mucosal and systemic disease, the latter with a 
mortality rate reaching up to 30-40% 1. C. albicans is recognized by the innate immune 
system through pathogen recognition receptors (PRRs) such as C-type lectin receptors 
or Toll-like receptors (TLRs) that interact with pathogen-associated molecular patterns 
on the Candida cell wall. Candida mannans are recognized by the macrophage 
mannose receptor and Dectin-2 2,3, Dectin-1 recognizes β-glucan 4, while DC-SIGN 
(CD209) recognizes fucose and mannose/mannan residues 5. Furthermore, TLRs such 
as TLR2 6 and TLR4 7 also play an important role in the recognition of C. albicans. These 
interactions between C. albicans and the immune system lead to phagocytosis of the 
fungus 8, and the induction of proinflammatory cytokines, further promoting clearance 
of the infection 9.
 In addition to these well-known effects of PRR engagement, recent studies 
have shown that TLRs can also engage autophagy proteins 10, and this in turn modulates 
the inflammatory reaction against pathogens 11-13. Autophagy is a process essential for 
cell survival that allows the cell to efficiently regulate its biomass via degradation of 
individual proteins (chaperone-mediated autophagy), cytosolic content, and whole 
cell organelles (macro-autophagy) 14. Autophagy is characterized by the formation of a 
double membrane vesicle, the autophagosome, which engulfs the cytosolic content to 
be degraded 15. Subsequent fusion of the autophagosome with the lysosome and the 
breakdown of the inner membrane expose the content to hydrolases.
 In addition to its role in cell homeostasis, autophagy has also been linked 
to the host-defence against viruses 16, and to the processing of invading pathogens 
(xenophagy) 17,18. Inactivation of autophagy genes increases replication of intracellular 
pathogens: Singh et al. demonstrated that in mice, IRGM induces autophagy to 
eliminate intracellular Mycobacterium tuberculosis 19; Zhao et al. demonstrated that 
ATG5-/- mice have decreased resistance to the intracellular bacterium L. monocytogenes 
and the protozoan T. gondii 20. Interestingly, ATG5 and ATG10 have been implicated in 
the defense against fungi in plants 21.
 Little is known about whether autophagy is also involved in the immune 
response against fungal infections in mammals. Since several of the PRRs involved in 
the recognition of C. albicans have been demonstrated to induce autophagy, such as 
recruitment of the autophagosome marker LC3-II by TLR2 and TLR4 10,22, it is rational 
to hypothesize that autophagy might play an important role in the anti-Candida host 
immune response. In this study the role of autophagy in the immune response against 
C. albicans was investigated using mouse knockout models, as well as human genetic 
association studies and in vitro experiments. We could not identify a major role for 
autophagy in anti-Candida host defense.
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MATERIALS AND METHODS
Study population
To investigate the correlation between autophagy and candidemia, 338 adult 
candidemia patients (positive blood culture) and 351 healthy controls were enrolled 
in a study between January 2003 and January 2009 23. The candidemia study was 
approved by the Institutional Review Boards from the Duke University Hospital 
(Durham, North Carolina, USA) and the Radboud University Nijmegen Medical Center 
(Nijmegen, The Netherlands). Participants were included after giving written informed 
consent, with the exception of patients who were no longer hospitalized or died before 
a positive blood culture report was made. To investigate the link between autophagy 
and cytokine production, 67 healthy individuals donated blood. The age ranged from 
23-73 years and 77% was male. Blood was collected by venipuncture into 10 mL EDTA 
syringes (Monoject, s-Hertogenbosch, The Netherlands). The study with the healthy 
blood-donors was approved by the Ethical Committee of the Radboud University 
Nijmegen Medical Center (Nijmegen, The Netherlands). Participants were included 
after giving written informed consent. The studies were performed in accordance with 
the declaration of Helsinki.
Mice
The LysM-Cre+ or LysMCre−ATG7flox/flox GFP-LC3+ (the conditional ATG7flox/flox mice is a kind 
gift from Masaaki Komatsu, Tokyo Metropolitan Institute of Medical Science, Tokyo) 
was described previously (kindly provided by Douglas R. Green, St. Jude Children’s 
Research Hospital, Memphis, TN). All mice were housed in a pathogen-free facility. The 
animal study was approved by the Animal Care and Use Committee from the St. Jude 
Children’s Research Hospital (protocol 482-100097-10/11). The study was performed in 
accordance with the guidelines set by the National Institutes of Health (NIH Publication 
No. 85-23, revised 1996).
Microorganism
Candida yeast (American type culture collection MYA-3573 (UC820)), a strain well 
described elsewhere 24, were grown overnight in Sabouraud broth at 37°C. Cells were 
harvested by centrifugation, washed twice, and resuspended in culture medium. C. 
albicans yeasts or hyphae were heat-killed for one hour at 100 °C.
Macrophage differentiation, stimulation and western blotting
Bone marrow-derived macrophages (BMDMs) were differentiated from the total cells 
isolated from the femurs of 6- to 10-week-old mice using supernatant from L929 cells as 
differentiation medium. BMDMs in 12-well culture plates (5×105/well) were stimulated 
with various Candida ligands (Live or heat-killed (HK) Candida yeast, live or HK Candida 
hyphae (moi 5)) for 8hrs. The cells were lysed in RIPA lysis buffer supplemented with 
complete protease inhibitor (Roche) and PhosSTOP (Roche). The cell lysates were 
separated on 15% SDS-PAGE and transferred to PVDF membranes. Membranes were 
blocked in 5% non-fat milk and incubated overnight with primary antibody at 4 °C and 
for 45 min with secondary HRP-tagged antibody at room temperature. The membranes 
were developed with SuperSignal West Femto Chemiluminescent Substrate (Pierce).
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Candida albicans infection model
The WT (LysM-Cre− ATG7f/f GFP-LC3+) and ATG7−/− (LysM-Cre+ ATG7f/f GFP-LC3+) mice 
were injected intravenously with the inoculum of C. albicans blastoconidia (1×106 CFU/
mouse) in a 100 μL volume of sterile pyrogen-free phosphate-buffered saline (PBS). 
Survival was assessed daily for 30 days. For assessing fungal burden, subgroups of 
5-10 mice were humanely terminated on days 3 or 7 of infection. To measure the 
fungal burden, the kidneys of the sacrificed animals were removed aseptically and 
homogenized in sterile phosphate buffered saline (PBS) using a tissue grinder. The CFUs 
of the viable Candida from the kidney homogenates were measured by plating serial 
dilutions on Sabouraud dextrose agar plates (50μg/ml of gentamycin) as described 
previously.
Fluorescence Microscopy
HeLa cells were transfected with a plasmid containing GFP-LC3 (kindly provided 
by Dr. T Yoshimori, Osaka, Japan) using the transfection medium Fugene 6 (Roche) 
according to the manufacturer’s instructions. GFP-LC3+ HeLa cells were grown and 
stimulated on coverslips (19-mm diameter) in 12-well plates. Cells were fixed with 2% 
paraformaldehyde for 15 minutes at room temperature and permeabilized for 10 min 
with cold methanol (100%). After washing with PBS (×3), the coverslips were mounted 
onto glass slides with Vectashield +DAPI and analyzed on a fluorescence microscope.
Phagocytosis and killing assays
Phagocytosis and killing was performed as described previously 24,25. In short, 5·105 
PBMCs (in a volume of 100 μl) were put in a flat-bottom well. The plate was incubated 
at 37 °C for one hour, to allow the monocytes to adhere to the plastic surface, in the 
absence or presence of 3MA (10 mM). Thereafter, the supernatant was removed, 
and the monolayer was rinsed with modified Eagle’s medium (MEM). 200 μL of live 
C. albicans (5×104/ml) in MEM, 2.5% serum was added, and the plate was incubated 
for 15 minutes to allow phagocytosis of the yeast. The supernatant was removed, and 
the monolayer was rinsed with MEM. 200 μl of MEM/Sabouraud was added to the 
monolayer after which the plate was incubated at 37°C for 2 hours and 45 minutes to 
allow intracellular killing of the yeast. After this incubation period, the monocytes were 
lysed. Both the supernatants with non-phagocytosed Candida and the lysed monocyte 
suspension with non-killed Candida were directly plated in duplicate in two different 
dilutions on agar plates. These plates were cultured for 24 hours, after which the 
number of colonies was counted. The percentage of phagocytosed and killed Candida 
was calculated.
PbMC isolation
Separation and stimulation of PBMCs was performed as described previously 26. Briefly, 
the PBMC fraction was obtained by density centrifugation of diluted blood (1 part blood 
to 1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). 
PBMCs were washed twice in saline and suspended in culture medium. The cells were 
counted in a Coulter counter (Coulter Electronics, Buckinghamshire, England) and their 
number was adjusted to 5×106/mL.
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Cell stimulation
A total of 5x105 human PBMCs in a 100 ml volume of RPMI was added to round-bottom 
96-wells plates (Greiner). Cells were stimulated with live C. albicans UC820 (1x104/mL) 
or E. coli derived LPS (E. coli O55:B5 LPS, Sigma Chemical Co), in the absence or presence 
of 3MA (Sigma). After 24 hours supernatants were stored at -20°C. IL-1β, IL-8 and IL-10 
was measured in cell culture supernatants using enzyme-linked immunosorbent assay 
(ELISA) (R&D Systems, MN, USA and Sanquin, Amsterdam, The Netherlands).
Autophagy gene SNP genotyping
Genomic DNA was isolated from EDTA blood of patients, matched controls and a cohort 
of healthy volunteers using standard methods, and 5 ng of DNA was used for genotyping. 
We selected 18 SNPs from 13 autophagy-related genes (Table 1). Multiplex assays 
were designed using Mass ARRAY Designer Software (Sequenom) and genotypes were 
determined using Sequenom MALDI-TOF MS according to manufacturer’s instructions 
(Sequenom Inc., San Diego, CA, USA). Briefly, the SNP region was amplified by a 
locus-specific PCR reaction. After amplification a single base extension from a primer 
adjacent to the SNP was performed to introduce mass differences between alleles. 
This was followed by salt removal and product spotting onto a target chip with 384 
patches containing matrix. MALDI-TOF MS was then used to detect mass differences 
and genotypes were assigned in real-time using Typer 4 software (Sequenom Inc. 
San Diego, CA, USA). As quality control, 5% of samples were genotyped in duplicate 
and each 384-well plate also contained at least 8 positive and 8 negative controls, no 
inconsistencies were observed. DNA samples of which SNPs failed were excluded from 
analyses. Variants with call-rates below 90% were also excluded from further analyses 
(n = 0).
Statistics
Data were analyzed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) and SAS (version 
9.3, SAS Institute, Cary, NC, USA). All statistical analyses were 2-sided and p < 0.05 was 
considered to be statistically significant (*). The survival was analyzed using the Log-
rank Mantel-Cox test, and the CFUs were analyzed with the Student’s t-test. Differences 
in cytokine production were analyzed using the Wilcoxon signed rank test. The Hardy-
Weinberg equilibrium (HWE) was checked for each SNP using the program HWE 
Version 1.10 (Rockefeller University, New York). The associations between autophagy 
SNPs and candidemia susceptibility and clinical outcome of disease (30-day survival, 
persistent disease and disseminated disease) were assessed using the Chi-squared test 
or Fisher’s Exact Test as appropriate. With application of the Bonferroni correction for 
multiple testing, p < 0.003 and p < 0.001 were considered to be statistically significant, 
respectively.
RESULTS
Candida albicans induces LC3-II shift in mouse bMDMs
Two forms of LC3 exist; LC3-I is located in the cytoplasm while LC3-II is a processed 
form of LC3, which is associated with the (auto)phagosome membrane. Mouse BMDMs 
73
5
Autophagy
were stimulated with live and HK C. albicans yeasts and hyphae. LC3-I and LC3-II were 
measured using Western blot. All forms, except HK C. albicans yeasts, induced a strong 
up-regulation of LC3-II expression (Figure 1). 
ATG7 is redundant for host defense against systemic Candida albicans infection
Because C. albicans induced autophagy in murine macrophages, we studied the effects 
of autophagy deficiency in myeloid cells on the outcome of systemic candidiasis. 
Although ATG7-/- KO mice appeared to have a slightly lower survival rate compared to 
WT mice, the difference was small and did not reach statistical significance (Figure 2A). 
Furthermore, there were no differences in the fungal burdens in the kidneys, the target 
organ of disseminated candidiasis, 3 or 7 days after C. albicans infection of wild-type or 
autophagy-defective mice (Figure 2B).
Candida albicans induces LC3-II shift in HeLa cells
Although autophagy does not seem to have a major impact on the outcome of 
murine candidiasis, different effects may be seen in humans. To investigate whether 
autophagy is induced upon Candida stimulation in human cells, we transfected HeLa 
cells with GFP-LC3 and stimulated them with HK C. albicans yeast. LC3-II was analyzed 
using immunofluorescence microscopy. HK C. albicans yeasts induced a strong up-
regulation of LC3-II expression, demonstrating induction of autophagy (Figure 3A). The 
induction of LC3-II was reverted in the presence of the autophagy inhibitors 3MA and 
wortmannin (Figure 3B,C) 
Figure 1. Candida albicans induces LC3-II in mouse bone BMDMs
Mouse BMDMs were stimulated with live and HK Candida albicans yeasts and hyphae. 
LC3-II was measured using Western blot (UT = unstimulated, +ve control = positive control).
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Figure 2. No difference in survival between wild-type (WT) and ATG7-/- mice
(A) 13 WT (white) and 14 ATG7-/- (black) mice were injected with live Candida albicans at day 1. 
Survival was monitored for 30 days. The survival was analyzed using the Log-rank Mantel-Cox test. 
(B) After 3 and 7 days of infection, colony forming units (CFUs) were counted in the kidneys (n=7 
mice/group n day 3, and n=9 mice/group on day 7). The CFUs were analyzed with the Student’s t-test.
Figure 3. Candida-induced LC3-II in GFP-LC3 transfected HeLa cells
(A) Fluorescence microscopy image (40x) showing LC3-II induction upon HK C. albicans 
stimulation in GFP-LC3 transfected HeLa cells. In the presence of the autophagy inhibitors (B) 
3MA and (C) wortmannin, LC3-II is no longer induced, demonstrating the specificity of the assay.
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Inhibition of autophagy does not influence the phagocytosis and killing capacity of 
monocytes, or their cytokine production upon stimulation with C. albicans
In the next set of experiments, we investigated the importance of autophagy for the 
human anti-Candida host response. Firstly, we investigated whether autophagy is 
important for the phagocytosis and killing of live C. albicans by human monocytes. 
Freshly isolated human primary monocytes were stimulated with live C. albicans in the 
absence or presence of 3MA. Blocking autophagy with 3MA did not affect the capacity 
of human monocytes to phagocytose and kill C. albicans (Figure 4A).
 In a subsequent set of experiments, human PBMCs were stimulated with live 
C. albicans or E. coli-derived lipopolysaccharide (LPS), in the absence or presence of the 
autophagy inhibitor 3MA. While 3MA strongly increased LPS-induced IL-1β production, 
the increase in IL-1β production in C. albicans stimulated cells was more modest and 
did not reach statistical significance (Figure 4B). Stimulation of other proinflammatory 
cytokines such as TNF-α and IL-6 by C. albicans was not influenced by the modulation 
of autophagy (not shown).
SNPs in autophagy genes are not associated with candidemia 
In order to further assess the importance of autophagy in the anti-Candida host 
defense in humans, we investigated whether polymorphisms in autophagy genes were 
correlated to susceptibility with systemic candidiasis. Although 18 SNPs in 13 different 
autophagy genes were studied, chosen based on their likelihood to influence the 
autophagy process, none of them were significantly associated with susceptibility to 
disseminated candidiasis (Table 1). Furthermore, none of the 18 SNPs studied were 
correlated with circulating cytokine concentrations in patients with candidemia or 
clinical outcome of disease (data not shown).
Figure 4. Blocking autophagy does not inhibit the phagocytosis and killing capacity of human 
monocytes nor the C. albicans-induced cytokine response
(A) Freshly isolated monocytes were stimulated with live C. albicans. The amount of phagocytosed 
and killed Candida was determined after 15 minutes and 3 hours, respectively. Bars represent mean 
± SEM of 4 healthy volunteers. (B) Human PBMC were stimulated for 24 hours with live C. albicans or 
E. coli derived LPS, in the absence or presence of 3MA. The concentration of IL-1β was measured in cell 
culture supernatants using ELISA. Bars represent mean ± SEM of 19 healthy volunteers. Differences 
in cytokine production were analyzed using the Wilcoxon signed rank test (*** = p < 0.001).
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Table 1. SNPs in autophagy genes are not correlated with susceptibility to candidemia
Gene SNP
(AA change)
Genotype Matched 
controls n (%)
Patients n 
(%)
Χ2 p
ATG10 rs1864183 GG 92 (39) 109 (40) 0,561 0,755
(Thr → Met) GA 103 (43) 111 (41)
AA 42 (18) 54 (20)
rs3734114 TT 156 (66) 191 (69) 1,521 0,467
(Pro → Ser) TC 71 (30) 79 (29)
CC 8 (3) 5 (2)
ATG16L1 rs2241880 TT 77 (32) 86 (31) 0,743 0,69
(Thr → Ala) TC 107 (45) 134 (49)
CC 53 (22) 55 (20)
ATG16L2 rs11235604
(Arg → Trp)
CC 237 (100) 275 (100) - -
ATG2A rs77228473
(Glu → Asp)
CC 237 (100) 275 (100) - -
rs77833427 CC 234 (99) 273 (99) 0,024 0,878
(Arg → His) CT 2 (1) 2 (1)
ATG2B rs3759601 CC 93 (39) 127 (46) 2,795 0,247
(Gin → Glu) CG 105 (44) 112 (41)
GG 39 (16) 36 (13)
rs74719094 TT 237 (100) 272 (99) 2,601 0,107
(Arg → Ser) TG 0 (0) 3 (1)
rs9323945 CC 228 (98) 270 (99) 0,886 0,347
(Asn → Asp) CT 5 (2) 3 (1)
ATG5 rs2245214 GG 39 (18) 40 (19) 0,74 0,691
(Intron) GC 104 (49) 93 (45)
CC 70 (33) 75 (36)
ATG9B rs61733329 CC 237 (100) 273 (99) 1,73 0,188
(Gly → Ser) CT 0 (0) 2 (1)
EREG rs34477425 AA 237 (100) 275 (100) - -
(Arg → Gly) GG 8 (3) 9 (3)
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SNPs in autophagy genes do not correlate with Candida induced cytokine production
Finally, we investigated whether the same SNPs in autophagy genes influenced 
Candida-induced cytokine production in PBMCs isolated from healthy volunteers. 
There were no statistically significant associations between the autophagy genotypes 
and Candida-induced cytokine production. A small number of these SNPs showed a 
tendency to influence cytokine production, but the associations were not statistically 
significant (Figure 5).
DISCUSSION
In this study we investigated the role of autophagy in the anti-Candida host immune 
response. Using complementary immunological and genetic approaches in both mice 
and humans, we show that autophagy is redundant for the systemic host defense 
against C. albicans.
 C. albicans is recognized by PRRs on the surface of the innate immune cells, and 
recent studies have shown that engagement of PRR receptors can induce autophagy. 
Huang et al. demonstrated that LC3-II is recruited to the phagosome upon zymosan 
IRGM rs4958847 AA 15 (6) 24 (9) 1,334 0,513
(Intron) AG 77 (32) 81 (30)
GG 145 (61) 168 (61)
rs72553867 CC 221 (93) 257 (93) 1,17 0,557
(Thr → Lys) CA 15 (6) 18 (7)
AA 1 (0) 0 (0)
LAMP1 rs9577229 CC 215 (96) 241 (91) 4,911 0,086
(Ala → Val) CT 9 (4) 24 (9)
TT 1 (0) 1 (0)
LAMP3 rs482912 AA 43 (18) 54 (20) 0,67 0,715
(Ile → Val) AG 94 (40) 114 (42)
GG 100 (42) 106 (39)
P2RX7 rs2393799 TT 48 (20) 48 (17) 0,664 0,717
(Upstream) TC 90 (38) 107 (39)
CC 99 (42) 120 (44)
WIPI1 rs883541 AA 153 (65) 176 (64) 0,004 0,998
(Thr → Ile) AG 76 (32) 88 (32)
GG 8 (3) 9 (3)
The association between autophagy SNPs and candidemia susceptibility was 
assessed using the Chi-squared test or Fisher’s Exact Test as appropriate.
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stimulation, through a Dectin-1-dependent pathway 27. Indeed, both C. albicans 
and the Dectin-1 ligand β-glucan induce LC3 lipidation 28. Furthermore, Nicola et al. 
demonstrated that also Cryptococcus neoformans can induce LC3 recruitment to the 
phagosome, although to a lesser extent than C. albicans 29. LC3 lipidation does not 
necessarily implicate autophagy activation, but could also be a sign of LC3-associated 
phagocytosis (LAP) 30. Here we confirm the LC3-inducing activity of C. albicans by 
demonstrating that Candida stimulation was able to induce LC3-II in mouse BMDMs. 
Altogether, these data demonstrate that fungi could induce the process of autophagy, 
and this prompted us to investigate its role in host defense against disseminated 
candidiasis.
 Surprisingly however, mice with a specific deletion of the autophagy gene 
ATG7 in their myeloid cells did not display an increased mortality due to disseminated 
candidiasis. Furthermore, there was no difference in the fungal burden in the kidneys 
between wild type and ATG7-/- mice. These data are paralleled by those of Nicola and 
colleagues who also failed to find any difference in the survival between wild-type and 
conditional ATG5-/- mice infected with C. neoformans 29. Although the authors reported 
that ATG5-/- mice die slightly sooner compared to wild-type mice upon infection with 
C. albicans, this difference was small (2 days), and they did not replicate this finding. 
Furthermore, the effect on Candida burdens in the kidneys was not reported 29. In 
short, although both Nicola et al. and we show that LC3-II can be induced upon fungal 
Figure 5. No significant correlation between cytokine production and genotype in healthy 
volunteers
PBMC of healthy volunteers were stimulated with HK C. albicans conidia for 24 hours. Cytokines 
were measured in cell culture supernatants using ELISA. Data are presented as mean 95% ± CI.
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stimulation, the absence of autophagy has no major effect in in vivo infection models.
 Because the immune system of mice can differ substantially from that of 
humans 31, we next investigated the potential role of autophagy in the immune 
response against C. albicans in humans. Similarly to what we have seen in mouse cells, 
we observed that LC3-II activation was induced upon Candida stimulation in the human 
HeLa cell line. Due to the fact that autophagy modulates inflammation induced by TLR 
ligands in human cells 32-34, we also tested whether anti-Candida immune responses are 
modulated by autophagy. Firstly, blocking autophagy with pharmacological inhibitors 
did not affect important aspects of the Candida-induced immune response, such as 
phagocytosis and killing of the fungus, or Candida induced-cytokine production. 
Of note, the inhibitors we used here are not completely specific. 3MA has been 
demonstrated to also be able to actually induce autophagy in some specific situations, 
and to influence cell survival through AKT1 35. Fortunately, similar results were obtained 
with 3MA and wortmannin. More importantly, Ma et al. previously demonstrated 
that the phagocytosis and killing of Candida albicans is unaffected in LC3β deficient 
mouse BMDCs 28. The same is true for Salmonella enterica, which can be recognized by 
autophagy machinery in the absence of LC3 recruitment 36.
 Secondly, the (mostly) non-synonymous SNPs in autophagy genes (ATG10, 
ATG16L1, ATG16L2, ATG2A, ATG2B, ATG5, ATG9B, EREG, IRGM, LAMP1, LAMP3, P2RX7 
and WIPI1) did not influence susceptibility to candidemia, nor did they influence serum 
cytokine levels in the patients, or clinical outcome of disease. While several of these 
SNPs have been demonstrated to be associated with immune function. For example, 
rs2241880 in ATG16L1 influences IL-1β and IL-6 production upon NOD2 stimulation 
34, and rs72553867 in IRGM has been associated with inflammatory bowel disease 37. 
The lack of association here could be explained by the fact that systemic candidiasis 
is a relatively rare disease with a population frequency of 6:100,000 38. However, the 
genetic association study presented here has been performed in the largest cohort 
available to date. With the current sample size we should be able to detect differences 
in proportions from 9% and higher with a power of 80% 39. So although we cannot 
fully exclude that these polymorphisms do influence susceptibility tot candidiasis, at 
least we can conclude that these effects, if existent, are very small. While several PRR 
and cytokine polymorphisms have been shown to be associated with susceptibility 
to candidemia 40,41, the fact that none of the autophagy SNPs is associated with an 
increased susceptibility or severity of candidemia is another argument for a redundant 
role of autophagy for the systemic anti-Candida host defense in humans. Thirdly, 
we have identified no correlation between genetic variants in autophagy genes and 
ex vivo cytokine production by PBMCs of healthy controls. In line with this, Ma et 
al. demonstrated that cytokine production was normal in LC3β deficient cells that 
completely lack functional autophagy 28.
 Despite these complementary data demonstrating that autophagy does not 
play a central role for the systemic host defense against Candida spp, we cannot exclude 
a role of autophagy in other anti-Candida host defense mechanisms, e.g. mucosal 
antifungal defense. In order to prevent lysosomal degradation, Candida actively 
stimulates the recycling of LAMP-1 from the phagosome 42, an important protein 
involved in chaperone mediated-autophagy 43. The C-type lectin receptor Dectin-1 is 
crucial for recognition of β-glucans from Candida 44,45, and defects in Dectin-1 have been 
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previously shown to be associated with mucosal and skin Candida infections, but not 
systemic candidiasis 23,46,47. While Dectin-1-dependent mechanisms induce autophagy 
27, interestingly, it has been also demonstrated that the autophagy protein Rubicon can 
bind CARD9, dampening the signaling downstream of Dectin-1 48. Furthermore, Ma et 
al. showed that recruitment of MHCII to the phagosome was reduced in LC3β deficient 
cells, demonstrating that autophagy-related proteins may play a role in enhancing 
antigen presentation and adaptive immune responses 28. Indeed, adaptive Th17 and 
Th1 responses are known to play an important role especially for mucosal antifungal 
infections, as demonstrated in STAT1 mutations and STAT3 deficiency syndromes 
characterized by defective Th17 responses and chronic mucocutaneous candidiasis 
49-51. Taking into consideration all this body of information, autophagy induction by 
Candida through Dectin-1-dependent mechanisms may play a role in the modulation of 
adaptive Th17 responses and mucosal antifungal defense, but this hypothesis remains 
to be demonstrated.
 In conclusion, although C. albicans can induce LC3-II both in mice and human 
cells, the consequences at the level of phagocytosis, killing and cytokine induction are 
limited, and autophagy is redundant for the host defense against systemic candidiasis. 
However, this does not exclude that autophagy could play a role in the mucosal 
anti-Candida immune response through antigen presentation and/or T-helper cell 
activation, and future studies are warranted to assess this possibility.
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AbSTRACT
Candida albicans is the most common human fungal pathogen causing mucosal and 
systemic infections. However, human antifungal immunity remains poorly defined. By 
integrating transcriptional analysis and functional genomics we identified Candida-
specific host defense mechanisms in humans. Candida induced significant (p<10-35) 
expression of genes from the type I interferon (IFN) pathway in human peripheral 
blood mononuclear cells. This unexpectedly prominent role of type I IFN pathway 
in anti-Candida host defense was supported by additional evidence. Polymorphisms 
in type I IFN genes modulated Candida-induced cytokine production and were 
correlated with susceptibility to systemic candidiasis. In in vitro experiments, type I 
IFNs skewed Candida-induced inflammation from a T helper (Th)17-response toward 
a Th1-response. Patients with chronic mucocutaneaous candidiasis (CMC) displayed 
defective expression of genes in the type I IFN pathway. These findings indicate that 
the type I IFN pathway is a main signature of Candida-induced inflammation and plays 
a crucial role in anti-Candida host defense in humans.
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INTRODUCTION
Candida albicans (C. albicans) is a commensal microorganism that inhabits human skin 
and mucosa. Candida can be isolated from up to 70% of the general population at any 
given moment, and it is believed that all individuals have been colonized with Candida 
at a some point 1. Although it is a commensal organism, C. albicans can also cause 
mucosal and systemic infections, especially in immunocompromised hosts 2. Despite 
the availability of novel classes of antifungal agents (e.g., azoles, echinocandins), 
mortality due to systemic candidiasis, the fourth most common form of sepsis3-5, 
reaches 37-44% 3,6,7. In addition, vaginal and oral candidiasis can also occur in healthy or 
only mildly immunocompromised individuals 8, with up to 5% of women in the general 
population suffering from recurrent vulvovaginal candidiasis 9.
 Despite the introduction of modern antifungal drugs and intensive care 
facilities, progress in improving the outcome of Candida infections in the last decade 
has been disappointing. Given this lack of progress, it is currently believed that only 
adjuvant immunotherapy will be able to further reduce the burden of morbidity 
and mortality caused by C. albicans infections 10. Understanding the host defense 
pathways involved in candidiasis is therefore crucial for identifying novel targets for 
immunotherapy. To date, all investigations aimed at identifying antifungal host defense 
mechanisms in humans have relied on candidate-target approaches that are based on 
biologic plausibility of hypotheses extracted from in vitro or animal studies. While this 
approach has been fruitful in confirming important pathways of antifungal defense, 
it has lacked the power to provide a hierarchy of the importance of these pathways, 
and to identify potentially novel and unexpected host defense mechanisms against 
Candida.
 In the present study, we have taken an alternative, unbiased approach to 
this biological problem. Using a combination of transcriptional analysis and systems 
biology, we have stimulated human primary cells with the fungus, identifying Candida-
specific transcription profiles in human immune cells. While C. albicans induced the 
transcription of multiple inflammatory gene sets commonly stimulated by other 
inflammatory stimuli, it also specifically induced several additional gene sets, among 
which we identified an unexpectedly strong type I IFN signature profile. We confirmed 
the importance of the type I IFN pathway for anti-Candida host defense in humans 
through immunological and genetic studies in both healthy volunteers and in patients 
with systemic candidiasis or suffering from CMC.
METHODS
Study populations
For assessing the transcriptome and the cytokine production capacity, blood was 
collected after written informed consent from healthy volunteers. Adult patients 
with candidemia were enrolled after informed consent (or waiver as approved by the 
Institutional Review Board) at the Duke University Hospital (DUMC, Durham, North 
Carolina, USA) and Radboud University Nijmegen Medical Centre (RUNMC, Nijmegen, 
The Netherlands). The study was approved by the Institutional Review Boards at each 
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study center, and enrollment occurred between January 2003 and January 2009 11. 
The study was performed in accordance with the declaration of Helsinki. In addition, 
blood was collected from two patients with CMC (on two different occasions) and eight 
healthy controls in order to investigate the induction of IFN genes by Candida. After 
informed consent was given, blood was collected by venipuncture into 10 ml EDTA 
syringes (Monoject, s-Hertogenbosch, The Netherlands).
PbMC isolation
Separation and stimulation of peripheral blood mononuclear cells (PBMCs) was 
performed as described previously 12. Briefly, the PBMC fraction was obtained by 
density centrifugation of diluted blood (1 part blood to 1 part pyrogen-free saline) 
over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). PBMCs were washed twice in 
saline and suspended in culture medium. The cells were counted in a hemocytometer 
and their number was adjusted to 5·106/mL.
Cell stimulation
For the transcriptome analysis, cells were stimulated for 4 or 24 hours with RPMI, heat-
killed (HK) Borrelia burgdorferi13, C. albicans (UC 820)(1×106/mL) 14, Mycobacterium 
tuberculosis (1 μg/mL) or E. coli-derived LPS (10 ηg/mL). In order to correlate cytokine 
production to SNPs in the type I IFN pathway, 5x105 PBMCs from healthy volunteers 
were stimulated with HK C. albicans (1×106/mL) for 24 hours. In order to investigate 
the effect of type I IFNs on cytokine production, 5x105 PBMCs were stimulated with HK 
C. albicans (1×106/mL) in the absence or presence of IFN-α2b (1×105 U/mL)(IntronA, SP 
Labo N.V., Heist-op-den-berg, Belgium), IFN-β (10 ng/mL), or anti-IFNAR (100 ηg/mL)
(21385-1, PBL Inferon Source, Piscataway, USA). To assess the development of Th1 and 
Th17 cells, a total of 1x106 mononuclear cells was added to 96-wells flat-bottom plates 
(Greiner). Subsequently, the monocytes within the PBMC pool were differentiated 
towards dendritic cells (DCs) by addition of IL-4 (50 ng/ml, R&D Systems), GM-CSF (50 
ng/ml, R&D Systems) and 10% human serum for seven days. After every second day, 
half of the medium was replaced by fresh DC differentiation medium. At day seven of 
the culture, cells were stimulated with 1x106 Candida conidia for another six days.
Transcriptome analysis 
Global gene expression was profiled using Illumina Human HT-12 Expression BeadChip 
according to manufacturer’s instructions. Image analysis, bead-level processing and 
quantile normalization of array data were performed using the Illumina LIMS platform, 
BeadStudio. A gene-wise linear model was fitted to the data and was performed in 
R programming language (http://www.r-project.org), utilizing functions from Linear 
Models for Microarray Data 15. For each probe, a moderated t-statistic (with standard 
errors moderated across genes) was computed using a Bayesian model. The associated 
p-values were adjusted for multiple testing, using the Benjamini and Hochberg’s (BH) 
method 16. For each transcript, Signal-to-Noise ratios (SNR) were computed for each 
stimuli group relative to the untreated (RPMI) control group. The expression SNR 
profiles of transcripts identified as differentially expressed (BH-adjusted p<0.05 and 
fold-change>2x) were clustered using the K-means algorithm 17. We performed feature 
(attribute) selection 18,19 on differentially expressed transcripts using Information Gain 
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(Kullback-Leibler divergence or relative entropy) to identify discriminatory features or 
transcripts that are most informative of the state stimulation. The accuracy of class 
prediction using a Java implementation of a naïve Bayes classifier 19,20 incorporating 
these features was evaluated using 10-fold cross-validation. 
Cytokine measurements
The concentration of IL-1β, IL-17, IL-22, TNF-α (R&D Systems, Abingdon, UK), IL-6, IL-8, 
IL-10, IFN-γ (Sanquin, Amsterdam, the Netherlands), and IFN-α, IFN-β (PBL Interferon 
Source, Piscataway, USA) was measured in cell culture supernatants using enzyme-
linked immunosorbent assay (ELISA) according to the instructions of the manufacturer.
SNP selection 
DNA was isolated using the Gentra Pure Gene Blood kit (Quiagen, Venlo, The 
Netherlands), according to the protocol of the manufacturer. Illumina Immunochip is 
a custom designed High-Density array to densely genotype 186 loci associated with 
12 different autoimmune or inflammatory diseases reaching genome-wide association 
study significance threshold (P<5x10-8) 21. The candidemia cohort and volunteers DNA 
samples were genotyped on this Immunochip Illumina platform. Only SNPs in 11 of 
the 101-gene dataset identified earlier were studied, as the other genes were not 
represented on the Immunochip. We selected tag-SNPs (Supplementary Table 3) at 
each region that are located within ± 250 kb of the locus by employing Haploview22 and 
we excluded SNPs with r2 ≥ 0.8 from association analysis. 
Statistical analysis
Analyses were performed using PLINKv1.07 23,24. We performed Multidimensional 
scaling (MDS) analysis to reveal genetic background of cases and controls in Candidemia 
cohort (Supplementary Figure 8). The association between tag-SNPs and Candidemia 
susceptibility was tested by logistic regression with the first four components from 
MDS analysis as covariates. The correlation between cytokine levels and genotypes 
was tested by Wilcoxon rank sum test using R. P-values less than 0.05 was considered 
significant.
Real-time PCR
Two million freshly isolated PBMCs were incubated with various stimuli as described 
above. After 24 hours of incubation at 37°C, total RNA was extracted in 800 μl of TRIzol 
reagent (Invitrogen, Breda, The Netherlands). Isolated RNA was reverse-transcribed 
into complementary DNA using oligo(dT) primers and MMLV reverse transcriptase. 
PCR was performed using a 7300 Real-Time PCR system (Applied Biosystems, Lennik, 
Belgium). Primer sequences for human IFN-β: sense: 5’-ATG-ACC-AAC-AAG-TGT-
CTC-CTC-C-3’ and antisense: 5’-GGA-ATC-CAA-GCA-AGT-TGT-AGC-TC-3’; IRF9: sense 
5’-GAT-ACA-GCT-AAG-ACC-ATG-TTC-CG-3’and antisense: 5’-TGA-TAC-ACC-TTG-TAG-
GGC-TCA-3’; IRF7: sense: 5’-GCT-GGA-CGT-GAC-CAT-CAT-GTA-3’ and antisense: 
5’-GGG-CCG-TAT-AGG-AAC-GTG-C-3’; ISG15: sense: 5’-CGC-AGA-TCA-CCC-AGA-AGA-
TCG-3’ and antisense: 5’-TTC-GTC-GCA-TTT-GTC-CAC-CA-3’; IFI44: sense: 5’-ATG-
GCA-GTG-ACA-ACT-CGT-TTG-3’ and antisense: 5’-GCA-GGA-TCT-TTC-GTG-CAA-CC-3’; 
IFI44L: sense: 5’-AGG-GAA-TCA-TTT-GGC-TCT-GTA-GA-‘3 and antisense: 5’-AGC-CGT-
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CAG-GGA-TGT-ACT-ATA-AC-3’; IRF3: sense:  5’-AGA-GGC-TCG-TGA-TGG-TCA-AG-3’ and 
antisense: 5’-AGG-TCC-ACA-GTA-TTC-TCC-AGG-3’; IRF5: sense: 5’-GGG-CTT-CAA-TGG-
GTC-AAC-G-3’ and antisense: 5’-GCC-TTC-GGT-GTA-TTT-CCC-TG-3’. B2M was used as 
a reference gene, for which the primers were: 5-ATG-AGT-ATG-CCT-GCC-GTG-TG-3 
(forward) and 5-CCA-AAT-GCG-GCA-TCT-TCA-AAC-3 (reverse). PCR conditions were 
as follows: 2 minutes at 50°C and 10 minutes at 95°C, followed by 40 cycles of PCR 
reaction at 95°C for 15 seconds and 60°C for 1 minute.
RNA sequencing
RNA sequencing experiments were performed on 4 hour unstimulated and C. albicans-
stimulated PBMC from three healthy controls and two CMC patients. Total RNA was 
isolated as described above. The RNA integrity (RNA integrity score ≥ 7) was measured 
on the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, USA) using an Agilent RNA 6000 
Pico Chip according to the manufacturer’s instructions. Enrichment of mRNA was done 
using the MicroPoly(A)Purist Kit (Ambion, Life Technologies, Foster City, USA) according 
to manufacturer’s instructions, starting with 5μg of total RNA and using two rounds of 
Oligo(dT) selection. Whole transcriptome library preparation was performed using the 
SOLiD Total RNA-Seq Kit (STaR Kit, Life Technologies) and the corresponding low input 
amount protocol (version July 2011, Life Technologies). In brief, 25ng high quality poly(A) 
RNA was fragmented by RNAse III digestion, cleaned up using the PureLink RNA Micro 
Kit (Invitrogen, Life Technologies) and checked for quantity and size-distribution on a 
Agilent 2100 Bioanalyzer. RNA adapters were hybridized and ligated to the fragmented 
RNA, followed by reverse transcription. After purification and size-selection of cDNA 
using Agencourt AMPure XP Reagent beads, the cDNA was amplified and used as input 
for the SOLiD system bead preparation using the SOLiD Easy bead system (E120 scale). 
Paired-end sequencing (50+25 bases) was performed on one flowcell of a 5500XL 
sequencer (Life Technologies) For each sample deep sequencing was performed 
resulting in a sequencing depth ranging from 75.6 million to 105.5 million paired-end 
reads. Paired-end colorspace reads were mapped against the human genome (hg19) 
using Tophat (version 1.4.1)25. To increase mapping performance a GTF-file containing 
the exon boundries of all known RefSeq genes  (25,024 genes) was supplied to Tophat 
and the insert size was set to 110 bases. For all genes FPKM (Fragments per Kilobase per 
Million mapped reads) values were calculated using Cufflinks (version 2.0.0) 26. Further 
statistical analyses was done using Partek® Genomic Suite software (version 6.6, build 
6.12.0109, Partek Inc., St. Louis, USA). Fold changes and p-values were calculated for 
each gene by performing a multifactorial Analysis of Variance (ANOVA) on log2 (with 
an offset of 1.0) transformed FPKM expression values. Factors included in the ANOVA 
model were group (patient or control), treatment (stimulation status), individual (data 
from same individual), and the interaction between group and treatment. Fold changes 
for the heatmaps were calculated for each individual by dividing the FPKM expression 
values of the C. albicans stimulated sample by the unstimulated (RPMI) sample. Fold 
changes with values below 1 were replaced by the negative of the inverse. A gene list 
containing 101 differentially expressed transcripts known from the expression array was 
used to select genes for further downstream analysis. Of this list, 10 transcripts were 
not considered; 7 because another isoform was already used for FPKM calculations, 
and 3 hypothetical proteins without concordant refseq genes.
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RESULTS
Candida albicans induces a type I interferon response 
We measured genome-wide transcriptional profiles in peripheral blood mononuclear 
cells (PBMCs) from healthy volunteers upon stimulation with C. albicans, as well as 
with inflammatory stimuli unrelated to fungal pathogens: Escherichia coli-derived 
lipopolysaccharide (LPS), Borrelia burgdorferi, Mycobacterium tuberculosis (MTB), and 
RPMI culture medium as a control. Measurements were performed at 4 and 24 hours. 
693 transcripts that showed >2-fold higher expression compared to corresponding RPMI 
stimulation were selected (BH-adjusted P < 0.05). K-means analysis identified profile 
clusters that indicated shared and specific genes that were differentially expressed 
in response to each stimulus. We grouped shared genes into signatures representing 
common early response genes (clusters 1, 6, 14, 27), common late response genes 
(clusters 2, 3), and common inflammatory genes induced by all stimulations (clusters 9, 
21, 25) (Figure 1A and Supplementary Figure 1-3).
 More importantly, to identify a set of discriminatory features (from the 
693 differentially expressed transcripts) that would be most informative of the state 
of Candida stimulation and could distinguish Candida stimulation from the other 
inflammatory stimuli, we utilized information gain (Kullback-Leibler divergence/
relative entropy) feature selection, to reduce the dimensionality of the feature space 
27,28. We performed 10-fold cross-validation which stratifies the data into 10 random 
partitions in which each (in turn) is held out for testing and the remainder for training 
a Bayesian classifier. Class prediction was evaluated by computing the area under the 
receiver-operating characteristic (ROC) curve (AUROC), which assesses true- and false-
positive rates. A 101-transcript (95-gene) Candida-response signature (Figure 1B and 
Supplementary Table 1) was defined using this supervised learning approach for class 
prediction, achieving an AUROC of 97.8%, which would indicate an excellent classifier 
performance with very high discriminative value. Principal component analysis (PCA) 
of the Candida-response signature further demonstrated good class separation on 
the basis of Candida status and stimulation duration (Figure 1C). As a set, the 101 
features collectively identify expression signatures that are informative of Candida 
stimulation across the 4-hour, 24-hour or both time-points that sufficiently distinguish 
Candida from the rest. Enrichment analysis for the 101-transcript Candida-response 
signature revealed a striking over-representation of the interferon (IFN) signaling 
pathway (p=3.8x10-35) (Figure 1D and Supplementary Table 2). This set of genes was 
strongly induced at both 4 hours and 24 hours of Candida stimulation and establishes 
a definitive Candida-responsive signature distinct from that observed with LPS, MTB or 
Borrelia stimulation.
Type I IFN SNPs modulate susceptibility to candidemia 
In order to assess whether the type I IFN genes specifically induced by C. albicans in 
human leukocytes are indeed involved in antifungal host defense, we investigated 
whether common polymorphisms in a subset of these genes influence susceptibility to 
systemic Candida infections. From a cohort of 217 Caucasian patients with candidemia, 
well described elsewhere 10,29, we had Immunochip genotyping data available and 
11 genes of the 101-transcript (95-gene) dataset were covered by the Immunochip 
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Figure 1. Transcriptional responses to Candida
(A) K-means clustering identifies shared and specific gene signatures in response to infection or 
stimulation. For example, clusters 21 and 25 indicate common inflammatory genes (details in 
Supplementary Fig. S2) that are significantly differentially induced genes (Benjamini-Hochberg-
adjusted-p<0.05, fold-change>2) in response to Borrelia burgdorferi, Candida albicans, E.coli-
derived LPS, and Mycobacterium tuberculosis (M.tb), compared to RPMI stimulations (Untreated), 
while clusters 7, 11 and 20 identify Candida-dominant response genes. Signal-to-noise ratio relative 
to untreated is shown in the heatmap. (B) Using feature selection, naïve Bayes classifier and 10-
fold cross-validation, a 101-transcript feature set was identified from 693 differentially expressed 
transcripts shown in (A), which distinguishes Candida from the other stimulants and an area under 
the ROC (Receiver operating characteristic) curve of 97.8%, indicating a high discriminative value. 
The expression profile (Z-transformed) of this feature set is displayed. (C) Principal component 
analysis (PCA) of the Candida-response signature. Data from each individual sample is plotted 
along the three main principal components (PC1, PC2, PC3). The three main principal components 
account for 45% of the total variance in gene expression. Samples from the various stimulations 
and infections are color coded as follows: Candida albicans (2h: bright red; 24 hr: dark red), 
Borrelia burgdorferi (Green), E.coli-derived LPS (Blue), Mycobacterium tuberculosis (M.tb) (Purple) 
and untreated (Yellow). (D) Enrichment analysis (MetaCore pathways) of the 101-transcript 
feature set reveals a striking enrichment of the interferon (IFN) signaling pathway. Supplementary 
Table S2 displays all the signaling/biological processes shown and their enrichment p-values.
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array (Supplementary Table 3). We tested these 11 genes for association by taking 
immunochip data on 12,228 non-candidemia Caucasian healthy volunteers as controls 
21. Analysis of the loci associated with these 11 genes revealed significant association 
of genetic variation with susceptibility to systemic candidiasis in four regions: CCL8 
SNP 1kg_17_29697448 (p = 0.00069), STAT1 SNP rs16833172 (p = 0.0042), SP110 
SNP rs3769845 (p = 0.012) and PSMB8 SNP rs3198005 (p = 0.01) (Figure 2A-D)
(Supplementary Figure 1-3, clusters 10, 11, 20, 11 respectively) (Supplementary Table 
3). After applying a stringent Bonferroni correction for multiple testing, the association 
between susceptibility to candidemia and STAT1 and CCL8 remained significant. This 
finding confirms that the C. albicans-specific genes we identified in our transcriptional 
arrays play an important role in host defense against systemic fungal infections. We also 
attempted to assess whether the polymorphisms in these genes also modified disease 
severity. However, only 51 patients fulfilled the criteria of severe candidiasis based on 
clinical scores and persistence of positive blood cultures, and this number was too low 
for allowing the identification of significant differences between genetic variation and 
disease severity (disseminated disease, persistent fungemia and mortality at 14 or 30 
days) (data not shown).
Figure 2. SNPs of type I IFN responsive genes are associated with susceptibility to candidemia
Regional association plots, at (A) STAT1 region (B) CCL8/CCL13 region (C) SP110 region and (D) PSMB8 
region, showing chromosome position in the x-axis and the –log of logistic p-values for each SNP in the 
y-axis. Black diamond indicates the top p-value; while dark and light grey diamonds indicates r2 ranges 
of 0.6 to 0.8 and 0.4 to 0.59, respectively with the top associated SNP. SNP names shown are as in 
dbSNP130 where available. Otherwise, the Illumina Immunochip manifest name is shown. For example 
1kg_17_29697448 indicates the location of SNP on chromosome 17 at position 29697448 (hg18).
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Type I IFN SNPs modulate Candida-induced cytokine responses
In an additional approach to validate the role of the type I IFN pathway for host 
defense against Candida, we isolated PBMCs from an additional group of 74 healthy 
volunteers and stimulated the cells with the fungus. Genetic variation in 11 type I IFN 
pathway genes present on the Immunochip was correlated with C. albicans-induced 
release of TNF-α, IL-1β, IL-8, IL-6, IL-10, IFN-γ and IL-17. In contrast to other microbial 
stimuli such as LPS and MTB, C. albicans induced higher levels of TNF-α, IL-1β and IL-10 
production, and lower levels of IL-8 and IL-6 in human PBMCs (Supplementary Figure 
4). The correlation of cytokine concentrations with genotypes at tag SNPs of Candida-
induced IFN pathway genes revealed significant associations at IRF1 and STAT1 regions 
(Figure 3A-D) in which IRF1 SNPs were associated with TNFα (p = 0.0028) and IL-10 
levels (p = 0.0024), while STAT1 SNPs were associated with TNF-α (p = 0.001) and IL-6 
levels (p = 0.0002). Consistent with the specificity of the type I IFN pathway for Candida 
stimulation, the association was significant with cytokine levels induced by Candida, 
but not by LPS or MTB stimulation (Supplementary Figure 5).  
Type I IFNs skew cytokine responses from Th17 towards Th1
To investigate the importance of type I IFN signaling in host defense against Candida, 
PBMCs from healthy individuals were stimulated with HK C. albicans. In line with the 
transcriptional profile described above (Figure 1), IFN-β could be detected in cell 
culture supernatants only after C. albicans stimulation. In contrast, neither live (Figure 
4A), nor HK C. albicans induced any detectable IFN-α production 
Figure 3. SNPs of type I IFN responsive genes are associated with Candida-induced cytokine levels
Correlation plots showing the association between genotypes in the x-axis and cytokines 
levels in the y-axis. Association between (A) TNF-α levels and genotypes at IRF1 SNP 
rs2548997,  (B)  IL-10 levels and genotypes at IRF1 SNP rs1124211, (C) TNF-α  and genotype 
at STAT1 SNP rs2280234 and (D) IL-6 levels and genotypes at STAT1 SNP rs41511150.
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We next assessed the role of type I IFN pathways in the induction of cytokines by 
C. albicans. When PBMCs were stimulated with HK C. albicans in the presence of an 
antibody against IFN-α/β receptor (IFNAR), IFN-γ production was significantly lower 
compared to PBMCs stimulated in the presence of a control antibody. Blocking of IFNAR 
did not influence the production of the monocyte-derived cytokines IL-β or TNF-α 
(Figure 4B). Conversely, adding IFN-α or IFN-β to Candida-stimulated cells increased 
IFN-γ production, while significantly decreasing IL-17 and IL-22 production (Figure 4C). 
Together these data suggest that type I interferons (in the context of infection, most 
likely IFN-β) modulate the immune reaction induced by C. albicans, skewing host 
defense toward a Th1 response.
Figure 4. Type I IFNs skew cytokine production from a Th1 towards a Th17 response
(A) 5×105 PBMC in a volume of 200 μL, were stimulated for seven days, in the presence of 10% 
human pooled serum, with live Candida albicans (1×106/mL), in duplo. IFN-α and IFN-β were 
measured in cell culture supernatants using ELISA. (B) 5×105 PBMC in a volume of 200 μL, were 
stimulated for one and two days, with HK Candida albicans (1×106/mL), in the absence or 
presence of anti-IFN-α/βR2, in duplo. IFN-γ, IL-1β and TNF-α were measured in cell culture 
supernatants using ELISA. (C) 5×105 PBMC in a volume of 200 μL, were stimulated for two and 
seven days, with HK Candida albicans (1×106/mL), in the absence of presence of IFN-α or IFN-β, 
in duplo. When cells were cultured for seven days, this was done in the presence of 10 % human 
pooled serum. IFN-γ, IL-17 and IL-22 were measured in cell culture supernatants using ELISA. 
(A-C) After stimulation, supernatants were pooled and stored at -20 C° until further assayed. 
Data were analyzed using the Wilcoxon signed rank test. Data are presented as mean + SEM.
98
Chapter 6
sTaT1 mutations cause reduced expression of type I IFN genes
Patients with autosomal dominant CMC have increased susceptibility to mucosal 
fungal infections and often carry gain-of-function mutations in STAT1 30,31, which lead 
to STAT1 hyperphosphorylation, that in turn likely makes STAT1 unavailable for forming 
heterodimers with other STAT molecules 32. In co-cultures of DCs and T-cells from 
CMC patients, this led to defective Th1 and Th17 responses (Supplementary Figure 6). 
In order to validate the role of Candida-specific genes in human antifungal mucosal 
defense, we assessed the expression of these genes in cells from CMC patients. PBMCs 
from healthy controls and CMC patients were stimulated with RPMI, E. coli-derived LPS, 
HK C. albicans, or HK MTB. The expression of type I IFN pathway genes (including IRF5, 
IRF7, ISG15, IFI44 and IFI44L) that are induced downstream of STAT1-STAT2 showed 
patterns of defective expression in CMC patients compared to healthy controls, 
supporting a role of the type I IFN pathway in this immunodeficiency (Figure 5). The 
expression of IRF3, IRF9 and IFN-β, three genes in the type I IFN pathway upstream of 
STAT1-STAT2, was not decreased in cells from CMC patients. In fact, Candida-induced 
IFN-β expression appeared to be higher in cells from CMC patients, possibly indicating 
a compensatory feedback mechanism.
Figure 5. Reduced expression of type I IFN pathway genes in patients with a STAT1 mutation
5·105 PBMC from 8 healthy controls and 2 CMC patients (measured twice), in a volume of 200 μL, were 
stimulated for 24 hours, with RPMI, E. coli-derived LPS (10 ηg/mL), HK C. albicans (1×106/mL), or HK M. 
tuberculosis (1 μg/mL). mRNA was isolated from cell lysates using TRIzol. Transcription of IFN-β, IRF3, 
IRF9, IRF5, IRF7, ISG15, IFI44 and IFI44L was measured using qPCR. Data are presented as mean + SEM.
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In order to investigate the type I IFN pathway in CMC patients in a more systematic 
way, we also performed RNA sequencing in PBMCs stimulated with C. albicans from 
both controls and CMC patients. The differential expression of 91 genes in response to 
C. albicans stimulation was compared between CMC patients and healthy controls (10 
genes from the 101-gene signature characteristic for Candida were not considered: 7 
because another isoform was already used for FPKM calculations, and 3 hypothetical 
proteins without concordant refseq genes). In cells from healthy controls, two genes 
showed downregulation (LFNG, RGC32), while all other genes were upregulated 
upon stimulation (Supplementary Figure 7), validating the previous findings based 
on expression array analysis. In order to observe differences between patients and 
controls, the standardized fold change was used to create the respective heatmap 
(Figure 6). The patients show a much lower standardized fold change in genes 
downstream of STAT1, again supporting the role of type 1 IFN pathway in CMC. We 
found 27 out of 91 genes, to be significantly differently regulated upon Candida-
stimulation in patients compared to controls based on an ANOVA analysis (p-value 
interaction group and treatment <0.05) (MX1, OAS3, IFIT2, RTP4, XAF1, OAS2, IFI44, 
IFIH1, IFIT3, ADAR, PRIC285, FAM46A, SAMD9L, EIF2AK2, PARP12, TRIM22, ZBP1, 
HERC6, RSAD2, IFNG, OAS1, STAT2, DHX58, IRF7, TNFSF10, ISG15, HERC5). To determine 
the role of these 27 genes we calculated Gene ontology (GO) enrichment scores using 
the Database for Annotation, Visualization and Integrated Discovery (DAVID). Enriched 
gene clusters were generated using Functional Annotation Clustering. GO terms 
associated with response to type I interferon and viral infections showed significant 
enrichment (p=1.09x10-14) (Supplementary Table 4). 
DISCUSSION
The last decade has witnessed a significant increase in knowledge related to the 
mechanisms involved in antifungal host defense. However, most of this knowledge 
is based on in vitro and animal studies; these studies led to hypotheses to be tested 
in human systems, leading to a somewhat biased view of human immunity against 
fungi. In the present study we have used a different approach based exclusively on 
complementary human studies: transcriptomics analysis in human primary cells, 
correlation of genetic variability and antifungal immunity in healthy volunteers 
(functional genomics), case-control association studies in patients with disseminated 
C. albicans infections, and assessment of antifungal immunity in CMC patients.
 In our initial approach, we designed a hypotheses-generating set of 
experiments by assessing the transcriptional profile induced in circulating primary 
leukocytes by C. albicans. Human PBMCs were stimulated with C. albicans or other 
inflammatory stimuli. Pathway analysis of the genes induced by Candida indicated two 
broad categories: (i) a first set of genes that was strongly induced and shared by both 
C. albicans and other inflammatory stimuli (LPS, MTB, or B. burgdorferi), constituted 
expected pathways involved in inflammation and innate immunity, many of which have 
important roles in antifungal immunity 33, and (ii) a feature set comprising an expression 
signature of 101 transcripts (95 genes) that distinguishes the Candida-specific response 
and is characterized by a strikingly strong and unanticipated type I IFN response. 
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Figure 6. Heatmap of response of CMC patients and controls to C. albicans in vitro stimulation
The standardized fold change gene expression in stimulated vs. unstimulated cells was calculated. The 
scale of this heatmap is given as standardized log2 fold change with a range from -1.8 (blue) to +1.8 (red).
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Because the identification of the type I IFN pathway as the most prominent Candida-
specific transcriptional signature was surprising, we initiated a series of studies to 
confirm this finding. Firstly, we assessed whether genetic polymorphisms in several of 
the genes identified in the Candida-specific dataset influenced susceptibility to systemic 
Candida infections. In a cohort of patients with candidemia that were genotyped using 
the Immunochip platform (Illumina 21), on which 11 genes of the Candida-specific 
dataset were covered, we identified significant association of genetic variation with 
susceptibility to candidiasis in four of these genes: CCL8 locus, STAT1, SP110 locus, and 
PSMB8 locus. This finding confirms that genes from the 101 Candida-specific dataset 
influence susceptibility to systemic fungal infections. 
 Secondly, the role of the type I IFN pathway for the anti-Candida immune 
response was subsequently validated in a study in which PBMCs isolated from a group 
of healthy volunteers were stimulated with the fungus. Genetic variation in the 11 type I 
IFN pathway genes present on the Immunochip was correlated with C. albicans-induced 
cytokine production. The correlation of cytokine concentrations with genotypes at tag 
SNPs of Candida-induced IFN pathway genes revealed significant associations at IRF1 
and STAT1 regions, both crucial components of type I IFN pathway. We cannot exclude 
however that the effect of these polymorphisms on TNF-α production are exerted 
through type II interferons; IFN-γ is stimulated by type I interferons 34, and is known to 
induce TNF-α production 35. These data support the hypothesis of the specificity of the 
type I IFN pathway for Candida stimulation, as this association was significant only for 
cytokine production induced by Candida, but not by other stimuli.
 Thirdly, we performed classical immunological studies to assess the role of 
type I IFNs for Candida-induced immune responses, and we demonstrated that type 
I IFNs induced by Candida modulate Th1/Th17 cytokine profiles; IFN-α and IFN-β 
increased IFN-γ production, while decreasing IL-17 production. Moschen et al previously 
demonstrated that type I interferons decrease IL-17 production in vitro and in vivo 36. 
TNF-α production did not seem to be influenced by blocking the IFNAR, suggesting that 
genetic effects in STAT1 exert their effect on TNF-α production either through direct 
intracellular pathways, or indirectly through IFN-γ. Interestingly C. albicans seems to 
induce only IFN-β, rather than IFN-a, consistent with earlier studies in mice 37,38.
 Finally, using both qPCR and RNA sequencing analysis, we demonstrated that 
the expression of type I IFN pathway-induced genes was defective in CMC patients 
harboring a gain of function mutation in STAT1 30. These mutations lead to increased 
STAT1 phosphorylation and IFN-γ signaling. Liu et al. demonstrated increased STAT1 
phosphorylation in response to IFN-γ stimulation in U3C cells transfected with 
mutated STAT1 31. They hypothesize that IFN targeted genes can lead to decreased IL-
17 production. However, freshly isolated PBMC from CMC patients do not produce 
any IFN-γ in response to C. albicans stimulation 30. Therefore, it is more likely that the 
inability of mutated STAT1 to form heterodimers with STAT3 and STAT4 causes defective 
Th1/Th17 responses 32, which are likely to represent the main immunological defect in 
this disease. Additional defects in the expression of type I interferon-induced genes, 
as shown here, may also contribute to the increased susceptibility to mucosal fungal 
infections. Whether this is truly caused by a defect in STAT1-STAT2 heterodimerization 
remains to be demonstrated.
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Taken together, these complementary studies represent a compelling body of evidence 
that the type I IFN pathway is an important component of the immune response 
during infections with C. albicans in humans. Moreover, the data presented here are 
supported by emerging information from murine studies. For example, Bourgeois et al. 
and Biondo et al. have reported that mouse conventional dendritic cells produce IFN-β 
upon stimulation with Candida spp. and have proposed a role for MyD88, TLR7 and 
TLR9 in this induction 37,38. On the other hand, these results are relatively surprising, 
as no earlier study has reported a role for type I IFNs in human antifungal host 
defense. In this respect, primary immunodeficiencies in type I IFN pathway are mainly 
associated with viral, rather than fungal, infections 39. Therefore, our data suggest that 
type I IFN defects determine an increase susceptibility risk for fungal infections, as 
demonstrated here by the association with candidemia in risk groups, rather than an 
overt immunodeficiency associated with severe fungal infections.
 The precise effect of type I IFNs for anti-Candida host defense is still being 
debated. One study in type I IFNAR knockout mice suggested a deleterious role for this 
pathway 37, whereas another study reported that IFNAR-/- mice die from their inability 
to control fungal growth 38. While type I IFNs play an important role in the immune 
response against viral infections 40, they seem to be deleterious in bacterial infections 
41. In humans with Candida infections, the role of type 1 IFNs is not yet settled, although 
the defects seen in type I IFN gene expression in CMC patients, the susceptibility to 
candidemia by STAT1 polymorphisms, and the potentiation of Th1 responses by type I 
IFNs, all suggest a beneficial effect of the type I IFN pathway in human antifungal host 
defense.
 Although viruses have long been known to induce type I IFN production, other 
microorganisms have been recently reported to induce this pathway. MTB stimulation 
induces the expression of IFNB and IFNA1 in human macrophages 42 and in murine 
bone marrow-derived macrophages 43; type I IFNs are required for caspase-1 activation 
during Francisella tularensis infection 44; and Listeria monocytogenes induces the 
transcription of IFNB in macrophages 45. However, the complete transcriptional profile 
of the type I IFN pathway performed here shows important differences from the type 
I IFN profile induced by MTB 46 and is significantly more pronounced for Candida than 
for MTB (Supplementary Figure 4). Interestingly, the very strong induction of type I IFN 
pathway genes by Candida may explain the well-known, yet unexplained, beneficial 
effects of injecting Candida-derived extracts for the treatment of warts in patients 47,48.
 In summary, this work presents complementary arguments from several 
studies to propose that the type I IFN pathway plays an important role in the immune 
responses to the fungal pathogen C. albicans in humans. The cross-validation between 
these approaches supports the value of this systems biology approach, combining 
transcriptomics with functional genomics and immunological data. Using this 
approach, we have confirmed the role of pathways known to be involved in antifungal 
host defense (e.g., common inflammatory pathways and the Th1/Th17 pathways) and 
we have identified a novel pathway (the type I IFN pathway). It is expected that this 
knowledge will have an important contribution in devising novel immunotherapeutic 
strategies for fungal infections, as well as influencing decision-making for vaccine 
design.
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supplementary Figure 1. K-means cluster analysis of transcriptional responses (1-9) to Candida
An expanded view of expression profiles clusters 1-9 shown in Figure 1, 
describing responses to stimulation with Borrelia burgdorferi, Candida albicans, 
E.coli-derived LPS, and Mycobacterium tuberculosis (M.tb) is displayed.
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supplementary Figure 2. K-means cluster analysis of transcriptional responses (10-20) to Candida
An expanded view of expression profiles clusters 10-20 shown in Figure 1, 
describing responses to stimulation with Borrelia burgdorferi, Candida albicans, 
E.coli-derived LPS, and Mycobacterium tuberculosis (M.tb) is displayed.
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supplementary Figure 3. K-means cluster analysis of transcriptional responses (21-30) to Candida
An expanded view of expression profiles clusters 21-30 shown in Figure 1, 
describing responses to stimulation with Borrelia burgdorferi, Candida albicans, 
E.coli-derived LPS, and Mycobacterium tuberculosis (M.tb) is displayed.
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supplementary Figure 4. Correlation plots for cytokines versus corresponding stimuli
In contrast to other microbial stimuli such as LPS and MTB, C. albicans induced 
higher levels of TNF-α, IL-1β and IL-10 production, and lower levels of IL-8 
and IL-6 in human PBMCs. Boxplots represent median ± interquartile range. 
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supplementary Figure 5. Correlation plots for all cytokines and SNP polymorphisms
Consistent with the specificity of the type I IFN pathway for Candida stimulation, the association 
was significant with cytokine levels induced by Candida, but not by LPS or MTB stimulation.
supplementary Figure 6. Defective Th1 and Th17 development in DC/T-cell cocultures from CMC 
patients harboring a gain of function mutation in STAT1. Bars represent mean ± SEM.
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supplementary Figure 7. Heatmap showing the differential expression for 91 genes as a 
response to C. albicans stimulation in cells from healthy controls
This compares the fold change genes expression levels of 91 genes in in 
vitro stimulated vs. unstimulated cells (Candia Albicans). The scale of this 
heatmap is given as log2 fold change with a range from -5 (blue) to +5 (red).
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supplementary Figure 8. Genetic background in candidemia cohort
The multidimensional scaling (MDS) analysis (implemented in PLINK, MDS on the N x N matrix 
of genome-wide IBS pairwise distances) was performed on individuals from Candidemia 
cohort (pink colour) by including healthy control samples of known ethnicity as reference. 
Only samples which overlap with the known ethnic populations were included (shown 
within dashed lines) and outliers (n=40) were excluded from further case-control analysis.
Supplementary Table 1. Candida-response signature
ProfileSummary UniqueID Symbol RefSeq
Down LFNG___NM_002304.1 LFNG NM_2304.1
Down RGC32___NM_014059.1 RGC32 NM_14059.1
Up STOM___NM_004099.4 STOM NM_4099.4
Up TNFSF13B___NM_006573.3 TNFSF13B NM_6573.3
Up FAM46A___NM_017633.1 FAM46A NM_17633.1
Up PRF1___NM_005041.3 PRF1 NM_5041.3
Up GZMB___NM_004131.3 GZMB NM_4131.3
Up TMEM126B___NM_018480.2 TMEM126B NM_18480.2
Up CD40___NM_001250.3 CD40 NM_1250.3
Up HAPLN3___NM_178232.2 HAPLN3 NM_178232.2
Up LTA___NM_000595.2 LTA NM_595.2
Up IRF8___NM_002163.2 IRF8 NM_2163.2
Up XRN1___NM_019001.2 XRN1 NM_19001.2
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Up KIAA1618___NM_020954.2 KIAA1618 NM_20954.2
Up NCOA7___NM_181782.2 NCOA7 NM_181782.2
Up PSMB9___NM_002800.4 PSMB9 NM_2800.4
Up IFI27___NM_005532.3 IFI27 NM_5532.3
Up SOCS1___NM_003745.1 SOCS1 NM_3745.1
Up IRF1___NM_002198.1 IRF1 NM_2198.1
Up DYNLT1___NM_006519.1 DYNLT1 NM_6519.1
Up FAS___NM_152877.1 FAS NM_152877.1
Up CXCL9___NM_002416.1 CXCL9 NM_2416.1
Up LINCR___NM_001080535.1 LINCR NM_1080535.1
Up IFNG___NM_000619.2 IFNG NM_619.2
Up CD38___NM_001775.2 CD38 NM_1775.2
Up LGALS9___NM_009587.2 LGALS9 NM_9587.2
Up APOL3___NM_030644.1 APOL3 NM_30644.1
Up PSMB8___NM_148919.3 PSMB8 NM_148919.3
Up LAMP3___NM_014398.2 LAMP3 NM_14398.2
Up LBA1___XM_940627.1 LBA1 XM_940627.1
Up LAG3___NM_002286.4 LAG3 NM_2286.4
Up ZBP1___NM_030776.1 ZBP1 NM_30776.1
Up TRIM5___NM_033034.1 TRIM5 NM_33034.1
Up FLJ11286___NM_018381.1 FLJ11286 NM_18381.1
Up PARP10___NM_032789.1 PARP10 NM_32789.1
Up C20orf18___NM_006462.2 C20orf18 NM_6462.2
Up IFITM2___NM_006435.1 IFITM2 NM_6435.1
Up IFITM3___NM_021034.1 IFITM3 NM_21034.1
Up CHMP5___NM_016410.2 CHMP5 NM_16410.2
Up CHMP5___NM_016410.4 CHMP5 NM_16410.4
Up TRAFD1___NM_006700.1 TRAFD1 NM_6700.1
Up WARS___NM_004184.3 WARS NM_4184.3
Up FLJ11000___NM_018295.1 FLJ11000 NM_18295.1
Up TRIM21___NM_003141.3 TRIM21 NM_3141.3
Up DDX58___NM_014314.2 DDX58 NM_14314.2
Up TNFSF10___NM_003810.2 TNFSF10 NM_3810.2
Up CCL8___NM_005623.2 CCL8 NM_5623.2
Up CXCL10___NM_001565.1 CXCL10 NM_1565.1
Up PARP14___NM_017554.1 PARP14 NM_17554.1
Up DNAPTP6___NM_015535.1 DNAPTP6 NM_15535.1
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Up LAP3___NM_015907.2 LAP3 NM_15907.2
Up GBP2___NM_004120.3 GBP2 NM_4120.3
Up FBXO6___NM_018438.4 FBXO6 NM_18438.4
Up IFITM1___NM_003641.2 IFITM1 NM_3641.2
Up STAT2___NM_005419.2 STAT2 NM_5419.2
Up TAP1___NM_000593.5 TAP1 NM_593.5
Up GBP4___NM_052941.2 GBP4 NM_52941.2
Up GBP5___NM_052942.2 GBP5 NM_52942.2
Up GBP1___NM_002053.1 GBP1 NM_2053.1
Up UBE2L6___NM_004223.3 UBE2L6 NM_4223.3
Up STAT1___NM_139266.1 STAT1 NM_139266.1
Up STAT1___NM_007315.2 STAT1 NM_7315.2
Up EPSTI1___NM_033255.2 EPSTI1 NM_33255.2
Up ADAR___NM_015840.2 ADAR NM_15840.2
Up FTSJD2___NM_015050.2 FTSJD2 NM_15050.2
Up LGP2___NM_024119.1 LGP2 NM_24119.1
Up SP110___NM_004510.2 SP110 NM_4510.2
Up PARP9___NM_031458.1 PARP9 NM_31458.1
Up LY6E___NM_002346.1 LY6E NM_2346.1
Up IFI6___NM_022872.2 IFI6 NM_22872.2
Up G1P3___NM_002038.2 G1P3 NM_2038.2
Up IFIT5___NM_012420.1 IFIT5 NM_12420.1
Up ISG20___NM_002201.4 ISG20 NM_2201.4
Up RTP4___NM_022147.2 RTP4 NM_22147.2
Up IFI35___NM_005533.2 IFI35 NM_5533.2
Up TRIM22___NM_006074.2 TRIM22 NM_6074.2
Up FLJ20035___NM_017631.3 FLJ20035 NM_17631.3
Up PARP12___NM_022750.2 PARP12 NM_22750.2
Up SAMD9L___NM_152703.2 SAMD9L NM_152703.2
Up XAF1___NM_199139.1 XAF1 NM_199139.1
Up PHF11___NM_001040443.1 PHF11 NM_1040443.1
Up PHF11___NM_016119.1 PHF11 NM_16119.1
Up HERC6___NM_001013005.1 HERC6 NM_1013005.1
Up IFI44L___NM_006820.1 IFI44L NM_6820.1
Up IFI44___NM_006417.2 IFI44 NM_6417.2
Up EIF2AK2___NM_002759.1 EIF2AK2 NM_2759.1
Up IFIT3___NM_001031683.1 IFIT3 NM_1031683.1
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Supplementary Table 2. Enrichment analysis for the 101-transcript Candida-response signature
# MetaGO_GeneGO_Process_Networks Enrichment p-value
1 Interferon signaling 3,82E-35
2 Innate immune response to RNA viral infection 1,25E-12
3 Inflammasome 2,50E-6
4 Jak-STAT Pathway 1,52E-5
5 IFN-gamma signaling 2,39E-5
6 NK cell cytotoxicity 3,00E-4
7 Death Domain receptors & caspases in apoptosis 2,87E-3
8 Negative regulation of cell proliferation 3,21E-3
9 Chemotaxis 4,56E-3
10 Antigen presentation 4,62E-3
11 IL-10 anti-inflammatory response 4,98E-3
12 IL-12,15,18 signaling 1,15E-2
13 Leucocyte chemotaxis 2,33E-2
14 T helper cell differentiation 2,57E-2
15 Lymphocyte proliferation 2,60E-2
16 Apoptotic nucleus 3,76E-2
17 Glycoconjugates 4,22E-2
18 Proteolysis in cell cycle and apoptosis 7,76E-2
Up IRF7___NM_004029.2 IRF7 NM_4029.2
Up OAS3___NM_006187.2 OAS3 NM_6187.2
Up IFIH1___NM_022168.2 IFIH1 NM_22168.2
Up IRF7___NM_004030.1 IRF7 NM_4030.1
Up PRIC285___NM_033405.2 PRIC285 NM_33405.2
Up MX1___NM_002462.2 MX1 NM_2462.2
Up RSAD2___NM_080657.3 RSAD2 NM_80657.3
Up IFIT3___NM_001549.2 IFIT3 NM_1549.2
Up OAS1___NM_001032409.1 OAS1 NM_1032409.1
Up IFIT2___NM_001547.3 IFIT2 NM_1547.3
Up ISG15___NM_005101.1 ISG15 NM_5101.1
Up OAS2___NM_016817.2 OAS2 NM_16817.2
Up HERC5___NM_016323.1 HERC5 NM_16323.1
Up OAS2___NM_002535.2 OAS2 NM_2535.2
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Supplementary Table 3. Number of tag-SNPs tested in each locus for case-control and cytokine 
correlation analyses
(Continuation Supplemantary Table 3)
Analysis Number of cases Number of controls Locus Tag-SNPs Top SNP P-logistic  bonferroni threshold-P (0.05/number of SNPs) 
Case-control 217 12.068 CCL8-CCL13 40 1kg_17_29697448 0.00069*$ 0,001
(Logistic regression) 217 12.068 STAT1 77 imm_2_191584314 0.0042$ 0,001
217 12.068 SP110-140 75 imm_2_230863948 0.012 0,001
217 12.068 PSMB8-9 38 rs3198005 0.019 0,001
Cytokine levels vs. SNP genotypes
(Wilcoxon rank-sum test)
74 STAT1 77 rs2280234 vs TNF-α 0.001$ 0,001
74 STAT1 77 rs4511150 vs IL-6 0.00026*$ 0,001
74 IRF1 35 rs2548997 vs TNF-α 0.0028$ 0,001
74 IRF1 35 rs1124211 vs IL-10 0.0024$ 0,001
* Clear the Bonferroni correction taking into account the number of SNPs tested in each locus
$ Clear the Bonferroni correction for number of genes tested (11 → p < 0.0045)
1kg_17_29697448 indicates a SNP on chromosome 17 at position 29697448 (hg18)
Supplementary Table 4. GO term enrichment of 27 differentially expressed genes for Candida 
albicans response in patients vs. controls
(Continuation Supplementary Table 4)
GO Term Gene count Frequency Genes P-value bonferroni
Antiviral defense 9 33,3 IFIH1, ISG15, IRF7, IFNG, RSAD2, MX1, EIF2AK2, TRIM22, STAT2 1,09E-14 7,62E-13
GO:0009615~response to virus 10 37 IFIH1, ISG15, IRF7, IFNG, RSAD2, IFI44, MX1, EIF2AK2, TRIM22, STAT2 1,59E-14 5,77E-12
GO:0006955~immune response 9 33,3 IFIH1, TNFSF10, IFNG, OAS3, RSAD2, OAS1, OAS2, TRIM22, DHX58 3,21E-6 0,001
GO:0003723~RNA binding 9 33,3 IFIH1, OAS3, OAS1, PRIC285, OAS2, EIF2AK2, DHX58, ZBP1, ADAR 5,85E-6 3,86E-4
IPR018952:2’-5’-oligoadenylate synthetase 1, domain 2/C-terminal 3 11,1 OAS3, OAS1, OAS2 1,19E-5 8,34E-4
IPR006117:2-5-oligoadenylate synthetase, conserved site 3 11,1 OAS3, OAS1, OAS2 1,19E-5 8,34E-4
IPR006116:2-5-oligoadenylate synthetase, ubiquitin-like region 3 11,1 OAS3, OAS1, OAS2 1,98E-5 0,001
Host-virus interaction 6 22,2 IFIH1, ISG15, IRF7, EIF2AK2, TRIM22, STAT2 3,51E-5 0,002
RNA-binding 7 25,9 IFIH1, OAS3, OAS1, OAS2, EIF2AK2, DHX58, ADAR 6,79E-5 0,005
Hsa04622:RIG-I-like receptor signaling pathway 4 14,8 IFIH1, ISG15, IRF7, DHX58 1,39E-4 0,002
Polymorphism 25 92,6 IFIH1, RTP4, OAS3, RSAD2, OAS1, FAM46A, SAMD9L, ISG15, IFNG, 
XAF1, MX1, DHX58, ZBP1, HERC6, HERC5, IFI44, TRIM22, STAT2, IFIT2, 
TNFSF10, PARP12, IRF7, PRIC285, EIF2AK2, ADAR
2,80E-4 0,019
Shown are significantly enriched GO terms ordered for p-value
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Supplementary Table 3. Number of tag-SNPs tested in each locus for case-control and cytokine 
correlation analyses
(Continuation Supplemantary Table 3)
Analysis Number of cases Number of controls Locus Tag-SNPs Top SNP P-logistic  bonferroni threshold-P (0.05/number of SNPs) 
Case-control 217 12.068 CCL8-CCL13 40 1kg_17_29697448 0.00069*$ 0,001
(Logistic regression) 217 12.068 STAT1 77 imm_2_191584314 0.0042$ 0,001
217 12.068 SP110-140 75 imm_2_230863948 0.012 0,001
217 12.068 PSMB8-9 38 rs3198005 0.019 0,001
Cytokine levels vs. SNP genotypes
(Wilcoxon rank-sum test)
74 STAT1 77 rs2280234 vs TNF-α 0.001$ 0,001
74 STAT1 77 rs4511150 vs IL-6 0.00026*$ 0,001
74 IRF1 35 rs2548997 vs TNF-α 0.0028$ 0,001
74 IRF1 35 rs1124211 vs IL-10 0.0024$ 0,001
* Clear the Bonferroni correction taking into account the number of SNPs tested in each locus
$ Clear the Bonferroni correction for number of genes tested (11 → p < 0.0045)
1kg_17_29697448 indicates a SNP on chromosome 17 at position 29697448 (hg18)
Supplementary Table 4. GO term enrichment of 27 differentially expressed genes for Candida 
albicans response in patients vs. controls
(Continuation Supplementary Table 4)
GO Term Gene count Frequency Genes P-value bonferroni
Antiviral defense 9 33,3 IFIH1, ISG15, IRF7, IFNG, RSAD2, MX1, EIF2AK2, TRIM22, STAT2 1,09E-14 7,62E-13
GO:0009615~response to virus 10 37 IFIH1, ISG15, IRF7, IFNG, RSAD2, IFI44, MX1, EIF2AK2, TRIM22, STAT2 1,59E-14 5,77E-12
GO:0006955~immune response 9 33,3 IFIH1, TNFSF10, IFNG, OAS3, RSAD2, OAS1, OAS2, TRIM22, DHX58 3,21E-6 0,001
GO:0003723~RNA binding 9 33,3 IFIH1, OAS3, OAS1, PRIC285, OAS2, EIF2AK2, DHX58, ZBP1, ADAR 5,85E-6 3,86E-4
IPR018952:2’-5’-oligoadenylate synthetase 1, domain 2/C-terminal 3 11,1 OAS3, OAS1, OAS2 1,19E-5 8,34E-4
IPR006117:2-5-oligoadenylate synthetase, conserved site 3 11,1 OAS3, OAS1, OAS2 1,19E-5 8,34E-4
IPR006116:2-5-oligoadenylate synthetase, ubiquitin-like region 3 11,1 OAS3, OAS1, OAS2 1,98E-5 0,001
Host-virus interaction 6 22,2 IFIH1, ISG15, IRF7, EIF2AK2, TRIM22, STAT2 3,51E-5 0,002
RNA-binding 7 25,9 IFIH1, OAS3, OAS1, OAS2, EIF2AK2, DHX58, ADAR 6,79E-5 0,005
Hsa04622:RIG-I-like receptor signaling pathway 4 14,8 IFIH1, ISG15, IRF7, DHX58 1,39E-4 0,002
Polymorphism 25 92,6 IFIH1, RTP4, OAS3, RSAD2, OAS1, FAM46A, SAMD9L, ISG15, IFNG, 
XAF1, MX1, DHX58, ZBP1, HERC6, HERC5, IFI44, TRIM22, STAT2, IFIT2, 
TNFSF10, PARP12, IRF7, PRIC285, EIF2AK2, ADAR
2,80E-4 0,019
Shown are significantly enriched GO terms ordered for p-value
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AbSTRACT
We recently reported the genetic cause of autosomal dominant chronic mucocutaneous 
candidiasis (AD-CMC) as a mutation in the STAT1 gene. In the present study we show that 
STAT1 Arg274Trp mutations in the coiled-coil (CC) domain is the genetic cause of AD-
CMC in three families of patients. Cloning and transfection experiments demonstrate 
that the mutated STAT1 inhibits interleukin (IL)-12receptor(R)/IL-23R signaling, with 
hyperphosphorylation of STAT1 as the likely underlying molecular mechanism. Inhibition 
of signaling through the receptors for IL-12 and IL-23 leads to strongly diminished T 
helper (Th)1/Th17 responses and hence to increased susceptibility to fungal infections. 
The challenge for the future is to translate this knowledge into novel strategies for the 
treatment of this severe immunodeficiency.
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INTRODUCTION
CMC is a hereditary primary immunodeficiency characterized by severe skin and 
mucosal Candida infections, dermatophytosis and onychomycosis 1. CMC is a 
heterogeneous syndrome, the best characterized clinical entities being the autosomal 
recessive autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) 
syndrome and AD-CMC 2. 
 APECED is due to mutations in the gene autoimmune regulator (AIRE) 3, and 
these explain the autoimmune phenomena, including autoantibodies against the 
antifungal cytokines IL-17A, IL-17F and IL-22 4,5. In contrast, the genetic cause of AD-
CMC has remained unknown until very recently. In a study performed in 5 families 
with AD-CMC, we reported that the disease is caused by mutations in the gene coding 
for the signal transducer and activator of transcription (STAT)1 signaling molecule 
6. The discovery of STAT1 mutations as cause of AD-CMC was remarkable, as STAT1 
deficiency had been previously reported to be associated with mycobacterial and 
viral, but not fungal, infections 7,8. The presence of the AD-CMC mutations in the CC 
domain of STAT1, rather than in the Src homology 2 (SH2) or DNA-binding domains of 
the protein as in patients with mycobacterial/viral infections, is believed to explain 
the difference 6. Nevertheless, the cellular and molecular mechanisms responsible for 
the increased susceptibility to fungal infections in patients with AD-CMC and STAT1 
mutations remains to be deciphered.
 In the present study we assessed the presence and function of STAT1 mutations 
in the index family published previously 6, and in two additional previously unreported 
families with AD-CMC. We also assessed the immune abnormalities underlying the 
increased susceptibility to infections in these patients.
PATIENTS AND METHODS
Family #1 
The clinical characteristics and pedigree of a Dutch Caucasian non-consanguinous 
family are represented in Figure 1A and in Supplementary Table 1. The patients of the 
first two generations have been previously presented 6. Since then, the son of one 
of the patients from the second generation was also diagnosed with the disease. The 
patients have severe chronic oropharyngeal candidiasis and dermatophytosis of the 
feet. 
Family #2
The clinical characteristics and pedigree of a non-consanguinous British Caucasian 
family are presented in Figure 1B and in Supplementary Table 1. Three generations are 
affected with severe persistent candidiasis of the oropharynx, nails and skin (perineum 
in the child), all have iron-deficiency anemia. The grandmother and daughter have 
hypothyroidism while the boy has thyroid (peroxidise) autoantibodies but has still not 
developed clinical hypothyroidism.
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Family #3
The clinical characteristics and pedigree of a non-consanguinous British Caucasian 
family are presented in Figure 1C and Supplementary Table 1. The mother, her son and 
daughter all suffer with oral candidiasis and hypothyroidism. The children unusually 
also suffer with mouth ulcers and herpetic whitlow. 
Ethics approval
The study was approved by the Ethics Committee of Radboud University Nijmegen 
Medical Centre, and the Newcastle and North Tyneside Local Research Ethics 
Committee. Informed consent was obtained from all family members and healthy 
controls.
Sequencing of sTaT1 and aiRE mutations
To assess for the presence of STAT1 mutations in the patients, conventional PCR and 
Sanger sequencing were performed. All coding exons of the CC-domain of STAT1, 
including exon 10, were amplified and analyzed. AIRE mutations were excluded by 
sequencing the gene as previously described 13.
Figure 1. Pedigrees of three families with AD-CMC
(A) Pedigree of a Dutch family with four patients affected from 3 generations. 
(B) Pedigree of a UK sample with 3 patients affected from 3 generations. (C) 
Pedigree of a UK sample with 3 patients affected from 2 generations. Patients with 
candidiasis = closed black symbols; male patients = squares; female patients = circles.
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Cell isolation and stimulation
PBMCs were isolated by density gradient centrifugation of PBS-diluted blood (1:1) 
over Ficoll-Paque, as previously described 6. T cells were positively selected using CD4 
microbeads (130-045-101, Miltenyi Biotec, Utrecht, the Netherlands). Cells (5x106/mL) 
were stimulated in 96-well plates (Greiner, Nuremberg, Germany), with combinations 
of IFN-γ (1 μg/mL) (Boehringer Ingelheim, Alkmaar, the Netherlands) and LPS (1 ng/mL), 
IL-1β (10 ng/mL) and IL-23 (10 ng/mL), or IL-12 (1 ng/mL) and IL-18 (10 ng/mL). After 24 
or 48 hours (without serum) or 5 days of incubation (in the presence of 10% serum), 
cytokine concentrations were measured using ELISA: TNF-α, IL-17, IL-22 (R&D Systems); 
IFN-γ (Pelikine).
western blotting
For immunoblotting, 10x106 cells were lysed in 100 ml lysis buffer (50 mM Tris, 1 mM 
EDTA, 150 mM NaCL, 1% ND40, 5 mM NaF, 0.05% Sodium Deoxycholate, PhosSTOP and 
cOmplete proteinase inhibitor (Roche, Almere, the Netherlands)). The homogenate was 
frozen, thawed then centrifuged at 4 °C for 10 min at 14,000 rpm, and the supernatant 
was taken for Western blotting. Equal amounts of protein were subjected to SDS-PAGE 
using 10% and 15% polyacrylamide gels at a constant voltage of 100V. After SDS-PAGE, 
proteins were transferred to nitrocellulose membrane (0.2 mm). The membrane was 
blocked with 5% (w/v) milk powder in PBS for 1 hour at room temperature followed by 
incubation overnight at 4°C with a STAT1 or pSTAT1 (Tyr701) antibody (9172 and 9167 
respectively, Cell Signaling, Leiden, the Netherlands) in 5% BSA/TBS/T (5% bovine serum 
albumin/Tris-buffered saline/Tween 20). After overnight incubation the blots were 
washed three times with TBS/T and incubated with HRP-conjugated goat anti-rabbit 
antibody at a dilution of 1:10,000 in 5% (w/v) milk powder in PBS for 1 hour at room 
temperature. After washing the blots three times with TBS/T, they where developed 
with ECL according to manufacturer’s instructions (GE Healthcare, Diegem, Belgium).
STAT1 Immunofluorescence
CD4+ cells were stimulated for 10 minutes with IFN-γ on cover slides. Subsequently, the 
cells were fixed with 10% PFA, and stained with α-pSTAT1 (Tyr701) or α-STAT1 and goat 
anti-rabbit Alexa 488 according to manufacturer instructions. The coverslides were 
mounted using Vectashield containing DAPI.
STAT1 cloning and transfection experiments
The Arg274Trp mutation was introduced into a plasmid containing the human STAT1α 
gene (pUNO-hSTAT1a, Invivogen, Toulouse, France), using the QuickChangeTM Site-
Directed Mutagenesis Kit (200518, Stratagene, Eindhoven, the Netherlands). The 
following primers were used for the PCR reaction: 5’-GAG-AGT-CTG-CAG-CAA-GTT-
TGG-CAG-CAG-CTT-AAA-AAG-3’ (forward) and 5’-CTT-TTT-AAG-CTG-CTG-CCA-AAC-
TTG-CTG-CAG-ACT-CTC-3’ (reverse). Human CD4+ cells were transfected using HIPerfect 
reagent (Qiagen, Venlo, the Netherlands), according to manufacturer instructions.
Quantitative PCR of IL-12R/IL-23R/IFN-γ-responsive genes
One million freshly isolated PBMCs or (transfected) CD4+ cells were stimulated with 
IFN-g, IL-β and IL-23 or IL-12 and IL-18. After two hours, total RNA was extracted in 400 μL 
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TRIzol reagent (Invitrogen). Isolated RNA was reverse transcribed into complementary 
DNA using oligo(dT) primers and MMLV reverse transcriptase. PCR was performed using 
a 7300 realtime PCR system (Applied Biosystems, Lennik, Belgium). PCR conditions 
were as follows: two minutes at 50°C and 10 minutes at 95°C, followed by 40 cycles of 
PCR reaction at 95°C for 15 seconds, and 60°C for one minute. Primer sequences used 
for RT-PCR assessment were: STAT4: 5’-ACA-ATG-AAA-CCA-TGG-CAA-CGA-3’ (forward) 
and 5’-TGA-AAT-TTT-CCC-TGA-AGG-ACC-TTC-3’ (reverse); ICAM: 5’-TTG-AAC-CCC-ACA-
GTC-ACC-TAT-3’ (forward) and 5’-CCT-CTG-GCT-TCG-TCA-GAA-TC-3’ (reverse); MCP-1: 
5’-CCA-GTC-ACC-TGC-TGT-TAT-AAC-3’ (forward) and 5’-TGG-AAT-CCT-GAA-CCC-ACT-
TCT-3’ (reverse); PD-L1: 5’-GCT-GAA-CGC-ATT-TAC-TGT-CAC-G-3’ (forward) and 5’-AGT-
GCA-GCC-AGG-TCT-AAT-TGT-3’ (reverse). B2M was used as a reference housekeeping 
gene, for which the primers were: 5’- ATG-AGT-ATG-CCT-GCC-GTG-TG-3’ (forward) and 
5’- CCA-AAT-GCG-GCA-TCT-TCA-AAC-3’ (reverse).
RESULTS AND DISCUSSION
In the present study we report that mutations in the CC-domain of STAT1, the genetic 
cause of AD-CMC, lead to hyperphosphorylation of STAT1 resulting in increased 
responsiveness to IFN-γ and impaired IL-12 and IL-23 signaling pathways. We 
strengthened our recent observation that STAT1 mutations are responsible for AD-
CMC 6 by showing the Arg274Trp mutation in the CC-domain of STAT1 in patients from 
three additional families with AD-CMC. These data further establish the role of STAT1-
mediated signaling as a crucial mechanism for mucosal antifungal defense.
Missense mutation in sTaT1
Individual P4 from the Dutch family (#1) (Figure 1A) was demonstrated to carry 
the Arg274Trp mutation in exon 10 of STAT1 similar to his father (P3), aunt (P2) and 
grandfather (P1) 6. The same STAT1 variant (c.820C>T; p.Arg274Trp) was detected in all 
three individuals from the British family #2 (Figure 1B), and all three individuals from 
British family #3 (Figure 1C). The discovery of STAT1 mutations as a cause of AD-CMC 
was rather surprising, as mutations in the SH2 or DNA-binding domains of the protein 
had been previously shown to be associated with mycobacterial and viral, but not 
fungal, infections 9,10. We therefore sought to identify the molecular mechanism behind 
this difference.
Lower production of IFN-γ and IL-17 in AD-CMC patients
IL-12 induced no IFN-γ production in cells obtained from AD-CMC patients (Figure 2A), 
and IL-1β and IL-23 induced less IL-17 production in cells from P3 and P4 from family #1 
(Figure 2B). In contrast, production of TNF-α in response to IFN-γ and LPS was higher 
in PBMCs from CMC patients compared to healthy controls (Figure 2C). With these 
findings we have confirmed our observations in experiments with cells from other AD-
CMC patients, as reported previously 6.
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Figure 2. AD-CMC cells or transfection of cells with the mutated STAT1 inhibited IL-12R- 
and IL-23R-induced genes, but increased IFN-γ signaling
Defective IL-12R (A) and IL-23R (B) pathways in cells isolated from AD-CMC patients. Data 
represent mean + SEM from 3 healthy controls and 3 AD-CMC patients (P3 and P4 from family 
#1 and P3 from family 2). (C) Stimulation of the IFN-γ receptor pathway results in increased 
production of the proinflammatory cytokine TNF-α. Data represent mean + SEM from 3 healthy 
controls and 3 AD-CMC patients. CD4+ T cells from healthy controls were transfected with 
wild-type or mutant STAT1 plasmid. (D) Decreased transcription of STAT4 upon stimulation 
with IL-1β (10 ng/mL) and IL-23 (50 ng/mL), (E) and decreased transcription of MCP1 upon 
IL-12 (10 ng/mL) and IL-18 (10 ng/mL) stimulation. (F) The CD4+ cells transfected with 
mutant STAT1 plasmid showed increased transcription of PD-L1 upon stimulation with IFN-γ 
(1 μg/mL). Data represent mean + SEM from 6 healthy controls from 3 separate experiments.
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Arg274Trp sTaT1 inhibits signaling via IL-12R and IL-23R
The transcription of several IFN-γ-regulated genes was measured in CD4+ T-cells from 
healthy controls transfected with either wild-type STAT1 plasmid or mutant STAT1 
plasmid. The cells were stimulated for 24 hours with either IFN-γ (1 μg/mL), or IL-β 
(10 ng/mL) and IL-23 (50 ng/mL), or IL-12 (10 ng/ml) and IL-18 (10 ng/ml). In line with 
the experiments performed in the primary cells isolated from AD-CMC patients, CD4+ 
T-cells transfected with the mutated STAT1 allele, but not with the wild-type allele, 
exhibited decreased transcription of STAT4 after exposure to IL-1β and IL-23 (Figure 
2D), and decreased transcription of MCP1 upon IL-12 and IL-18 stimulation (Figure 
2E). In contrast, CD4+ T-cells transfected with the mutant STAT1 plasmid showed 
increased transcription of PD-L1 upon stimulation with IFN-γ (Figure 2F). Cells that 
were transfected with STAT1 plasmid exhibited highly increased expression of STAT1 
as compared to untransfected cells. Furthermore, no difference in STAT1 mRNA 
expression was observed between cells either transfected with wild-type or mutant 
STAT1 plasmid (Supplementary Figure 1). These data correct for the possibility that the 
observed effects are due to a differential expression of the wild-type compared to the 
mutant STAT1 plasmid. 
 Based on the results of these transfection studies, it can be concluded that the 
differences in gene expression observed in AD-CMC patients as compared to healthy 
controls can be fully ascribed to the presence of the Arg274Trp mutation in STAT1.
Increased phosphorylation and activity of STAT1 in AD-CMC patients
The consistent finding of increased responsiveness to IFN-g in cells from patients and 
in cells transfected with the mutated STAT1 suggested a gain of function of STAT1. We 
therefore assessed whether the Arg274Trp mutation affects phosphorylation of STAT1. 
PBMCs were incubated with various stimuli and STAT1 phosphorylation was assessed 
by Western blotting. Phosphorylation of STAT1 after IFN-γ stimulation was higher in 
AD-CMC patients than in healthy controls (Figure 3A). The lower bands observed on the 
Western blot of phosphorylated STAT1 very likely represent breakdown products of the 
phosphorylated STAT1 protein. Immunofluorescence microscopy also demonstrated 
increased phosphorylated STAT1 in IFN-γ-stimulated CD4+ cells from AD-CMC patients, 
but no difference in total STAT1 (Figure 3B). These data are supported by Begitt et al, 
demonstrating that mutations in the CC domain of STAT1 result in hyperphosphorylation 
and prolonged entrapment of STAT1 in the nucleus, leading to inhibited nuclear export 
of STAT1 11. Also, Lui et al. demonstrated that the Arg274Trp mutation in STAT1 leads to 
increased phosphorylation of STAT1 12.
 Upon IFN-γ stimulation through the IFN-γ receptor in physiological conditions, 
the downstream signaling molecules JAK1, JAK2 and STAT1 are activated 13. Upon 
activation, STAT1 forms homodimers, which translocate to the nucleus, in order 
to induce transcription of numerous genes, including ICAM-114 and MCP-1 15. We 
measured the transcription of several IFN-γ regulated genes in AD-CMC patients and 
in healthy controls, to determine whether the Arg274Trp mutation in STAT1 affects its 
function as a transcription factor. When PBMCs were stimulated for two hours with 
IFN-γ (1 μg/mL), AD-CMC patients showed increased transcription of ICAM1 and MCP-1 
compared to healthy controls (Figure 3C). The transcription of STAT1, STAT3, IDO and 
PD-L1 was also increased (data not shown), supporting a gain of function mechanism for 
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Figure 3. Increased STAT1 phosphorylation in cells of AD-CMC patients
(A) PBMC from two healthy controls and two AD-CMC patients were stimulated for two 
hours with culture medium, IFN-β (500 U/mL), IFN-γ (1 μg/mL), IL-23 (50 ng/mL) or IL-12 
(10 ng/mL). Cells were lysed, and total STAT1, phosphorylated STAT1 and actin were assessed 
by Western blot. Figure is representative of two separate experiments. (B) Increased 
immunofluorescence of pSTAT1 in IFN-γ-stimulated CD4+ cells from AD-CMC patients. Figure 
is representative of three separate experiments. (C) PBMCs from three controls and two 
AD-CMC patients were stimulated with culture medium, IFN-β, or IFN-γ for two hours. The 
transcription of ICAM1 and MCP-1 was measured using RT-PCR. Bars represent means + SEM
128
Chapter 7
STAT1 in AD-CMC. Moreover, also unstimulated cells from AD-CMC patients exhibited 
elevated expression of these genes compared to cells from healthy controls, which 
could potentially be ascribed to the presence of constitutively phosphorylated STAT1 
in these cells.
 How do these molecular mechanisms explain the defective antifungal defense 
in AD-CMC patients? In the present study we show that these patients display significant 
deficiencies in the capacity to mount Th1 and Th17 responses, due to defective IL-12R 
and IL-23R pathways. The contributing role of a defective IL-12R signaling for CMC is 
strengthened by the observation that 23% of patients with isolated IL-12R deficiency 
have a mild form of CMC 16. However, STAT1 mutations in the CC domain additionally 
lead to a defective response to the cytokines IL-1β and IL-23. These cytokines play 
an important role in the development of Th17 responses, which in turn are crucial 
in the host defense against mucosal fungal infections. This notion is derived from 
the observation that APECED patients develop neutralizing anti-IL-17 and anti-IL-22 
antibodies during the course of the disease 4, and that hyper-IgE syndrome patients, 
who suffer from chronic onychomycosis and oropharyngeal candidiasis, display 
defective Th17 responses due to STAT3 defects 17. In line with this, we and others have 
also reported chronic fungal infections in patients with defects in the dectin-1/CARD9 
pathway, leading to defective Th17 responses 18,19. We have also previously reported 
decreased IL-17 production and Th17 cell proliferation in patients with AD-CMC 20. 
Defective Th17 responses, in turn, are accompanied by decreased production of IL-17 
and IL-22 which translates into decreased production of antifungal beta-defensins as 
well as impaired influx of neutrophils 21,22. Therefore, the combined deficiency in IL-12R 
signaling and impaired Th17 responses are likely to explain the susceptibility to fungal 
infections in patients with AD-CMC.
 In conclusion, we strengthen the very recent observations that STAT1 
mutations in the CC-domain are the genetic cause of AD-CMC. Moreover, we have now 
deciphered the cellular and molecular mechanisms leading to this clinical phenotype: 
hyperphosphorylation of STAT1, resulting in hyper-responsiveness to IFN-γ stimulation, 
but defective IL-12R and IL-23R pathways. In the end, these defects result in markedly 
diminished Th1/Th17 immunity leading to increased susceptibility to fungal infections. 
Future studies are warranted to investigate the disease mechanisms in more detail, 
especially to elucidate the extent of which STAT1-STAT3 and STAT1-STAT4 heterodimers 
are formed in AD-CMC patients upon stimulation with either IL-12 or IL-23. Furthermore, 
the challenge for the future will be to assess the proportion of patients with AD-CMC, 
but also sporadic CMC, that harbor STAT1 mutations, but especially to translate this 
knowledge into novel strategies for the treatment of this severe immunodeficiency.
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Supplementary Table 1. Clinical characteristics of 8 patients with AD-CMC from 3 families (Continuation Supplementary Table 1)
Family Patient Gender Age Origin Fungal infection Hypothyroidism Other autoimmune 
disease
Eczema 
boils
Other diseases Mutation 
identified by
1 1 * Male 67 NL Oral, nails, skin No AI hepatitis Yes Chest infections NGS
2 * Female 38 NL Oral, nails, skin No AI hemolytic anemia 
Anti-phospholipid 
antibodies
No Chest infections, bronchiectasis 
pneumocystis, pneumonia, CMV, pulm. 
embolism
NGS
3 * Male 37 NL Oral, nails, skin No No No No NGS
4 Male 6 NL Oral, nails No No No No Sanger
2 1 Female 47 UK Oral, nails, skin Yes Irritable bowel syndrome Yes Chest & sinus infections, Fe-deficiency 
anemia
Sanger
2 Female 19 UK Oral, nails, skin Yes No No Fe-deficiency anemia Sanger
3 Male 2 UK Oral, nails, perineum No, thyroid ABs No Chest infections, Fe-deficiency anemia Sanger
3 1 * Female 40 UK Oral, nails, skin, vaginal Yes No Yes Chest infections, Fe-deficiency anemia Sanger
2 Male 9 UK Oral Yes AI hepatitis No Mouth ulcers, herpetic whitlow Sanger
3 Female 7 UK Oral Yes No No Mouth ulcers, herpetic whitlow Sanger
*These patients have been previously reported in van de Veerdonk et al., NEJM 2011.
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supplementary Figure 1. STAT1 expression in transfected CD4+ T-cells
STAT1 mRNA expression in CD4+ T cells untransfected or transfected with wild-type or 
mutant STAT1 plasmid. Cells were left unstimulated or stimulated with IFN-γ for 1 hour.
Supplementary Table 1. Clinical characteristics of 8 patients with AD-CMC from 3 families (Continuation Supplementary Table 1)
Family Patient Gender Age Origin Fungal infection Hypothyroidism Other autoimmune 
disease
Eczema 
boils
Other diseases Mutation 
identified by
1 1 * Male 67 NL Oral, nails, skin No AI hepatitis Yes Chest infections NGS
2 * Female 38 NL Oral, nails, skin No AI hemolytic anemia 
Anti-phospholipid 
antibodies
No Chest infections, bronchiectasis 
pneumocystis, pneumonia, CMV, pulm. 
embolism
NGS
3 * Male 37 NL Oral, nails, skin No No No No NGS
4 Male 6 NL Oral, nails No No No No Sanger
2 1 Female 47 UK Oral, nails, skin Yes Irritable bowel syndrome Yes Chest & sinus infections, Fe-deficiency 
anemia
Sanger
2 Female 19 UK Oral, nails, skin Yes No No Fe-deficiency anemia Sanger
3 Male 2 UK Oral, nails, perineum No, thyroid ABs No Chest infections, Fe-deficiency anemia Sanger
3 1 * Female 40 UK Oral, nails, skin, vaginal Yes No Yes Chest infections, Fe-deficiency anemia Sanger
2 Male 9 UK Oral Yes AI hepatitis No Mouth ulcers, herpetic whitlow Sanger
3 Female 7 UK Oral Yes No No Mouth ulcers, herpetic whitlow Sanger
*These patients have been previously reported in van de Veerdonk et al., NEJM 2011.
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AbSTRACT
Chronic mucocutaneous candidiasis (CMC) and hyper IgE syndrome (HIES) are primary 
immunodeficiencies mainly caused by mutations in signal transducer and activator of 
transcription (STAT)1 and STAT3, respectively. CMC and HIES patients have an increased 
risk for skin and mucosal infections with fungal pathogens and Staphylococcus aureus. 
However, it is unknown whether the genetic defects in these patients also affect the 
skin and mucosal microbiome, which in turn may influence host defense mechanisms.
 The skin and oral microbiome of CMC and HIES patients was compared to 
that of healthy controls at five body sites using 16S ribosomal ribonucleic acid (rRNA) 
sequencing. The influence of skin colonizers on the immune response was investigated 
using in vitro experiments.
 The microbiome of CMC and HIES patients contained more Gram-negative 
bacteria, especially Acinetobacter spp, and less of the normal Corynebacterium spp., 
compared to healthy controls. Exposure of human primary leukocytes to Acinetobacter 
suppressed the cytokine response to C. albicans and S. aureus, while the normal 
Corynebacteria did not suppress cytokine responses.
 These results demonstrate that central mediators of immune responses 
like STAT1 and STAT3 not only directly influence immune responses, but also result 
in changes of the skin microbiome that in turn can amplify the defective immune 
response against fungal and microbial pathogens.
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INTRODUCTION
CMC and HIES are primary immunodeficiencies characterized by defective mucosal host 
defense mechanisms, due to impaired T helper (Th)1 and Th17 responses. Currently it is 
not known how these immune defects influence the regular colonizers on the skin and 
mucosa of these patients. In this study we investigated the interaction between the 
host genotype, microbiome and host immunity.
 CMC patients display chronic fungal infections of the skin, nails and oropharynx 
1,2. CMC is classified into autosomal recessive (AR) CMC, autosomal recessive 
autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), and 
autosomal dominant (AD) CMC. It has been demonstrated that APECED is caused by 
mutations in the autoimmune regulator (AIRE) gene 3,4, leading to the production of 
autoantibodies against interleukin (IL)-17 and IL-22 5,6. Recently, we and others have 
demonstrated that AD-CMC is mainly caused by dominant negative mutations in the 
signal transduced and activator of transcription (STAT) 1 gene 7-10. These mutations lead 
to decreased Th1 and Th17 responses, explaining the increased susceptibility to fungal 
infections and lung pathology seen in these patients 2,11,12.
 HIES was first described in 1966 as Job’s syndrome 4,13,14. HIES is a heterogeneous 
disease, but the main characteristics include increased serum IgE levels, eczematoid 
dermatitis, recurrent skin en pulmonary infections with predominantly Staphylococcus 
aureus, and mucocutaneous candidiasis. Interestingly, AD-HIES is mainly caused 
by dominant negative mutations in the STAT3 gene 6,15-17. Similar to AD-CMC, these 
mutations decrease production of Th1 and Th17 cytokines 8-10,18-22, explaining the 
increased susceptibility to infections with Staphylococcus and Candida species.
 Since HIES and CMC are well defined primary immunodeficiencies with 
similar immune defects in mucosal and skin immunity, one may hypothesize that the 
mutations in STAT1 and STAT3 could also influence the microorganisms that colonize the 
skin and oral mucosa, the main sites affected by these diseases. Kong et al. previously 
demonstrated that patients with atopic dermatitis lesions carry a statistically significant 
higher portion of S. aureus compared to healthy controls, which may have contributed 
to the pathogenesis of the disease 23,24. Since colonizing microorganisms are known to 
modulate the host immune response, we consequently hypothesize that a potentially 
skewed microbiome on the skin or mucosa of CMC and HIES patients may further 
increase the imbalance in the host immune response, augmenting the immune defects.
 From recent human microbiome studies, the microbial communities on the 
skin are now more comprehensively characterized than before, particularly for healthy 
people 25-27. The human skin can be divided intro three different habitats: dry, moist 
and sebaceous; the dry skin areas are the most diverse, containing various mixtures 
of predominantly Actinobacteria, Proteobacteria, Firmicutes and Bacteroidetes. 
Staphylococcus and Corynebacterium are the most common organisms on moist skin 
and Propionibacterium is the most abundant phylum on sebaceous skin 28-30.
 No information currently exists on how host genotype specifically affects 
the skin microbiome in humans, whereas several strong interactions have now been 
described between the host genotype and the gut microbiome 31. For example, 
mice with different genetic backgrounds display quantitative differences in their gut 
microbiome 32,33. Khachatryan et al. demonstrated that mutations in the MEFV gene, 
136
Chapter 8
leading to familial Mediterranean fever (FMF), are associated with a decreased number 
and diversity of bacteria in the gut. Furthermore, during disease flares there is a shift 
in the bacterial populations within the Bacteroidetes, Firmicutes and Proteobacteria 
34. Li et al. demonstrated that in patients with inflammatory bowel disease there is a 
correlation between NOD2 genotype and overall microbial composition of the ilium 1. 
TLR5-/- mice develop hallmark features of metabolic syndrome, and this is correlated to 
an altered gut microbiome. Interestingly, the altered microbiome in its turn can induce 
features of metabolic syndrome 3.
 Clearly, genetic variation in the host genome can strongly influence the gut 
microbiome. Unfortunately, there is not a lot known about the interaction between 
the skin microbiome and the host immune system. To our knowledge the only paper 
published on this subject was about research conducted in mice. In 2012, Naik et 
al. demonstrated that unlike the gut microbiome, the skin microbiome has a great 
influence on immunity against cutaneous pathogens 5.
 In the current study, the skin and oral microbiome of patients with CMC and 
HIES was compared to that of healthy controls. We demonstrate that the microbiome 
of CMC and HIES patients contains more Gram-negative bacteria and less of the normal 
Corynebacterium spp. compared to that of healthy controls, and that this shift has the 
capacity to impair the host defense against Candida and Staphylococci.
MATERIALS AND METHODS
Patients and healthy controls
In January 2012, 4 CMC patients, 7 HIES patients and 10 age-matched healthy controls 
were included in this study. Both HIES and CMC are very rare primary immunodeficiencies, 
with only a few hundred patients known worldwide. The hands, feet, trunk, mouth and, 
if present the skin lesion were swapped aseptically using Catch-All™ Sample Collection 
Swab, moistened with sterile SCF-1 solution (50 mM Tris buffer [pH 8], 1 mM EDTA, and 
0.5% Tween-20). Immediately after swabbing, each swab was swirled in a 2 ml Collection 
Tube containing 300 µl MicroBead Solution. The samples were stored at -20°C until 
further processing. 9 healthy controls, 4 CMC and 2 HIES patients also donated blood 
for in vitro immunological studies. The study was approved by the Ethical Committee of 
the Radboud University Nijmegen, and the participants gave written informed consent. 
The study was performed in accordance with the declaration of Helsinki. The patients 
were asked to stop using any prophylactic antibiotics one week before the initiation of 
the study. Of the 7 patients using antibiotics, 3 used flucloxacilline for the prophylaxis 
of skin Staphylococcus infections, and the other patients used prohylaxis with different 
antibiotics for respiratory infections. One CMC patient was not able to stop antibiotic 
therapy (cotrimoxazol, ganciclovir) due to a chronic pulmonary infection and CMV 
infection associated with low CD4 counts.
Microbial DNA isolation
Microbial DNA was isolated using the UltraCleanTM Microbial DNA Isolation Kit (MO BIO 
laboratories, Uden, The Netherlands), according to instruction of the manufacturer. 
The presence of microbial DNA was confirmed using a PCR to detect 16S rRNA gene. The 
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following page-purified primers were used: F338: 5’-act-cct-acg-gga-ggc-agc-ag-3’ (V3) 
and 1061R: 5’-crr-cac-gag-ctg-acg-ac-3’ (V6) (Biolegio, Nijmegen, The Netherland). The 
PCR reaction was performed using KOD DNA polymerase (EMD Millipore, Amsterdam, 
The Netherlands). The PCR reaction was as follows: 2 minutes 95°C, followed by 30 
cycles of 20 seconds 95°C; 10 seconds 55°C; 15 seconds 70°C, followed by 10 minutes 
70°C. 5 μL of PCR product was checked on agarose gel.
16S rRNA gene profiling and sequencing
The 16S rRNA gene dataset consists of Illumina MiSeq paired-end sequences targeting 
the V4 variable region. Genomic DNA was subjected to 16S amplifications using the 
515 Fwd and 806 Rev primers as previously described in detail 7, with the following 
modifications to the previously described protocol: (1) only one PCR amplification was 
performed, instead of three; (2) only 30 PCR cycles, instead of 35; (3) an extension 
time of 5 minutes, instead of 1.5 to reduce chimera formation; (4) a size selection 
was applied to retrieve amplicons between 375 bp - 425bp using SAGE pippin prep, 
in order to reduce a-specific amplification products derived from host DNA, and (5) 
the amplicons were sequenced for 175 bases in each direction, using custom designed 
primers that are complimentary to the V4 amplification primers. Sequencing was 
performed according to the manufacturer’s specifications.
Processing 16S rRNA gene sequence data
Sequences were processed using a pipeline implemented in QIIME 1.4.0 11 as pick_
reference_otus_through_otu_table.py, which picks OTUs by mapping the sequences 
against a subset of the latest Greengenes database (version Oct 2012) 13 filtered at 
97% identity, resulting in a table of counts by OTU and sample, with a representative 
sequence for each OTU. Classification was used as provided through Greengenes. The 
resulting OTU tables were checked for mislabeling 15 and contamination 18, and further 
microbial community analysis and visualizations. Statistical association analysis was 
done both with a univariate approach using LEfSe 23,35, and in a multivariate approach 
as described previously 25,27. LEfSe is a non-parametric factorial Kruskal-Wallis (KW) 
sum-rank test to detect organisms with significant differential abundance between 
sample sets; biological significance is subsequently investigated using a set of pairwise 
tests among subclasses using the (unpaired) Wilcoxon rank-sum test. As a last step, 
LEfSe uses Linear Discriminant Analysis to estimate the effect size of each differentially 
abundant feature.
Isolation of PbMC
Peripheral blood mononuclear cells (PBMCs) were obtained by density centrifugation of 
diluted blood (1 part blood to 1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia 
Biotech, Uppsala, Sweden). PBMCs were washed twice in saline and suspended in 
culture medium (RPMI 1640 Dutch modifications (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) supplemented with 1% gentamicin, 1% l-glutamine and 1% pyruvate 
(Life Technologies, Nieuwekerk, the Netherlands). The cells were counted in a 
hemocytometer, and their number was adjusted to 5x106 cells/mL.
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Microorganisms
C. albicans ATCC MYA-3573 (UC 820) as grown overnight in Sabouraud broth at 37°C, 
cells were harvested by centrifugation, washed twice, and resuspended in culture 
medium. C. albicans was heat-killed for one hour at 100°C. Staphylococcus aureus 
(American type culture collection) 25923 was heat-killed for 30 minutes at 100 °C. 
Acinetobacter baumannii (ATCC-15308) and Corynebacterium jeikeium (ATCC-BAA-949) 
were obtained from American Type Culture Collection, grown overnight, harvested by 
centrifugation, washed twice, and resuspended in culture medium. 
In-vitro stimulation assays
5x105 PBMCs in a volume of 100 μL per well were pre-stimulated for 24 hours at 37°C 
in round-bottom 96-wells plates (Greiner, Nurnberg, Germany), with Corynebacterium 
jeikeium, Acinetobacter baumannii or Staphylococcus aureus (1x106/mL). Cells were 
restimulated with C. albicans (1x106/mL) or S. aureus (1x107/mL) for 24 hours or 7 
days. When cells were stimulated for 7 days this was done in the presence of 10% 
human pooled serum. Experiments were performed in duplicate. After 1 or 7 days of 
incubation, duplicate supernatants were pooled and stored at –20°C until assayed.
Cytokine assays
The concentration of IL-1β, IL-17, IL-22 and TNF-α (R&D Systems, Abingdon, UK) and 
IFN-y (Sanquin, Amsterdam, the Netherlands) was measured in cell culture supernatants 
using enzyme-linked immuno sorbent assay (ELISA), according to the instructions of 
the manufacturer. These particular cytokines were measured because they play an 
important role in the host immune response against C. albicans 36 and S. aureus 37.
Immunological statistical analysis
The differences between groups were analyzed using the Wilcoxon signed rank test. 
All statistical analyses were 2-sided, and differences were considered statistically 
significant if p≤ 0.05 (*) or p ≤0.01 (**).
RESULTS
Patient and control characteristics
The microbiome structure of 11 immunodeficient patients (4 CMC and 7 HIES patients) 
was obtained from several skin and oral locations during their regular visit in the 
outpatient clinic (January 2012). In addition, 10 non-affected healthy individuals served 
as controls. Controls were matched on age, but not on gender as it was previously 
shown that this is not associated with substantial variation in the human micriobiome 
2,27. At the time of sampling, 4 out of 4 CMC patients, and 1 out of 7 HIES patients had 
an active skin lesion, which was also sampled (Table 1). DNA was extracted from skin 
and oral samples, and the 16S rRNA gene was amplified and sequenced on the Illumina 
MiSeq platform. The resulting sequences were then processed with QIIME taking 
a reference-based approach (see Methods). At the end of this process, the median 
sequencing depth was 6,389 reads per sample.
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Sample diversity
We compared the microbial community profiles among subjects to relate disease 
phenotype to variation in microbiome structure (Figure 1). Oral and skin samples were 
analyzed separately, as between-site variation in the human microbiome is greater than 
between-subject variation within-site 4,27. The skin microbiome composition was very 
similar among healthy controls and was dominated by Staphylococcus, Streptococcus 
and Corynebacterium as expected. In contrast, in HIES and CMC patients there was 
more variation in microbiome structure, which was characterized by an increase of 
Moracellaceae (mainly Actinobacter) (Figure 1A). The oral samples of healthy controls 
are largely defined by the presence of Prevotella and Fusobacterium, with an effect of 
disease on oral composition in a non-unidirectional way (Figure 1B). In general, both 
CMC and HIES patients have relatively little Gram-positive bacteria on their hands 
and feet compared to healthy controls (Figure 2). The relative abundance of phyla per 
individual is displayed in Supplemental Figure 1.
Table 1. Baseline characteristics of participants
Characteristic CMC patients HIES patients Age-matched healthy controls
Number 4 7 10
Gender (male:female) 2:2 5:2 8:2
Age (mean ± SD) 46 ± 16 46 ± 5 47 ± 10
Active lesion 4 (100%) 2 (29%) -
Genetic defect STAT1 STAT3 -
Figure 1. Covariance of skin and oral microbial community structure with disease subtype
The variation in microbial diversity of (A) 35 skin and (B) 21 oral samples from healthy controls 
(HC, light grey squares), chronic mucocutaneous candidiasis (CMC, dark grey circles), and 
hyper IgE syndrome (HIES, black triangles) patients. The principle coordinates plot uses the 
weighted UniFrac beta-diversity metric, with the covariance of selected microbial taxa overlaid 
as a biplot. Organisms characteristic for the healthy skin samples are Staphylococcus and 
Corynebacterium spp., with Moracellaceae spp. driving the different community in disease.
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Assessing significant covariation of microbiome structure with disease
Next, we looked in more detail at the differences between healthy controls and 
immunodeficient patients using univariate association tests taking into account disease 
phenotype, and body site for skin samples. The results found in skin samples were 
verified using multivariate tests (Figure 3, Supplementary Table 1). Using the univariate 
LEfSe test for microbial biomarkers, we observed lower levels of Corynebacterium on 
the hands and feet of HIES patients. On the other hand, the levels of Acinetobacter were 
strongly increased in both HIES and CMC patients (Figure 3A). The relative abundance of 
Prevotella and Fusobacteria, which are key species in oral samples of healthy controls, 
was lower in both CMC and HIES patients (Figure 3B, see Methods). The composition 
of the microbiome in skin lesions varied substantially between immunocompromised 
individuals, but in general contained a lot of Fusobacteria and Firmucutes (data not 
shown). There was no significant association between microbiome composition and 
gender (data not shown).
CMC/HIES-related skin colonizers impair innate immune host responses
To investigate whether microorganisms abundantly found on the skin of CMC and 
HIES patients can modify host immune responses to the pathogens encountered in 
these diseases, PBMC of healthy volunteers were exposed either to C. jeikeium (normal 
colonizer), A. baumannii (HIES/CMC colonizer) or S. aureus (CMC colonizer). After 24h 
of incubation, the cells were restimulated with C. albicans or S. aureus. Exposure of 
PBMCs to Corynebacteria normally found in the human skin microbiota did not affect 
Candida and Staphylococcus-induced cytokine responses. In contrast, exposure of 
immune cells to Acinetobacter found on the skin of HIES and CMC patients strongly 
inhibited the normal TNF-α, IFN-γ and IL-22 responses of human PBMCs, while the IL-1β 
and IL-17 responses remained relatively unaffected (Figure 4). A similar inhibitory effect 
on TNF-α and IFN-γ production by Acinetobacter was found in PBMCs isolated from 
CMC and HIES patients (data not shown), while PBMC of CMC and HIES patients already 
had absent IL-17 and IL-22 production due to their genetic defect 6,22,38.
Figure 2. CMC and HIES patients are colonized by relatively little gram-positive bacteria
Mean percentage of Gram-positive and Gram-negative bacteria per 
body site, per group. Bars represent mean + SEM from 1- 10 subjects.
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Figure 3. Selected associations of microbial clade abundance with body site and disease subtype
A subset of taxa that significantly differ in relative abundance as determined by LEfSe between 
disease subtypes at skin (A) or oral body sites (B). Subclasses of disease subtype are separated, 
with specific body sites differentially colored. The mean and median relative abundance 
of the taxa are indicated with a solid and dashed lines, respectively (LEfSe * = p < 0.05).
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DISCUSSION
In this study, we characterized the microbiome of CMC and HIES patients and 
compared it to that of healthy controls. The skin and oral microbiota of our healthy 
controls was dominated by typical human-associated phyla, mainly the Firmicutes and 
Proteobacteria, as expected 8-10,27. In contrast, patients with HIES displayed significantly 
Figure 4. Acinetobacter suppress typical immune responses
PBMC of healthy volunteers were prestimulated for 24 hours with RPMI, Corynebacterium, 
Acinetobacter or Staphylococcus, and stimulated with C. albicans or S. aureus for 1 or 7 
days. Cytokine concentrations were measured in cell culture supernatants using ELISA. 
Bars represent mean + SEM of 10 healthy volunteers (Wilcoxon * = p < 0.05, ** = p < 0.01).
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decreased colonization by Corynebacteria, while Acinetobacter was more prevalent in 
both CMC and HIES patients. Additionally, exposure of healthy PMBCs to Acinetobacter 
decreased subsequent cytokine production in response to either C. albicans or S. 
aureus exposure.
 This is one of the first studies on the microbiome of patients with a primary 
immunodeficiency. Because of their specific defects in cellular immunity, the 
microbiota of patients with STAT1 and STAT3 mutations provide a unique opportunity 
to define the role of Th17 immunity for the composition of the normal flora of an 
individual. One important observation of the present study was the identification of an 
overrepresentation of Gram-negative bacteria (particularly Acinetobacter spp) in the 
skin microbiome of patients with STAT1/STAT3 defects, whereas the presence of the 
normal Corynebacteria was decreased. This is interesting in that it mirrors the findings 
of previous work in patients with multifactorial diseases like psoriasis 2,12,39, chronic 
obstructive pulmonary disease (COPD) 4,14,40, or AD 6,16,17,24. During AD disease flares the 
amount of Corynebacterium is decreased 8-10,19-22,24, similar to CMC and HIES patients.
 The functional consequence for the immune system of the shift from normal 
to Gram-negative flora in the CMC and HIES patients was investigated by exposing 
human primary leukocytes to either Corynebacterium or Acinetobacter, before their 
stimulation with C. albicans or S. aureus. They are two of the relevant pathogens for 
these diseases, as CMC and HIES patients often suffer from skin infections with fungal 
pathogens (especially dermatophytes) and HIES patients from skin abscesses with 
S. aureus 24,41. While Corynebacteria did not impair antifungal and antistaphylococcal 
responses, exposure of human PBMCs to Acinetobacter significantly inhibited 
their capacity to produce proinflammatory cytokines such as TNF-α or IFN-y when 
stimulated with C. albicans or S. aureus. Both cytokines are crucial for host defense 
against these two pathogens. Thus, while CMC and HIES patients have IL-17 immune 
defects mediated by mutations in STAT1 or STAT3, the microbiome skewed towards a 
Gram-negative microflora amplifies the susceptibility to infection by inhibiting TNF-α 
and IFN-y responses (Figure 5). Recently, the role of skin microbiota for T-cell responses 
has been demonstrated to involve IL-1R-dependent innate immune signals in mice 5,26,27. 
Our data confirm and extend for the first time these observations to humans, in which 
the shifted microbiota of patients with immunodeficiencies has the capacity to impair 
normal cellular immune responses.
 Remarkably, the presence of Staphylococcus was not significantly increased 
across all HIES patients, despite its regular role in skin abscesses 14,28,29. This could 
be related to the prophylaxis with narrow-spectrum antibiotics specifically directed 
towards S. aureus, such as flucloxacilline 31,42, that have been used previously by some of 
the patients. Although the HIES patients stopped the antibiotics before the collection of 
the microbiome samples, we cannot exclude that the long-term use of these regimens 
may be the cause of the low colonization with staphylococci. It has been previously 
demonstrated that S. aureus can secrete chemotaxis inhibitory protein of staphylococci 
(CHIPS), which binds to the formyl peptide receptor and C5a on neutrophils, thereby 
interfering with neutrophil chemotaxis 32,33,43. Interestingly, neutrophils are a critical 
component of innate immunity with respect to C. albicans infections. Therefore, the 
excess of S. aureus found in CMC patients might be another factor explaining their 
reduced resistance to C. albicans infections. It might be interesting to learn whether the 
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skin microbiome of these patients is also affected with respect to fungal colonization. 
However, better tools to detect fungal species still need to be developed 34,44.
 The present study has also a few limitations. Firstly, we do not have direct 
information on the actual bacterial loads, which might play an important role in the 
emergence of infections, as we only measured the relative abundance of different 
bacterial 16S genes. Kembel et al. demonstrated that correcting for an estimated 
amount of 16S gene copy number for all species can alter the community structure 45. 
Because of the above mentioned reasons, the bacterial numbers used in the stimulation 
experiments might not fully reflect the in vivo situation, but they nevertheless enabled 
us to study the immunomodulatory effect of the bacteria identified in the CMC/HIES 
microbiome. Secondly, these data are based on a relatively small cohort containing 
only 4 CMC and 7 HIES patients. CMC and HIES are both very rare diseases, making 
it impossible for us to include more patients at this time. However, all these patients 
are very homogeneous in terms of their immune defects, and the clear changes in 
microbiome suggest that the shifts identified are real. Nevertheless, larger studies to 
validate the data presented here are warranted. Thirdly, some of the CMC and HIES 
Figure 5. Acinetobacter suppresses TNF-α, IFN-y and IL-22
Proposed model of typical interactions between the microbiome and the immune 
system in healthy individuals (A) and in STAT1/STAT3 immunodeficient patients (B).
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patients were treated with antibiotics and antifungals in the period preceding the 
study, although with one exception of a CMC patient they temporarily stopped them 
prior to sampling. In addition, the patients recruited in this study were not hospitalized 
(with the exception of the same patient being continuously treated), precluding the 
possibility of hospital-acquired microorganisms. Antibiotic use has been associated 
with decreased bacterial diversity, and the prior antibiotic regimens used by some of 
the patients directed against fungi and staphylococci may have shifted the microbiome 
towards a Gram-negative bacteria-dominated colonization. This does not however 
influence the conclusion that CMC and HIES patients are colonized with relatively many 
Gram-negative bacteria, and that they can influence normal innate immune responses.
 In conclusion, the assessment of the skin and oral microbiome of CMC and HIES 
patients with STAT1/STAT3 mutations and Th17 defects shows a shift of the microbiota 
from normal microorganisms such as Corynebacteria and Actinomycetaceae to a Gram-
negative colonization with genera such as Acinetobacter. Importantly, Gram-negative 
colonization is capable of inhibiting immune responses to Candida and S. aureus, likely 
contributing to the increased susceptibility of the patients to these infections. These 
data in patients with immunodeficiencies proof that the microbiome can influence 
host defense and could open the possibility of microbiome-based adjuvant therapy in 
patients with immune defects.
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Supplementary Table 1. Covariation of microbiome structure with disease
Data-
set
Organism Supporting 
class
Logarithmic 
LDA score
wilcoxon 
p-value
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Corynebacteriaceae.
Corynebacterium.kroppenstedtii
CMC 4,632 0,004
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Corynebacteriaceae.
Corynebacterium.kroppenstedtii.69669
CMC 4,629 0,004
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Intrasporangiaceae
HIES 4,010 0,006
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Intrasporangiaceae.Knoellia
HIES 3,938 0,006
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Intrasporangiaceae.Knoellia.
subterranea.581352
HIES 3,931 0,006
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Intrasporangiaceae.Knoellia.
subterranea
HIES 3,932 0,006
skin Bacteria.Proteobacteria.
Gammaproteobacteria.Pseudomonadales.
Moraxellaceae
HIES 5,130 0,007
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Corynebacteriaceae
CMC 4,981 0,007
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Corynebacteriaceae.
Corynebacterium
CMC 4,981 0,007
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Corynebacteriaceae.
Corynebacterium.unclassified.320879
control 4,391 0,009
skin Bacteria.Proteobacteria.
Gammaproteobacteria.Pseudomonadales
HIES 5,131 0,009
skin Bacteria.Proteobacteria.Alphaproteobacteria.
Rhodobacterales.Rhodobacteraceae.
Paracoccus.unclassified
HIES 3,901 0,009
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Corynebacteriaceae.
Corynebacterium.unclassified.358019
CMC 4,150 0,014
skin Bacteria.Proteobacteria.
Gammaproteobacteria.Pseudomonadales.
Moraxellaceae.Acinetobacter.
unclassified.2326547
HIES 4,383 0,015
skin Bacteria.Proteobacteria.Alphaproteobacteria.
Rhodobacterales.Rhodobacteraceae.
Paracoccus.unclassified.138528
HIES 4,014 0,016
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skin Bacteria.Proteobacteria.Gammaproteobacteria HIES 5,071 0,024
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Micrococcaceae.Micrococcus
HIES 4,111 0,034
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Micrococcaceae.Micrococcus.
unclassified
HIES 4,111 0,034
skin Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Micrococcaceae.Micrococcus.
unclassified.562170
HIES 4,111 0,034
skin Bacteria.Proteobacteria.
Gammaproteobacteria.Pseudomonadales.
Moraxellaceae.Acinetobacter
HIES 4,811 0,038
skin Bacteria.Firmicutes.Bacilli.Lactobacillales.
Carnobacteriaceae.Granulicatella.
unclassified.162192
CMC 4,293 0,040
skin Bacteria.Firmicutes.Bacilli.Bacillales.
Staphylococcaceae.Staphylococcus.
unclassified.372254
control 3,993 0,046
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Veillonellaceae.unclassified.149091
control 2,796 0,001
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Veillonellaceae.unclassified
control 3,784 0,001
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae.Prevotella.
unclassified
control 4,011 0,002
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Clostridiaceae.unclassified.248474
control 2,908 0,003
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Lachnospiraceae.unclassified.71387
control 3,904 0,003
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Veillonellaceae.Megasphaera.
micronuciformis.521650
control 2,681 0,003
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Veillonellaceae.unclassified.511378
control 3,726 0,003
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Veillonellaceae.Megasphaera.micronuciformis
control 2,731 0,004
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Veillonellaceae.Megasphaera
control 2,731 0,004
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Veillonellaceae.Veillonella.unclassified.585419
control 3,172 0,004
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae
control 4,921 0,005
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae.Prevotella
control 4,922 0,005
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oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales._Paraprevotellaceae_._
Prevotella_.unclassified.93000
control 2,699 0,005
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae.Prevotella.
melaninogenica
control 4,815 0,008
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Veillonellaceae.Megasphaera.
micronuciformis.757622
control 2,778 0,009
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Lachnospiraceae.Butyrivibrio
control 2,752 0,009
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Lachnospiraceae.Butyrivibrio.unclassified
control 2,757 0,009
oral Bacteria.Firmicutes.Clostridia.
Clostridiales.Lachnospiraceae.Butyrivibrio.
unclassified.92512
control 2,753 0,009
oral Bacteria.Bacteroidetes control 4,905 0,010
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales
control 4,909 0,010
oral Bacteria.Bacteroidetes.Bacteroidia control 4,913 0,010
oral Bacteria.Proteobacteria.
Gammaproteobacteria.Pasteurellales.
Pasteurellaceae.Aggregatibacter.unclassified
control 3,085 0,010
oral Bacteria.Proteobacteria.
Gammaproteobacteria.Pasteurellales.
Pasteurellaceae.Aggregatibacter.
unclassified.891034
control 3,117 0,010
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae.Prevotella.
unclassified.851822
control 3,886 0,010
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Veillonellaceae.Veillonella.parvula.3747214
control 4,002 0,011
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Veillonellaceae.Veillonella.parvula
control 4,009 0,011
oral Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Actinomycetaceae.
unclassified.303554
CMC 3,829 0,012
oral Bacteria.Firmicutes.Bacilli.Lactobacillales.
Carnobacteriaceae.Granulicatella.
unclassified.162192
CMC 3,449 0,013
oral Bacteria.Fusobacteria.Fusobacteria.
Fusobacteriales.Leptotrichiaceae.Leptotrichia.
unclassified.31235
control 4,159 0,015
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oral Bacteria.Fusobacteria.Fusobacteria.
Fusobacteriales.Leptotrichiaceae.Leptotrichia.
buccalis
CMC 2,648 0,015
oral Bacteria.Fusobacteria.Fusobacteria.
Fusobacteriales.Leptotrichiaceae.Leptotrichia.
buccalis.529861
CMC 2,650 0,015
oral Bacteria.Proteobacteria.
Gammaproteobacteria.Pasteurellales.
Pasteurellaceae.Actinobacillus.
unclassified.204197
control 3,143 0,015
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae.Prevotella.
unclassified.2185
control 2,923 0,015
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae.Prevotella.
melaninogenica.525942
control 3,146 0,015
oral Bacteria.Firmicutes.Bacilli.Lactobacillales.
Streptococcaceae.Streptococcus.
unclassified.584109
CMC 2,838 0,015
oral Bacteria.Firmicutes.Bacilli.Bacillales CMC 2,774 0,016
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae.Prevotella.
pallens.2222
control 3,440 0,017
oral Bacteria.Firmicutes.Erysipelotrichi.
Erysipelotrichales.Erysipelotrichaceae.
Bulleidia.moorei
control 3,452 0,017
oral Bacteria.Firmicutes.Erysipelotrichi.
Erysipelotrichales
control 3,454 0,017
oral Bacteria.Firmicutes.Erysipelotrichi.
Erysipelotrichales.Erysipelotrichaceae.
Bulleidia
control 3,453 0,017
oral Bacteria.Firmicutes.Erysipelotrichi.
Erysipelotrichales.Erysipelotrichaceae
control 3,456 0,017
oral Bacteria.Firmicutes.Erysipelotrichi.
Erysipelotrichales.Erysipelotrichaceae.
Bulleidia.moorei.4030370
control 3,456 0,017
oral Bacteria.Firmicutes.Erysipelotrichi control 3,456 0,017
oral Bacteria.Proteobacteria.
Gammaproteobacteria.Pasteurellales.
Pasteurellaceae.Actinobacillus.unclassified
control 3,224 0,019
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Clostridiaceae.Mogibacterium.unclassified
control 3,197 0,021
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Clostridiaceae.Mogibacterium.
unclassified.46159
control 3,198 0,021
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oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Clostridiaceae.Mogibacterium
control 3,198 0,021
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae.Prevotella.
melaninogenica.958078
control 4,553 0,021
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Peptococcaceae.Peptococcus.unclassified
control 2,913 0,026
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Peptococcaceae.Peptococcus
control 2,913 0,026
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Peptococcaceae
control 2,913 0,026
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Peptococcaceae.Peptococcus.
unclassified.68340
control 2,914 0,026
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Veillonellaceae.Veillonella.unclassified.573384
control 3,315 0,026
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae.Prevotella.
nigrescens.747980
control 2,774 0,027
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae.Prevotella.
nigrescens
control 2,779 0,027
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales._Paraprevotellaceae_._
Prevotella_.unclassified.28952
control 3,541 0,027
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales._Paraprevotellaceae_._
Prevotella_.unclassified
control 3,844 0,028
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales._Paraprevotellaceae_
control 3,829 0,028
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales._Paraprevotellaceae_._
Prevotella_
control 3,838 0,028
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Lachnospiraceae
control 4,317 0,028
oral Bacteria.Firmicutes.Bacilli.unclassified HIES 3,380 0,029
oral Bacteria.Firmicutes.Bacilli.
unclassified.1935703
HIES 3,370 0,029
oral Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Actinomycetaceae.
Parascardovia
HIES 3,898 0,032
oral Bacteria.Actinobacteria.Actinobacteria.
Actinomycetales.Actinomycetaceae.
Parascardovia.unclassified
HIES 3,896 0,032
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oral Bacteria.Firmicutes.Bacilli.Lactobacillales.
Streptococcaceae.Streptococcus.
unclassified.736957
CMC 3,233 0,032
oral Bacteria.Fusobacteria.Fusobacteria.
Fusobacteriales.Fusobacteriaceae.
Fusobacterium.unclassified.545299
control 2,865 0,033
oral Bacteria.Firmicutes.Clostridia.Coriobacteriales.
Coriobacteriaceae.Atopobium.
unclassified.132328
control 3,624 0,035
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Veillonellaceae.Veillonella.parvula.4200871
control 3,582 0,039
oral Bacteria.Firmicutes.Bacilli.Bacillales.
Staphylococcaceae
CMC 2,726 0,039
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales._Paraprevotellaceae_._
Prevotella_.unclassified.539347
control 3,236 0,040
oral Bacteria.Fusobacteria.Fusobacteria control 4,622 0,040
oral Bacteria.Fusobacteria.Fusobacteria.
Fusobacteriales
control 4,622 0,040
oral Bacteria.Fusobacteria control 4,622 0,040
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae.Prevotella.
unclassified.239506
control 2,598 0,044
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Porphyromonadaceae.
Tannerella.unclassified.254492
control 2,725 0,044
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Porphyromonadaceae.
Tannerella.unclassified
control 2,709 0,044
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Porphyromonadaceae.
Tannerella
control 2,723 0,044
oral Bacteria.Firmicutes.Bacilli.Lactobacillales.
Streptococcaceae.unclassified.525391
HIES 2,829 0,045
oral Bacteria.Firmicutes.Clostridia.Clostridiales.
Clostridiaceae.unclassified
control 2,887 0,046
oral Bacteria.Firmicutes.Clostridia.Coriobacteriales control 3,631 0,048
oral Bacteria.Firmicutes.Clostridia.Coriobacteriales.
Coriobacteriaceae.Atopobium
control 3,624 0,048
oral Bacteria.Firmicutes.Clostridia.Coriobacteriales.
Coriobacteriaceae
control 3,628 0,048
oral Bacteria.Bacteroidetes.Bacteroidia.
Bacteroidales.Prevotellaceae.Prevotella.
nanceiensis.898309
control 3,397 0,049
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AbSTRACT
Humans with chronic granulomatous disease (CGD) due to mutations in p47-phox have 
defective NADPH activity, and therefore cannot generate reactive oxygen species (ROS). 
The role of ROS in inflammation is controversial: some in vitro studies suggest that 
ROS are crucial for secretion of interleukin (IL)-1β via inflammasome activation, while 
mice defective for ROS and patients with CGD have a proinflammatory phenotype. In 
this study, we evaluated the activation of the IL-1β inflammasome in cells from CGD 
patients. Contrary to reports using the small molecule diphenyleneiodonium (DPI) 
as a ROS inhibitor, we observed that neither caspase-1 activation nor secretion of 
IL-1β and IL-18 were decreased in primary CGD monocytes. Moreover, activation of 
CGD monocytes by uric acid crystals induced a 4-fold higher level of IL-1β secretion 
compared to monocytes from unaffected subjects, and this was not due to increased 
synthesis of the IL-1β precursor.  In addition, western blot analysis of CGD cells revealed 
that caspase1 activation was not decreased, but even higher compared to control cells. 
Upon examination of the effects exerted by the inhibition of ROS activity by DPI, we 
observed that the decrease in IL-1β secretion by DPI was actually due to inhibition of 
IL-1β gene expression. Thus, inconsistent with the proinflammatory role of ROS, the 
present findings support the concept that ROS likely dampen inflammasome activation. 
The absence of ROS in CGD monocytes may explain the presence of an inflammatory 
phenotype characterized by granulomas and inflammatory bowel disease occurring in 
CGD patients.
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INTRODUCTION
There is much recent interest in the processing and release of bioactive IL-1β, especially 
since the discovery that blockade of IL-1 receptors with the IL-1 receptor antagonist 
(IL-1Ra) is a very effective treatment in autoinflammatory disorders, such as familial 
Mediteranean fever 1, familial cold auto-inflammatory syndrome 2, Muckle-Wells 
syndrome 3, neonatal onset multisystem inflammatory disease 4, hyperimmunoglobulin 
D syndrome (HIDS) 5, and adult-onset Still’s disease 6. Blood monocytes from patients 
with some of these disorders, especially cryopyrinopathies and HIDS, readily release 
more IL-1β than monocytes from unaffected controls 7,8.
 Activation of caspase-1 by the protein complex termed the inflammasome 
leads to the conversion of pro-IL-1β to IL-1β 9. Several protein platforms/inflammasomes 
have been described for the activation of caspase-1, and each of them include members 
of the NOD-like receptor (NLR) family of proteins 10.  The most intensely studied have 
been the inflammasomes formed by the NLR family members NLRP3 and NLRP1. 
Several conditions are thought to be required for the activation of the inflammasome, 
including the interaction of “danger signaling molecules” with NLRP components, the 
induction of K+ efflux through the P2X7 receptor, and the generation of ROS 9,11. 
 The role of ROS in inflammation, however, is controversial. On the one hand, 
ROS have been suggested to induce NF-κB activation 12,13, and several in vitro studies 
proposed that the activation of the inflammasome is strictly dependent on ROS 
generation 11,14. On the other hand, other studies reported anti-inflammatory effects of 
the NADPH system and ROS 15, and a recent study in mice defective for the generation of 
ROS strongly suggested anti-inflammatory effects of oxygen species 16. In line with this, 
patients with CGD that have defects in the NADPH system and consequently defective 
ROS generation 17, display an inflammatory phenotype characterized by granulomas 
and Crohn-like colitis 18. 
 To evaluate the role of ROS in inflammasome activation, we investigated the 
activation of caspase-1 and the production of IL-1β in the presence of NADPH-inhibitors. 
In addition, we assessed inflammasome activation in cells isolated from CGD patients. 
MATERIALS AND METHODS
Patients and controls
Eight healthy volunteers without any known infectious or inflammatory disorders 
donated blood as a control group for the assessment of cytokine production capacity. 
In addition, peripheral blood mononuclear cells (PBMCs) were isolated from three 
patients with GGD harbouring homozygous mutations in the NCF1 gene (p47-phox), in 
which the complete absence of ROS production has been demonstrated. After informed 
consent, blood was collected by venipuncture from both patients and volunteers into 
10-ml EDTA tubes (Monoject, s-Hertogenbosch, The Netherlands). 
in vitro cytokine production
Separation and stimulation of PBMCs was performed as described previously 19. Briefly, 
the PBMCs fraction was obtained by density centrifugation of diluted blood (1 part 
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blood to 1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech, Uppsala, 
Sweden). PBMCs were washed twice in saline and suspended in culture medium 
supplemented with gentamicin 1%, l-glutamine 1%, and pyruvate 1%. The cells were 
counted in a Bürker counting chamber, and their number was adjusted to 5x106 cells/
mL. 5x105 PBMCs in a volume of 100 μl per well were incubated at 37°C in round-
bottom 96-wells plates (Greiner, Nuremberg, Germany). After 24h incubation with the 
various stimuli as described below, supernatants were collected and stored at -80°C 
until assayed for IL-1β and TNF-α production. DPI in a concentration of 10 µM was 
used as a ROS inhibitor 20. Two methodologies were employed to assess inflammasome 
stimulation: one assay used stimulation for 3h with LPS, followed by ATP-induced 
IL-1β release for 15 min 21, and a second assay used specific stimulation with LPS-free 
monosodium urate (MSU), also known as uric acid crystals, a putative NLRP3 ligand 22.
Cytokine assays
IL-1β and TNF-α concentrations were measured by commercial ELISA kits (R&D 
Systems, Minneapolis, USA). proIL-1β concentrations in the cell lysates were measured 
by a specific ELISA (R&D). The concentration of IL-18 was measured with a bio-Plex kit 
(Bio-rad laboratories, Veenendaal, the Netherlands).
RT-PCR
Two million freshly isolated PBMC were incubated with the various stimuli. After 
4 hours of incubation at 37°C, total RNA was extracted in 800 μl of TRIzol reagent 
(Invitrogen, Breda, The Netherlands). Isolated RNA was being reverse transcribed into 
complementary DNA using oligo(dT) primers and MMLV reverse transcriptase. PCR was 
performed using a 7300 realtime PCR system (Applied biosystems, Lennik, Belgium). 
Primer sequences for human IL-1β are: sense: 5’-GCC-CTA-AAC-AGA-TGA-AGT-GCT-C-3’ 
and antisense: 5’-GAA-CCA-GCA-TCT-TCC-TCA-G-3’. B2M was used as a reference gene, 
for which the primers were: 5-ATG-AGT-ATG-CCT-GCC-GTG-TG-3 (forward) and 5-CCA-
AAT-GCG-GCA-TCT-TCA-AAC-3 (reverse). PCR conditions were as follows: 2 minutes at 
50°C and 10 minutes at 95°C, followed by 40 cycles of PCR reaction at 95°C for 15 
seconds, and 60°C for 1 minute.
Immunoblotting for caspase-1
For immunoblotting, 10x106 cells were lysed in 100 ml lysis buffer (50 mM Tris, 
pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 10% glycerol, 1% Triton X-100, 40 mM 
a-glycerophosphate, 50 mM sodium fluoride, 200 mM sodium vanadate, 10 mg/mL 
leupeptin, 10 mg/mL aprotinin, 1 mM pepstatin A, and 1 mM phenylmethylsulfonyl 
fluoride). The homogenate was frozen, thawed then centrifuged at 4 for 10 min at 
14,000 rpm, and the supernatant was taken for Western blotting. Equal amounts of 
protein were subjected to SDS-PAGE using 10% and 15% polyacrylamide gels at a 
constant voltage of 100V. After SDS-PAGE, proteins were transferred to nitrocellulose 
membrane (0.2 mm). The membrane was blocked with 5% (w/v) milk powder in PBS for 
1 hour at room temperature followed by incubation over night at 4°C with a caspase-1 
p10 antibody (SC-515, Santa Cruz biotechnology, Heidelberg, Germany) in 5% BSA/
TBS/T (5% bovine serum albumin/Tris-buffered saline/Tween 20). After overnight 
incubation the blots were washed three times with TBS/T and incubated with HRP-
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conjugated goat anti-rabbit antibody at a dilution of 1:10 000 in 5% (w/v) milk powder 
in PBS for 1h at room temperature. After washing the blots three times with TBS/T 
the blots where developed with ECL according to manufacturer’s instructions (GE 
Healthcare, Diegem, Belgium).
Statistical analyses
The differences between groups were analyzed using the Mann-Whitney U test and the 
Wilcoxon signed rank test, for unpaired and paired data respectively. Differences were 
considered statistically significant when p < 0.05. Data are presented as cumulative 
results of all experiments performed, and given as mean ± SEM.
RESULTS
DPI inhibits transcription of  proinflammatory cytokines
LPS induced production of IL-1β and TNF-α from primary human PBMCs, as previously 
reported 23. ROS inhibition by DPI decreased production of both IL-1β and TNF-α 
induced by LPS (Figure 1A). As TNF-α release is independent of caspase-1 activation, 
this argues for DPI effects independent of the inflammasome. Indeed, the effect of 
DPI was exerted at a transcriptional level, as mRNA for both IL-1β and TNF-α were 
decreased by DPI (Figure 1B), while active caspase-1 was still present (Figure 1C). 
Figure 1. ROS inhibition decreases production and transcription of IL-1β and TNF-α
(A) Monocytes isolated from eight healthy controls were stimulated with LPS in the absence or 
presence of the ROS inhibitor DPI. In the presence of DPI, IL-1β production was completely inhibited 
(n=8). (B) TNF-α production was also decreased when LPS stimulated PBMC of healthy controls were 
cultured in the presence of DPI (n=2). (C) PBMC of healthy controls were stimulated for four hours 
with LPS, in the absence or presence op DPI. mRNA was isolated from the cell lysates using TRIzol. 
DPI decreased mRNA expression of IL-1β (n=6) (D) and TNF-α (n=2). (E) Active p10 caspase-1 was still 
expressed in cells cultured in the presence of  DPI (Data representative for four healthy volunteers).
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TLR-induced production of IL-1β is normal in CGD patients
The Toll-like receptor  (TLR) ligands Pam3Cys (TLR2 ligand) and lipopolysaccharide (LPS) 
(TLR4 ligand) induced a strong IL-1β response in PBMCs of both healthy volunteers 
and CGD patients (Figure 2A). Although ROS have been specifically implicated in the 
activation of the inflammasome 11, when PBMCs from CGD patients who lack ROS were 
primed with LPS and subsequently stimulated with the inflammasome activator ATP 
for 15 minutes, no differences were observed in the release of IL-1β between cells of 
healthy individuals and those of CGD patients (Figure 2B). As expected, intracellular pro-
IL-1β intracellular concentrations did not differ between healthy volunteers and CGD 
patients (Figure 2B). IL-18 is also an important proinflammatory cytokine of the IL-1β 
family that is processed by caspase-1. No differences of IL-18 production were observed 
between healthy volunteers and CGD patients (5.8 pg/mL v.s. 4.9 pg/mL), although one 
must observe the very low amounts of IL-18 released by primary monocytes.
Figure 2. Inflammasome activation and IL-1β production in CGD patients
(A) Both monocytes isolated from CGD patients and healthy controls produced IL-1β upon stimulation 
with LPS, Pam3cys and Candida. (B) IL-1β stimulation by LPS + ATP was similar in CGD and control 
individuals. Data are presented as means ± SEM of five healthy controls and three CGD patients.
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Inflammasome activation is increased in CGD patients
Despite a defective NADPH-dependent ROS generation, a more prominent activation of 
caspase-1 was apparent in monocytes isolated from CGD patients compared to healthy 
volunteers (Figure 3A). The NLRP3 inflammasome has been reported to be activated 
by uric acid crystals 11,22, and priming with a TLR stimulus such as LPS is needed to 
accomplish this activation 24. However, PBMCs from CGD patients were able to produce 
IL-1β when exposed to uric acid alone in the absence of LPS priming, a phenomenon 
not observed in normal volunteers (Figure 3B), demonstrating an increased activation 
status of the inflammasome in cells from CGD patients. In addition, DPI decreased 
cytokine production in both cells from healthy controls, and in cells isolated from CGD 
patients (Figure 4).
Figure 3. ROS inhibit inflammasome activation
(A) Active p10 caspase-1 was more strongly expressed in unstimulated monocytes from CGD 
patients than that from healthy controls. (B) NALP3 inflammasome stimulus uric acid crystals 
stimulated IL-1β release in monocytes isolated from CGD patients, but not healthy controls. Data 
are presented as mean ± SEM of five healthy controls, and separately of three CGD patients.
164
Chapter 9
DISCUSSION
In the present study we demonstrate that reactive oxygen species are not essential 
for inflammasome activation. This conclusion is based on several lines of evidence: 
firstly, treatment of human primary monocytes with the commonly used ROS inhibitor 
DPI did not inhibit generation of active caspase-1; secondly, cells from CGD patients 
express more constitutively active caspase-1 activation; and thirdly, ROS-deficient cells 
from CGD patients produce more IL-1β after stimulation with urate crystals, a classical 
inflammasome stimulus.
 These findings differ from the results of other recently published studies 
that suggest that ROS induce inflammasome activation and IL-1β production 11,14. 
However, these studies are based on the use of ROS inhibitors such as DPI in cell 
lines or mouse macrophages 11,14,25. We therefore investigated the effects of DPI on 
caspase-1 activation and IL-1β production in human PBMC. We report that DPI can 
indeed inhibit IL-1β production in human PBMC, as reported previously in THP-1 cells 
and mouse macrophages 11,14. However, this inhibition was accompanied not only by 
lower IL-1β release but also by a decreased TNF-α production as well, suggesting that 
DPI can exert its effects independently of the inflammasome. These effects of DPI 
were indeed exerted at the level of transcription, with mRNA for both TNF-α and IL-1β 
being repressed, while the active caspase-1 p35 fragment was normally present. Our 
data, demonstrating that the anti-inflammatory effects of DPI on IL-1β production are 
exerted at the transcriptional level, are in line with the large body of literature showing 
that ROS induce NF-kB activation 12,26,27. In addition, the clear inhibition of cytokine 
stimulation by DPI in cells of CGD patients, a system in which no ROS are present, clearly 
demonstrates DPI effects on cytokine production are largely independent of NADPH 
oxydase generation of ROS. Several candidate additional mechanisms modulated by 
DPI are inhibition of nitric oxide synthetase or mitochondrial complex 1-dependent 28,29. 
Figure 4. ROS inhibition decreased IL-1β production in both healthy controls and CGD patients
In both healthy controls and CGD patients, DPI decreased IL-1β 
production in LPS stimulated cells. Data are presented as means ± SEM.
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Results based on DPI as a sole method to inhibit ROS production should be therefore 
interpreted with caution.
 In addition to these arguments, it should be kept in mind that the concept 
that ROS induces inflammasome activation is at odds with the known proinflammatory 
phenotype of patients with CGD, characterized by the occurrence of sterile granulomas, 
colitis, inflammatory skin and urogenital reactions, in which IL-1β is thought to play an 
important pathogenic role 15. In contrast, the findings of the present study reporting 
inhibitory effects of ROS on caspase-1 activation, agree with a proinflammatory state in 
CGD, as we found that the release of mature IL-1β was normal and after certain stimuli 
even increased in cells of CGD patients. Our data do not stand alone, as they are in line 
with a number of studies that have previously demonstrated consistent up-regulation 
of various proinflammatory cytokines in cells isolated from CGD patients 30-33. 
 Unexpectedly, whereas primary monocytes from healthy volunteers do not 
produce IL-1β in response to uric acid alone, monocytes from CGD patients secreted 
substantial amounts of IL-1β. In addition, we observed more constitutively activated 
caspase-1 in monocytes from CGD patients compared to healthy volunteers. In line with 
our data, there is additional evidence that increased ROS production inhibits caspase-1 
activation. Superoxide dismutase 1 (SOD-1) degrades ROS, and SOD-1 deficiency 
therefore results in increased endogenous ROS production. It has been recently 
reported that the increased superoxide production in SOD-1 deficient macrophages 
specifically inhibit caspase-1 activation by oxidation and glutathionylation 34. SOD-1 
deficient mice produced less IL-1β in vivo and were less susceptible to LPS-induced 
shock 34. Another recent study demonstrates that silencing SOD-1 in human monocytes 
results in a reduction of IL-1β secretion upon stimulation with zymosan 35. Taken 
together, these data are in agreement with our observations and strongly suggest that 
ROS inhibit inflammasome activation and subsequently IL-1β production.
 In conclusion, the data presented in this study settle the controversy regarding 
the role of ROS for the inflammasome activation in human cells, by providing evidence 
that oxygen radicals have an inhibitory effect on caspase-1 activation and IL-1β release. 
These data explain the pro-inflammatory clinical phenotype seen in patients with CGD.
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AbSTRACT
Patients with chronic granulomatous disease (CGD) cannot produce reactive oxygen 
species (ROS) due to a genetic defect in the NADPH oxidase system. Dysregulation 
of the L-tryptophan metabolism in mice with defects in NADPH oxidase, resulting in 
overproduction of interleukin-17 (IL-17), has been proposed to link ROS defects with 
hyperinflammation and susceptibility to pulmonary aspergillosis. In this study, we 
assessed the L-tryptophan metabolism and cytokine profiles in response to fungal 
pathogens in CGD patients.
 Peripheral blood mononuclear cells (PBMC) from CGD patients showed 
increased production of IL-6, tumor necrosis factor (TNF)-α and interferon (IFN)-γ upon 
stimulation with Aspergillus or Candida species, while IL-17A production was strikingly 
low compared to healthy controls. Indoleamine 2,3-dioxygenase (IDO) expression was 
similar in PBMC and neutrophils from CGD patients compared to healthy controls. 
Conversion of L-tryptophan to L-kynurenine, as measured by high-performance liquid 
chromatography did not differ between CGD patients and healthy controls. Moreover, 
adding L-kynurenine to the cell cultures did not suppress fungal-induced IL-17A 
production.
 Although PBMCs of CGD patients produced more proinflammatory cytokines 
after stimulation, IL-17A production was strikingly low in response to fungal pathogens 
when compared to healthy controls. In addition, cells from CGD patients did not display 
a defective L-tryptophan metabolism. 
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INTRODUCTION
CGD is a rare (incidence 1/250.000 live births) inherited immunodeficiency disorder due 
to a defect in any of the structural components of nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase. NADPH oxidase is a key player in innate host-defense, and 
its activation results in production of superoxide anion and downstream ROS. Clinically, 
CGD patients suffer from life-threatening bacterial and fungal infections and are 
characterized by abnormal inflammatory responses leading to granuloma formation. 
The precise “microbial” pathogenesis in CGD patients is unclear.
 While the central role of ROS as direct antimicrobial effectors is still under 
discussion, ROS are also linked to key intracellular signaling events, such as the 
activation of transcription factors 1,2, among which nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) 3,4, induction of mitogenesis 5,6 and activation of 
proteases 7. ROS can also act as a substrate or cofactor for the catabolic indoleamine 
2,3-dioxygenase enzyme (IDO) 8-11. IDO is the rate-limiting enzyme in the tryptophan 
metabolism 12. Activation of IDO results in decreased levels of L-tryptophan, thus 
actively depriving invading microorganisms of an essential aminoacid 10,13,14. IDO is 
expressed in several tissues throughout the body, and in immune cells like dendritic 
cells (DCs) 15, macrophages 16,17, and eosinophils 18. IDO expression can be induced 
by mediators of immunity, such as interferon (IFN)-γ 19,20 and tumor necrosis factor 
(TNF)-α 21. In addition, activation of tryptophan catabolism induces maternal immune 
tolerance 22, indicating that IDO can regulate T cell responses. IDO can suppress the 
Th1 response 23-25, while in DCs IDO is able to induce a Th2 response 26. In contrast, 
pulmonary IDO decreased Th2 driven experimental asthma 27. The immunomodulatory 
functions of IDO have made it an important target of research in many inflammatory 
conditions.
 The tryptophan metabolism has also been linked to Th17 responses. In a 
collagen-induced arthritis mice model, L-kynurenine dampened the Th17 response 
28. Furthermore, in a murine candidiasis model, retinoic acid receptor related orphan 
receptor C transcription was decreased by the induction of IDO 29. In a recent paper, 
Romani et al. suggested that p47phox deficient mice that have a phenotype reminiscent of 
CGD, have a defective tryptophan metabolism, leading to an increased interleukin (IL)17 
production 30. It has thus been proposed that the activation of IDO and subsequently 
conversion of L-tryptophan to L-kynurenine suppresses the Th17 response.
A robust Th17 response is necessary for an adequate defense against Candida 31. Th17 
cells are characterized by the production of IL-17A 32, which is important for attracting 
neutrophils to the tissues 33. The importance of IL-17A in anti-fungal host defense 
is reflected by the fact that IL-17Areceptor(R)A deficient mice have an increased 
susceptibility to disseminated candidiasis 31. Furthermore, in a murine oropharyngeal 
candidiasis model, IL-17A or IL-23p19 deficient animals showed increased severity of 
oropharyngeal candidiasis 34. Also humans with chronic mucocuteneous candidiasis 
and hyper-IgE syndrome have decreased Th17 responses that are believed to be 
responsible for their susceptibility to fungal infections 35-40.
 CGD is the primary immunodeficiency with the highest incidence of invasive 
fungal infections 41, mainly due to Aspergillus spp. (life-time incidence 25-40%). Candida 
is commonly encountered in cases of fungal meningitis, fungemia and lymphadenitis 
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41-43. It is currently not clear why patients with CGD are specifically susceptible to fungal 
infections, although infections with bacterial pathogens such as Staphylococcus aureus 
are also often encountered. The absence of ROS has been shown not to be the direct 
explanation of the increased susceptibility 44.
 In the present study, the tryptophan metabolism and IL-17A response in human 
CGD patients were investigated. We demonstrate that CGD patients, in contrast to the 
p47phox deficient mice, are able to convert L-tryptophan to L-kynurenine, and that they 
have a lower IL-17A production in response to stimulation with the fungal pathogen C. 
albicans, which might explain their incapacity to clear fungal infections.
MATERIALS AND METHODS
Patients and healthy volunteers
Blood was collected from healthy volunteers who did not suffer from infectious or 
inflammatory diseases, and from eight CGD patients, harboring homozygous mutations 
in the NCF1 gene (p47-phox) or CYBB gene (p91-phox). After informed consent was 
given, blood was collected by venipuncture into 10 mL ethylenediaminetetraacetic acid 
(EDTA) tubes (367525, BD, Plymouth, UK). The clinical characteristics of all patients are 
presented in Table 1.
Table 1. Clinical characteristics of CGD patients
Patient Sex Age Disease history Active 
infection?
IFN-γ 
therapy?
Mutation
1 Male 38 S. aureus, liver abscess, 
pneumonia (3y).
No No NCF1
(p47-phox)
2 Male 26 Multiple S. Aureus infections, 
including liver abscesses, and 
abscesses near the spine
No No NCF1
(p47-phox)
3 Male 29 S. aureus liver abscess (7y), 
lung infection with exophiala 
dermatitidis (28y)
No No NCF1
(p47-phox)
4 Male 20 Therapy-resistant acne No No NCF1
(p47-phox)
5 Male 16 A. fumigatus infection (5y), no 
inflammatory complications
No No CYBB
(gp91-phox)
6 Male 9 Mucormycosis (10mo), no 
inflammatory complications
No No NCF1
(p47-phox)
7 Male 9 No history of invasive fungal 
disease, no inflammatory 
complications
No No NCF1
(p47-phox)
8 Male 19 A. nidulans infection (5y), A. 
fumigatus infection (8y), no 
inflammatory complications
No Yes CYBB
(gp91-phox)
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Reagents
The following study materials were used: Recombinant interferon (IFN)-γ  (Boehringer 
Ingelheim BV, Alkmaar, the Netherlands); L-kynurenine, L-tryptophan, 5-OH-
tryptophan, serotonin, melatonin, niacin and resveratrol were purchased from 
Sigma-Aldrich (Zwijndrecht, the Netherlands); αCD3αCD28 beads were prepared 
from a T cell activation/expansion kit (130-091-441, MACS, Miltenyi Biotec); LPS (E. 
coli serotype 055:B5) was purchased from Sigma and an extra purification step was 
performed as described previously 45. Purified lipopolysaccharide was tested in Toll-like 
receptor (TLR) 4-/- mice for the presence of contaminants and did not have any TLR4-
independent activity 46. As culture medium, RPMI 1640 Dutch modifications (Sigma-
Aldrich) was used, supplemented with 1% gentamicin, 1% l-glutamine and 1% pyruvate 
(Life Technologies, Nieuwekerk, the Netherlands).
Microorganisms
Candida albicans ATCC MYA-3573 (UC 820) 47 was grown overnight in Sabouraud broth 
at 37°C, cells were harvested by centrifugation, washed twice, and resuspended in 
culture medium. C. albicans was heat-killed for one hour at 100°C; Staphylococcus 
aureus (ATCC 25923) was heat-killed for 30 minutes at 100 °C; heat-killed conidia 
and hyphae of Aspergillus fumigatus (V4507) and Aspergillus nidulans (V44-46) were 
prepared as described previously 44,48.
Human mononuclear cells and neutrophils
Peripheral blood mononuclear cells (PBMC) and neutrophils were isolated from 
peripheral blood using density gradient centrifugation (800g) of diluted blood (1 part 
blood to 1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech, Uppsala, 
Sweden) 49. PBMC were harvested, washed twice in phosphate buffered saline (PBS) and 
suspended in culture medium. To remove the erythrocytes from the neutrophils, the 
pellet was shocked at least twice with an ice-cold lysing reagent (2.75 gram NH4Cl + 0.25 
gram KHCO3) for 15 minutes. Subsequently, cells were washed in PBS and resuspended 
in culture medium. The PBMC and neutrophils were counted in a hemocytometer, 
and their concentration was adjusted to 5x106 cells/mL. 5x105 PBMCs or neutrophils 
in a total volume of 200 μL per well were incubated at 37°C in round-bottom 96-wells 
plates (Greiner, Nurnberg, Germany) with the different stimuli, as indicated in the 
figure legends. After 24 hours, 48 hours or seven days of incubation, supernatants were 
collected and stored at -20°C until assayed. When cells were cultured for seven days, 
this was done in the presence of 10% human pooled serum.
Enzyme-linked immunosorbant assay
The concentration of IFN-γ, IL-6, IL-17A and TNF-α was measured in cell culture 
supernatants using enzyme-linked immunosorbant assay (ELISA) (IL-17A and TNF-α: 
R&D Systems, Abingdon, UK, IFN-γ and IL-6: Sanquin, Amsterdam, the Netherlands), 
according to the instructions of the manufacturer.
Real-time PCR
One million freshly isolated PBMC or neutrophils were incubated with the various 
stimuli. After 24 hours of incubation at 37°C, total ribonucleic acid (RNA) was extracted 
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in 400 μl of TRIzol reagent (Invitrogen, Breda, the Netherlands). Isolated RNA was 
being reverse transcribed into complementary DNA using oligo(dT) primers and 
MMLV reverse transcriptase. Polymerase chain reaction (PCR) was performed using 
a 7300 realtime PCR system (Applied biosystems, Lennik, Belgium). Primer sequences 
for human IDO: 5-GGT-CAT-GGA-GAT-GTC-CGT-AA-3 (forward) and 5-ACC-AAT-AGA-
GAG-ACC-AGG-AAG-AA-3 (reverse). β2M was used as a reference gene, for which the 
primers were: 5-ATG-AGT-ATG-CCT-GCC-GTG-TG-3 (forward) and 5-CCA-AAT-GCG-
GCA-TCT-TCA-AAC-3 (reverse). PCR conditions were as follows: 2 minutes at 50°C and 
10 minutes at 95°C, followed by 40 cycles of PCR reaction at 95°C for 15 seconds, and 
60°C for 1 minute. Data are expressed as fold increase compared to the unstimulated 
sample.
High-Performance Liquid Chromatography
To compare the amount of L-tryptophan metabolized and the amount of L-kynurenine 
produced upon stimulation with fungal pathogens between CGD patients and 
healthy controls, cell culture supernatants were subjected to high-performance 
liquid chromatography (HPLC) analysis. HPLC was performed on a Spectra-SYSTEM 
autosampler and pump (Thermo Separation Products, San Jose, CA). Chromatographic 
separation was performed using an Inertsil 5 ODS-2 column (100 mm x 3.0 I.D.) (Varian 
Inc., Middelburg, the Netherlands). Absorbance was monitored with a diode-array 
detector (UV6000LP; Thermo Separation Products, San Jose, CA) at wavelength of 280 
nm for tryptophan and 360 nm for kynurenine 50. The mobile phase for isocratic elution 
was made by dissolving 40 mM sodium acetate. The pH of the eluent was adjusted to 
pH 4.5 with a solution of 40 mM citric acid and 2% acetonitrile of the total volume buffer 
was added. The continuous flow rate was 0.3 mL per minute 51. Data are presented as 
area under the curve (AUC).
Statistical analysis
Experiments were performed in duplicate, and supernatants were pooled. The 
differences between groups of 3 or more subjects were analyzed using the Mann-
Whitney U test or the Wilcoxon signed rank test, for unpaired and paired data 
respectively. The level of significance between groups was set at p < 0.05 (*) and p < 
0.01 (**). Data are presented as mean ± standard error of the mean (SEM).
RESULTS
CGD patients have an increased production of proinflammatory cytokines in vitro
The cytokine profile of CGD patients upon stimulation with several stimuli was 
investigated. PBMCs of CGD patients produced more IL-6 and TNF-α upon stimulation 
with the specific TLR4 ligand LPS. (Figure 1). Similarly, heat-killed (HK) C. albicans induced 
more IL-6 and TNF-α production in PBMC isolated from CGD patients (Figure 1). In line 
with this, stimulation with live A. nidulans and A. fumigatus conidia, two commonly 
encountered species in CGD patients, resulted in a higher cytokine production by 
PBMC of CGD patients compared to healthy controls (Figure 1). HK Aspergillus conidia 
and hyphae showed to be poor stimulators of the pro-inflammatory cytokines.
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CGD patients have an intact L-tryptophan metabolism
Romani et al. showed that p47phox deficient mice have a hyperinflammatory phenotype 
due to a defect in the conversion of L-tryptophan into L-kynurenine 30. Therefore we 
assessed whether the increased production of proinflammatory cytokines in patients 
with CGD could also be explained by an incapability to convert L-tryptophan into 
L-kynurenine. Cells isolated from CGD patients had a higher transcription of IDO upon 
stimulation with Candida and IFN-γ in both PBMCs and neutrophils, compared to 
healthy controls (Figure 2A). Moreover, upon stimulation with Candida, both healthy 
controls and CGD patients were able to convert L-tryptophan into L-kynurenine (Figure 
2B). The conversion of L-tryptophan to L-kynurenine was independent of which fungal 
Figure 1. CGD patients show increased production of proinflammatory cytokines upon fungal 
stimulation in vitro
PBMC of healthy controls and CGD patients were stimulated for 24 hours with RPMI, live and 
HK A. nidulans (AN) and A. fumigatus (AF) conidia or hyphae, HK C. albicans (1x106/mL) or 
lipopolysaccharide (10 ng/mL). IL-6 and TNF-α were measured in cell culture supernatants using 
ELISA. Data represent 5 CGD patients and 5 healthy controls from 3 different experiments. Data 
were analyzed using the Mann Whitney U test (** = p < 0.01). Bars represent mean + SEM.
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pathogen was used for stimulation (data not shown). This indicates that IDO functions 
normally in human CGD patients.
 The tryptophan metabolite L-kynurenine has been suggested to be 
responsible for dampening the proinflammatory cytokine response, and has especially 
been associated with a lowering of IL-17A production by murine cells 28,52. To determine 
whether L-kynurenine is able to influence the IL-17A response in human cells in vitro, 
we tested Candida-induced IL-17A production in healthy volunteers in the absence or 
presence of tryptophan metabolites. PBMCs from healthy controls were also stimulated 
with Candida in the absence or presence of increasing concentrations of L-kynurenine. 
There was no clear dose-response relationship between L-kynurenine and IL-17A 
(Figure 2C). Furthermore, L-tryptophan significantly increased Candida-induced IL-17A 
production (Figure 2D), while the other metabolites (5-OH-tryptophan, serotonin, 
melatonin and resveratrol) did not influence Candida-induced IL-17 production.
CGD patients have a low IL-17A and high IFN-γ production upon stimulation with 
fungal pathogens
To investigate whether IL-17A production is affected in cells from CGD patients, PBMC 
from CGD patients and healthy controls were stimulated for 7 days with αCD3αCD28-
coated beads, LPS, different morphotypes of A. nidulans and A. fumigates and HK 
C. albicans. There was no difference in αCD3αCD28-induced IL-17 production between 
CGD patients and healthy controls (Figure 3A). It is well established that especially 
in hyphal anti-fungal host-defense, rapid and efficient recruitment of neutrophils is 
important 53. Here we found that in response to A. nidulans hyphae and A. fumigates 
hyphae the IL-17A production was relatively low in CGD patients although this was not 
significant (Figure 3B). CGD patients produced more IFN-γ in response to all stimuli 
(Figure 3B). PBMC of CGD patients produced significantly less IL-17A upon stimulation 
with C. albicans (Figure 3C).
DISCUSSION
In the present study we demonstrate that human CGD patients produce markedly lower 
IL-17A concentrations upon stimulation with the fungal pathogen C. albicans compared 
to healthy controls, despite an overall higher proinflammatory cytokine production. 
CGD patients are able to convert L-tryptophan into L-kynurenine, and ROS are not 
crucial for the IDO activity which is needed to facilitate this conversion in humans. 
Furthermore, L-kynurenine did not decrease Candida-induced IL-17A production. 
These data suggest that NADPH-oxidase deficiency in humans is not associated with 
a defective tryptophan metabolism, but with a lower Th17 response against fungal 
pathogens that might explain their susceptibility to fungal infections.
 Th17 responses have recently been described as a new T helper subset 
54. In recent years it has become apparent that the Th17 response is essential for 
antifungal host defense. The recurrent mucosal Candida infections in patients with 
primary immunodeficiency syndromes such as hyper IgE syndrome (HIES) and chronic 
mucocutaneous candidiasis (CMC) have been specifically linked to a deficiency in their 
Th17 response 35,36,40.
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Figure 2. CGD patients do not have a defective L-tryptophan metabolism
(A) PBMC and neutrophils of two healthy volunteers and of three CGD patients were stimulated 
for 48 hours with HK C. albicans (1x106/mL) or IFN-γ (50 ng/mL). IDO expression was measured 
using qPCR. Bars represent mean + SEM. (B) PBMC of healthy volunteers and CGD patients were 
cultured for 48 hours in the presence of L-tryptophan (50 μg/mL), with or without HK C. albicans 
(1x106/mL). L-tryptophan (285 nm) (black lines and arrows) and L-kynurenine (360 nm) (grey 
lines and arrows) were measured using HLPC. (C) PBMC of healthy volunteers were stimulated 
for seven days in the presence of 10% human pool serum with HK C. albicans yeast (1x106/
mL), in the absence or presence of L-kynurenine (200 ng/mL, 1 μg/mL or 10 μg/mL). IL-17 was 
measured in cell culture supernatants using ELISA. Experiments were performed in duplicate and 
cell culture supernatants were pooled. Data represent at least seven healthy volunteers from at 
least three different experiments. Data were analyzed using the Wilcoxon signed rank test (** = 
p < 0.01). Bars represent mean + SEM. (D) PBMC were stimulated for seven days in the presence 
of 10% human pool serum with HK C. albicans yeast (1x106/mL), in the absence or presence of 
L-tryptophan (50 μg/mL), 5-OH-tryptophan (200 ng/mL), serotonin (1 μg/mL), melatonin (200 
ρg/mL), or resveratrol (10 μg/mL). IL-17A was measured in cell culture supernatants using 
ELISA. Experiments were performed in duplicate and cell culture supernatants were pooled. 
Data represent at least 5 healthy volunteers from at least 2 different experiments. Data were 
analyzed using the Wilcoxon signed rank test (** = p < 0.01). Bars represent mean + SEM.
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Figure 3. CGD patients have a low IL-17A and high IFN-γ production upon stimulation with 
fungal pathogens
(A) PBMC of healthy controls and CGD patients were stimulated for seven days in the 
presence of 10% serum with RPMI or αCD3αCD28-coated beads. IL-17A was measured in cell 
culture supernatants using ELISA. Data represent four CGD patients and five healthy controls 
from three different experiments. (B) PBMC of healthy controls and CGD patients were 
stimulated for seven days in the presence of 10% serum with RPMI, HK A. nidulans (AN) and 
A. fumigatus (AF) conidia or hyphae or LPS (10 ng/mL). IL-17A and IFN-γ were measured in 
cell culture supernatants using ELISA. Data represent at least five CGD patients and six healthy 
controls from four different experiments. (C) PBMC of healthy controls and CGD patients were 
stimulated for seven days in the presence of 10% serum with RPMI or HK C. albicans (1x106/
mL). IL-17A was measured in cell culture supernatants using ELISA. Data represent eight CGD 
patients and eight healthy controls from seven different experiments. Data were analyzed using 
the Mann Whitney U test (* = p < 0.05). Data are presented separately, and as mean + SEM.
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The role of the Th17 response in the host defense against Aspergillus is controversial. 
On the one hand, IL-17 deficiency is associated with a higher susceptibility to Aspergillus 
infection in mice 55,56. On the other hand, studies suggest that a high IL-17 production 
is linked to a higher susceptibility to Aspergillus infection due to detrimental effects 
caused by a hyperinflammatory response 30,57. These observations do not need to be 
contradictory, and they might support the concept that there is an optimal window for 
IL-17 response in the host defense against Aspergillus. 
 The decreased IL-17 production in response to fungal PAMPs was rather 
unanticipated. We have previously shown that CGD patients have relatively high 
IL-1β production in response to fungal stimuli 58. IL-1β is a driver of Th17 responses 
59 and therefore we predicted a high Th17 response. Furthermore, it has been 
reported that T cells from CGD patients have increased IL-17 and IFN-γ production in 
response to mitogenic stimulation, because NADPH-oxidase deficient macrophages 
cannot sufficiently induce Tregs that are needed to control proinflammatory T helper 
responses 60. Interestingly we observed no difference in αCD3αCD28 induced IL-17 
production between CGD patients and healthy controls, indicating that the decreased 
IL-17 production observed in CGD patients is only present in the presence of a specific 
pathogen. This might explain why the rest of the phenotype of CGD patients is not 
similar to HIES or CMC. 
 A difference in proportion of γδ T-cells in PBMC from CGD patients compared 
to healthy controls could be an explanation for the observed differences in IL-17A 
production 61. Therefore we have determined the relative contribution of the γδ T-cells 
to IL-17A production in response to Candida in healthy volunteers. We found that a very 
low amount of γδ T-cells was IL-17 positive compared to CD4 T cells (data not shown). 
These data suggest that the large proportion of IL-17 in response to C. albicans is from 
the CD4 T cell population. Since CD4 lymphopenia is not described in CGD patients it is 
unlikely that differential T cell counts are responsible for the low IL-17A production in 
CGD patients.
 It is interesting to observe that both p47phox deficient mice and patients with 
CGD are susceptible to Aspergillus infections, but that the underlying mechanisms seem 
to differ. In mice it was suggested that the tryptophan metabolism was defective, which 
led to an increased level of IL-17 production that was detrimental for the mice. Here 
we confirm that in CGD patients the tryptophan metabolism is intact 62, and moreover 
we observed that they had a lower IL-17 production in response to fungal stimulation. 
In addition, L-kynurenine did not decrease IL-17A production induced by C. albicans 
in PBMC of healthy controls, indicating that in human primary cells L-kynurenine 
does not suppress the Th17 response. However, L-tryptophan itself could increase 
Candida induced IL-17A production in healthy controls. In line with this, Veldhoen et 
al. previously demonstrated that L-tryptophan is one of the aryl hydrocarbon receptor 
(AHR) agonists which can increase IL-17A production 63. The role of the tryptophan/
kynurenine metabolism of the different human leucocytes was recently evaluated 
by De Ravin et al. 64. They compared cultured dendritic cells, monocytes and isolated 
PMNs. In line with our data obtained from monocytes, De Ravin et al. found that highly 
purified PMN could indeed upregulate IDO expression after INF-γ treatment.
In contrast to a low IL-17A production, we observed that the cells from CGD patients 
have an increased IFN-γ production compared to healthy controls in response to 
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fungal stimuli. IFN-γ stimulates intracellular killing of C. albicans conidia by PMN in 
vitro 65,66, and in a recent overview it has been reported that a large proportion of 
patients with defects in IL-12Rβ1 experience fungal infections 67. However, both IFN-γ 
and IL-17 are required for an adequate anti-fungal host defense. So although there is no 
defect in IFN-γ production, the low IL-17A production might cause a sensitivity to fungal 
infections. CGD patients also have an increased susceptibility to S. aureus infection. 
Susceptibility to S. aureus has also been associated with a defective IL-17A response 
68,69, which is in line with the data presented here.
 In conclusion, human CGD patients have a specific lower production of fungal 
pathogen-induced IL-17A production compared to healthy controls, while mitogenic 
stimulation of T cells isolated from CGD patients does not result in an impaired IL-17 
production. This might explain their inability to clear fungal infections. Furthermore, 
in contrast to a mouse CGD model, human CGD patients do not have a defect in their 
L-tryptophan metabolism to explain their susceptibility to fungal infections and their 
hyperinflammatory status.
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SUMMARy AND DISCUSSION
Candida albicans is an opportunistic fungal pathogen that can cause severe local 
and systemic infections in immunocompromised hosts. Even in otherwise healthy 
individuals Candida albicans can cause mucosal infections accompanied with 
substantial morbidity, which is often the case with oral or vaginal candidiasis. In this 
thesis the immune response against Candida albicans was investigated, in order to gain 
more insight into anti-fungal immunity, with the long-term aim of identifying novel 
targets for antifungal immunotherapy.
 Monocytes are part of the first line of immune defense against infections. In 
Chapter 3 we investigated the role of two different monocyte subsets, the cluster of 
differentiation (CD)14++CD16- and CD14+CD16+ cells, in the host defense against Candida 
albicans. We show that although both monocyte populations posses potent innate 
antifungal properties, such as the capacity to phagocytose and kill C. albicans and the 
ability to produce proinflammatory cytokines, CD14++CD16- monocytes are the main 
monocyte population able to induce T helper (Th)17 responses when co-incubated with 
CD4+ cells. The Th17 response plays a crucial role in the host defense response against 
Candida infections. The superior Th17-inducing capacity of CD14++CD16- monocytes is 
likely to be explained by their higher basal expression of the mannose receptor, and 
higher production of interleukin (IL)-1β and prostaglandin E2 (PGE2) upon Candida 
stimulation, compared to CD14+CD16+ monocytes.
 PGE2 has been linked to Th17 responses in relation to autoimmune disorders 
1,2, but until recently the role of PGE2 in the development of the Th17 response upon 
microbial stimulation was unknown. In Chapter 4, we have investigated the role of PGE2 
in the induction of the Th17 response against C. albicans. We demonstrated that PGE2 
is induced when the fungal cell wall components mannan and β-glucan are recognized 
by the mannose receptor and Dectin-1/Toll-like receptor 2, respectively. Blocking PGE2 
with a non-steroidal anti-inflammatory drug (NSAID) reduces RORgT transcription 
and IL-17 and IL-22 production. Adding exogenous PGE2 to the cell culture can restore 
IL-17 production in the presence of NSAIDs. The inhibitory effect of NSAIDs on Th17 is 
possibly exerted through a reduced production of the Th17-inducing cytokines IL-6 and 
IL-23.
 It has been previously demonstrated that IL-1β production and release are 
influenced by the process of autophagy 3,4. However, little is known about the role 
of autophagy in the host defense against fungal pathogens. In Chapter 5, the role of 
autophagy in the host defense against C. albicans was assessed using complementary 
approaches in both mice and humans. We showed that although C. albicans induces the 
autophagy marker LC3-II in both human and murine cells, mice lacking the autophagy 
protein ATG7-/- do not have an increased susceptibility to disseminated candidiasis. In 
patients, there is no association between certain genetic variants in autophagy genes 
and susceptibility to candidemia. Furthermore, there was no association between 
these polymorphisms and the in vitro Candida-induced cytokine responses in cells 
from healthy volunteers. Furthermore, blocking autophagy does not influence the 
phagocytosis and killing of Candida in human cells. Therefore it is likely that autophagy 
is redundant in the host response against systemic infections with C. albicans.
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In the second part of this thesis we investigated the anti-C. albicans host immune 
response from a genetic point of view. Until now, all research aimed at identifying 
antifungal host defense mechanisms in humans has relied on candidate-gene 
approaches that are based on hypotheses extracted from in vitro or animal studies. 
While this approach has been fruitful in confirming important pathways of antifungal 
defense, it has lacked the power to identify novel host defense mechanisms against 
Candida in humans and to provide a hierarchy of the importance of these pathways. 
In Chapter 6 we have addressed this issue by using a combination of transcriptional 
analysis, systems biology, and functional genomics to investigate the C. albicans-
induced immune response. We identified several known common inflammatory host 
defense pathways, but we also discovered an unanticipated crucial role of the type 
I interferon (IFN) pathway in antifungal host defense in humans. The role of type I 
IFN pathway in humans was confirmed both with classical in vitro immunological 
assays, as well as in genetic studies in patients with systemic candidiasis and chronic 
mucocutaneous candidiasis (CMC). Hopefully, this knowledge can be applied in the 
development of adjuvant immunotherapy.
 A primary immunodeficiency syndrome that is associated with defective IFN-γ 
and IL-17 production and mucosal fungal infections is CMC 5,6. We recently reported 
mutations in the coiled-coil domain of STAT1 as the genetic cause of autosomal 
dominant (AD)-CMC) 7. However, the cellular and molecular mechanisms responsible 
for the increased susceptibility to fungal infections in patients with AD-CMC and STAT1 
mutations remained to be deciphered. In Chapter 7 we confirm Arg274Trp mutations 
in the coiled-coil (CC) domain of STAT1 as the genetic cause of AD-CMC in three 
additional families of patients. We demonstrate that the Arg274Trp mutation leads to 
increased phosphorylation of STAT1, with increased IFN-γ signaling, while signaling via 
the IL-12 and IL-23 receptor is inhibited. This leads to strongly diminished Th1 and Th17 
responses, explaining the increased susceptibility to fungal infections of CMC patients.
 Recently, it has been demonstrated that there are interactions between the 
host genome, the immune system and the gut microbiome in healthy volunteers 8,9. 
However, it is not known how primary immunodeficiencies influence the microbiome, 
and whether this in turn could influence innate immune responses. In Chapter 8 we 
investigated the skin microbiome in patients with CMC and hyper IgE syndrome (HIES), 
which are caused by STAT1 and STAT3 mutations respectively. We demonstrate that 
CMC and HIES patients have an imbalance in their skin microbiome towards Gram-
negative colonization. These Gram-negative bacteria can in turn impair host innate 
immune responses to Candida albicans and Staphylococcus aureus, the two major 
pathogens causing infections in these patients. This information can provide the basis 
for potential microbiome-based therapies in these patients.
 The inflammasome is a protein platform that cleaves pro-IL-β into active IL-β. It 
has been suggested that reactive oxygen species (ROS) are necessary for inflammasome 
activation, however chronic granulomatous disease (CGD) patients, who cannot 
produce ROS, have a proinflammatory phenotype 10. Therefore we investigated the 
role of ROS in inflammation. In Chapter 9 we demonstrate that ROS are not required 
for inflammasome activation. Monocytes isolated from CGD patients contain cleaved 
caspase-1, an indication for inflammasome activation, and they produce normal to high 
levels of IL-1β. Also in cells isolated from healthy individuals, inhibiting ROS production 
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with a synthetic inhibitor (DPI) cannot dampen activation of the inflammasome. In 
fact, DPI even increases the production of pro-inflammatory cytokines. Interestingly, 
monocytes from CGD patients readily produce IL-1β upon NLRP3 inflammasome 
stimulation with uric acid crystals alone, while cells from healthy controls need pre-
stimulation with lipopolysaccharide in order to be able to do this. This suggests that 
ROS may even dampen inflammasome activation. These findings may explain why CGD 
patients are characterized by an inflammatory phenotype in the absence of ROS.
 It has been suggested that ROS deficient mice have a defective tryptophan 
metabolism, and therefore have an increased IL-17 response. We tested this hypothesis 
in human CGD patients in Chapter 10. Interestingly, we demonstrate that CGD patients, 
who are susceptible for recurrent bacterial and fungal infections, have low IL-17 
production in response to C. albicans and Aspergillus spp., while the production of other 
pro-inflammatory cytokines is higher. We also demonstrate that in humans NADPH 
dependent ROS are not necessary for the conversion of L-tryptophan to L-kynurenine. 
Furthermore, L-kynurenine does not suppress IL-17 production in human cells.
GENERAL CONCLUSIONS AND FUTURE PERSPECTIvES
In this thesis we investigated several aspects of the anti-Candida immune response. 
In a large, fast-paced research field such as immunology, these findings are modest 
contributions to our overall understanding of disease and the functioning of the 
immune system. However, a thorough understanding of the immune system is essential 
when developing new treatment strategies, and jointly all these pieces of information 
can form the basis for the development of novel therapies. 
 The studies presented here have several relevant consequences for our 
understanding of human fungal diseases on the one hand, and for the improvement 
of therapy for these severe infections on the other hand. The use of adjunctive 
immunotherapy, such as recombinant IFN-y, has proven to have a beneficial effect 
against several fungal infections 11. In addition to that, we have now demonstrated 
the importance of the type I IFN pathway for human antifungal host defense, and this 
opens additional new possibilities for adjunctive immunotherapy during these severe 
infections. In order to improve further the chances of success of these therapies, 
additional transcriptome study in patients with systemic Candida infections will be 
performed in the near future.
 Furthermore, we have demonstrated that CMC and HIES patients have an 
altered skin microbiome, which in turn is able to influence host defense mechanisms. 
This could be a rationale for testing microbiome-based adjuvant therapies in patients 
with Th17 defects. However, currently there are no treatment options available 
targeting the skin microbiome. It has been proposed that this should be attempted using 
emollients or bacterial products in order to promote the growth of specific commensals 
12, but these therapies still need to be developed. There are some preliminary studies, 
mainly case-reports, looking at the effect of targeting the gut microbiome through 
fecal transplantation. Three patients with multiple sclerosis (MS), an IL-17-driven 
autoimmune disease resulting in neurological degradation, were successfully treated 
for constipation with daily fecal transplants for one to two weeks. They also experienced 
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MS symptom reversal and remained asymptomatic for two to 15 years after treatment 
13. Other studies have demonstrated that fecal transplantation can also be effective 
against infectious diseases, like diarrhea caused by Clostridum difficile 14. It is however 
not yet known whether fecal transplantation is also effective in boosting the immune 
response against fungal pathogens. Moreover, the gut microbiome of CMC and HIES 
patients would first need to be mapped accurately.
 In addition to the aspects discussed in this thesis, other aspects that need to 
be explored in fungal infections should also be mentioned. Firstly, diagnostic tools need 
to be improved in terms of accuracy and speed 15. Secondly, since drug resistance is 
becoming an increasing problem 16, more emphasize should be put on developing new 
pharmaceutical fungicides. Thirdly, alternative therapies for the most severe forms of 
acquired or inborn defects, such as adoptive T cell therapy or gene therapy 11 should 
be considered. Finally, development of active (vaccines) 17 or passive (antibodies) 18 
immunizations that have been shown to be effective in animal models, should become 
a priority in translational studies with the future aim to be able to use such approaches 
in a clinical setting.
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SAMENvATTING EN DISCUSSIE
 
Candida albicans is een opportunistisch pathogene schimmel die ernstige lokale en 
systemische infecties kan veroorzaken bij immuundeficiënte patiënten. Zelfs bij gezonde 
personen kan Candida albicans mucosale infecties veroorzaken die gepaard gaan met 
aanzienlijke morbiditeit, zoals bij orale of vaginale candidiasis. In dit proefschrift werd 
de immuunrespons tegen C. albicans onderzocht om meer inzicht te verwerven in de 
immuniteit tegen schimmels, met als uiteindelijk doel het identificeren van nieuwe 
aangrijpingspunten voor antifungale immunotherapie.
 Monocyten zijn onderdeel van de eerste lijn van afweer tegen infecties. 
In Hoofdstuk 3 hebben we de rol van twee verschillende soorten monocyten, de 
CD14++CD16- en CD14+CD16+ cellen, in de afweer tegen C. albicans onderzocht. 
We laten zien dat hoewel beide soorten monocyten krachtige schimmelwerende 
eigenschappen bezitten, zoals het vermogen om C. Albicans te fagocyteren en doden, 
en het vermogen om pro-inflammatoire cytokines produceren, het voornamelijk de 
CD14++CD16- monocyten zijn die de T helper (Th)17 respons induceren wanneer ze 
worden geïncubeerd samen met CD4+ cellen. De Th17 respons speelt een cruciale rol in 
de afweerreactie tegen Candida-infecties. De superieure Th17-inducerende capaciteit 
van CD14++CD16- monocyten kan waarschijnlijk worden verklaard door hun hogere 
basale expressie van de mannose receptor en hogere productie van interleukine (IL)-1β 
en prostaglandine E2 (PGE2) in vergelijking met CD14
+CD16+ monocyten, na Candida 
stimulatie.
 PGE2 is voorheen in verband gebracht met de Th17 respons in relatie tot 
auto-immuunziekten 1,2, maar tot voor kort was de rol van PGE2 in de ontwikkeling 
van de Th17 reactie op microbiële stimulatie onbekend. In hoofdstuk 4, hebben we 
de rol van PGE2 in de inductie van de Th17 respons tegen C. albicans onderzocht. 
Wij toonden aan dat PGE2 wordt geïnduceerd wanneer de celwandcomponenten 
mannan en β-glucan van de schimmel worden herkend door respectievelijk de 
mannose receptor en Dectine-1/Toll-like receptor 2. Het blokkeren van PGE2 met 
een prostaglandinesynthetaseremmer (NSAID) vermindert de RORγT transcriptie en 
de productie van IL-17 en IL-22. Het toevoegen van exogeen PGE2 aan de celkweek 
kan de IL-17 productie herstellen in aanwezigheid van NSAIDs. Het remmende effect 
van NSAIDs op de Th17 respons wordt mogelijk bewerkstelligd door een verminderde 
productie van de Th17-inducerende cytokines IL-6 en IL-23.
 In eerder onderzoek is aangetoond dat autofagie de productie en afgifte van 
IL-1β kan beïnvloeden 3,4. Er is echter weinig bekend over de rol van autofagie in de 
afweer tegen schimmels. In hoofdstuk 5 werd de rol van autofagie in de afweer tegen 
C. albicans beoordeeld met behulp van complementaire methoden bij zowel muizen 
als mensen. We hebben laten zien dat hoewel C. albicans de autofagie marker LC3-II 
induceert in cellen van zowel mensen als muizen, muizen geen verhoogde gevoeligheid 
voor gedissemineerde candidiasis hebben in de afwezigheid van het autofagie eiwit 
ATG7. Bij patiënten is er geen verband tussen bepaalde genetische varianten in 
autofagie genen en de gevoeligheid voor candidemie. Bovendien was er geen verband 
tussen deze polymorfismen en de in vitro Candida-geïnduceerde cytokine respons in 
cellen van gezonde vrijwilligers. Daarenboven worden de fagocytose en het doden van 
Candida niet beïnvloed door het blokkeren van autofagie in menselijke cellen. Daarom 
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is het waarschijnlijk dat autofagie niet essentieel is in de immuunrespons tegen 
systemische C. albicans infecties.
 In het tweede deel van dit proefschrift hebben we de anti-C. albicans 
immuunrespons vanuit een genetische invalshoek bekeken. Tot nu toe was al 
het onderzoek over de antifungale afweer bij de mens gericht op kandidaat-gen 
benaderingen die zijn gebaseerd op hypotheses gegenereerd in in vitro onderzoek 
of dierstudies. Hoewel deze aanpak vruchtbaar is geweest bij het  bevestigen van 
belangrijke routes van antifungale afweer, ontbreekt hierbij de kracht om nieuwe 
afweermechanismen te identificeren in mensen en om een hiërarchie in deze 
routes aan te geven. In hoofdstuk 6 hebben we dit probleem aangepakt door een 
transcriptoom analyse te combineren met  systeembiologie en functionele genetica 
om de C. albicans-geïnduceerde immuunrespons te onderzoeken. We identificeerden 
verscheidene bekende algemene inflammatoire signaalroutes, maar we ontdekten 
ook een onverwachte cruciale rol voor de type I interferonen (IFN) signaalroute in de 
antifungale afweer bij de mens. Het belang van de type I IFN route bij de mens werd 
bevestigd met zowel klassieke in vitro immunologische testen als in genetische studies 
bij patiënten met systemische candidiasis en chronische mucocutane candidiasis 
(CMC). Hopelijk kan deze kennis in de toekomst worden toegepast bij de ontwikkeling 
van ondersteunende immunotherapie.
 Een primaire immuundeficiëntie die is geassocieerd met defecte IFN-y en 
IL-17 productie en mucosale schimmelinfecties is CMC 5,6. Onlangs hebben we mutaties 
in het coiled-coil (CC) domein van STAT1 als de genetische oorzaak van autosomale 
dominante (AD)-CMC gerapporteerd 7. De cellulaire en moleculaire mechanismen 
die verantwoordelijk zijn voor de verhoogde gevoeligheid voor schimmelinfecties 
bij patiënten met AD-CMC en STAT1 mutaties moeten echter nog worden ontrafeld. 
In hoofdstuk 7 bevestigen we dat Arg274Trp mutaties in het CC-domein van STAT1 
AD-CMC veroorzaken in drie additionele families met patiënten. We zagen dat de 
Arg274Trp mutatie leidt tot verhoogde fosforylering van STAT1 en verhoogde IFN-y 
signalering, terwijl signalering via de IL-12 en IL-23 receptor is verminderd. Dit leidt 
tot sterk verminderde Th1 en Th17 responsen, wat de verhoogde gevoeligheid voor 
schimmelinfecties van CMC patiënten verklaart.
 Onlangs is in gezonde vrijwilligers aangetoond dat er een wisselwerking 
bestaat tussen het genoom van de gastheer, het immuunsysteem en het microbioom 
van de darm 8,9. Het is echter niet bekend hoe immuundeficiënties het microbioom 
beïnvloeden en of dit op zijn beurt aangeboren immuunresponsen kan beïnvloeden. 
In hoofdstuk 8 onderzochten we het microbioom van de huid bij patiënten met CMC 
en hyper IgE syndroom (HIES), die respectievelijk door STAT1 en STAT3 mutaties 
worden veroorzaakt. We tonen aan dat CMC en HIES patiënten een disbalans hebben 
in hun huid microbioom, neigend naar Gram-negatieve kolonisatie. Deze Gram-
negatieve bacteriën op hun beurt zijn in staat om de aangeboren immuunrespons aan 
te tasten tegen C. albicans en Staphylococcus aureus, de twee belangrijkste infectie 
veroorzakende pathogenen bij deze patiënten. Deze informatie kan de basis vormen 
voor potentiële microbioom gebaseerde therapieën voor deze patiënten.
 Het inflammasoom is een eiwit platform dat pro-IL-1β omzet in actief IL-1β. Er 
is gesuggereerd dat zuurstofradicalen (ROS) noodzakelijk zijn om het inflammasoom 
te activeren, echter patiënten met chronische granulomateuze ziekte (CGD), die 
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geen ROS kunnen produceren, hebben een pro-inflammatoir fenotype 10. Daarom 
werd de rol van ROS bij ontsteking onderzocht. In hoofdstuk 9 laten we zien dat ROS 
niet nodig zijn voor activatie van het inflammasoom. Monocyten geïsoleerd uit CGD 
patiënten bevatten gesplitst caspase-1, een indicatie voor inflammasoom activatie, en 
ze produceren normale tot hoge niveaus van IL-1β. Ook in de cellen geïsoleerd van 
gezonde individuen kan de activatie van het inflammasoom niet verminderd worden 
door de ROS productie te remmen met een synthetische remmer (DPI). Het is zelfs zo 
dat DPI de productie van pro-inflammatoire cytokines verhoogt. Wetenswaardig is dat 
monocyten van CGD patiënten reeds IL-1β produceren na stimulatie van het NLRP3 
inflammasoom met urinezuurkristallen alleen, terwijl cellen van gezonde controles 
vooraf met lipopolysaccharide moeten worden gestimuleerd om dat te kunnen 
doen. Dit suggereert dat ROS ook in staat zijn om de activatie van het inflammasoom 
te kunnen dempen. Deze bevindingen kunnen verklaren waarom CGD patiënten 
gekenmerkt worden door een inflammatoir fenotype in afwezigheid van ROS.
 Er is gesuggereerd dat ROS deficiënte muizen een defect hebben in het 
tryptofaan metabolisme en daardoor ook een verhoogde IL-17 respons hebben. 
We hebben deze hypothese getest in menselijke CGD patiënten in Hoofdstuk 
10. Merkwaardig genoeg tonen wij aan dat CGD patiënten, die gevoelig zijn voor 
terugkerende bacteriële en schimmelinfecties, een lage IL-17 productie hebben na 
stimulatie met verschillende soorten C. albicans of Aspergillus, terwijl de productie 
van andere pro-inflammatoire cytokines juist hoger is. We laten ook zien dat in mensen 
NADPH afhankelijke ROS niet noodzakelijk zijn voor de omzetting van L-tryptofaan naar 
L-kynurenine. Voorts onderdrukt L-kynurenine de IL-17 productie in humane cellen niet. 
ALGEMENE CONCLUSIES EN TOEkOMSTPERSPECTIEvEN
In dit proefschrift hebben we verschillende aspecten van de anti-Candida 
immuunrespons onderzocht. In een groot, dynamisch onderzoeksgebied zoals dat van 
de immunologie leveren deze bevindingen een bescheiden bijdrage aan ons algemene 
begrip van ziekte en de werking van het immuunsysteem. Een grondige kennis van het 
immuunsysteem is essentieel bij de ontwikkeling van nieuwe behandelingsstrategieën 
en gezamenlijk kan al deze informatie de basis vormen voor de ontwikkeling van 
nieuwe therapieën.
 De hier gepresenteerde studies hebben verschillende belangrijke gevolgen 
voor ons begrip van menselijke schimmelziekten enerzijds en voor de verbetering 
van therapie voor deze ernstige infecties anderzijds. Het gebruik van adjuvante 
immunotherapie, zoals recombinant IFN-y, blijkt een gunstig effect tegen verschillende 
schimmelinfecties te hebben 11. Daarbij hebben we nu het belang van de type I IFN 
signaalroute aangetoond voor de antifungale afweer in mensen en dit biedt nieuwe 
mogelijkheden voor adjuvante immunotherapie tegen ernstige schimmelinfecties. Om 
de kans op succes van deze therapieën verder te verbeteren, zal een extra transcriptoom 
studie bij patiënten met systemische Candida-infecties worden uitgevoerd in de nabije 
toekomst.
 Verder hebben we aangetoond dat CMC en HIES patiënten een afwijkend 
huid microbioom hebben, wat vervolgens het afweer systeem kan beïnvloeden. Dit 
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zou een aanleiding kunnen zijn om microbioom gebaseerde adjuvante therapieën te 
kunnen testen bij patiënten met Th17 defecten. Echter, op dit moment bestaan er geen 
behandelmogelijkheden die zijn gericht op het huid microbioom. Er is geopperd dat dit 
zou moeten worden getracht middels het gebruik van huidverzachtende middelen of 
bacteriële producten om de groei van specifieke commensalen bevorderen 12, maar 
deze therapieën moeten nog worden ontwikkeld. Er zijn een aantal preliminaire studies, 
voornamelijk patiëntbeschrijvingen, die kijken naar het effect van het beïnvloeden van 
het darm microbioom middels fecestransplantatie. Drie patiënten met multiple sclerose 
(MS), een IL-17-gedreven auto-immuunziekte waarbij het zenuwstelsel wordt aangetast, 
werden succesvol behandeld voor constipatie met dagelijks fecestransplantaties 
gedurende een tot twee weken. Zij ervoeren ook vermindering van MS-gerelateerde 
symptomen en bleven vervolgens symptoomvrij voor 2 tot 15 jaar na de behandeling 
13. Andere studies hebben aangetoond dat fecestransplantatie ook effectief is tegen 
besmettelijke ziekten, zoals diarree veroorzaakt door Clostridum difficile 14. Het is 
echter nog niet bekend of fecestransplantatie ook effectief is in het stimuleren van 
de immuunrespons tegen pathogene schimmels. Bovendien zou het darm microbioom 
van CMC en HIES patiënten eerst nauwkeurig in kaart moeten worden gebracht.
 In aanvulling op de aspecten die in dit proefschrift zijn besproken zijn er nog 
een aantal andere zaken die nader onderzocht moeten worden en hier ook vermelding 
verdienen. Ten eerste moeten diagnostische middelen worden verbeterd in termen 
van nauwkeurigheid en snelheid 15. Ten tweede, moet er meer nadruk worden gelegd 
op het ontwikkelen van nieuwe fungiciden omdat resistentie is een groeiend probleem 
is 16. Ten derde moeten alternatieve therapieën voor de meest ernstige vormen van 
verworven of aangeboren defecten worden overwogen, zoals adoptieve T-celtherapie 
of gentherapie 11. Tot slot moet de ontwikkeling van actieve (vaccins) 17 of passieve 
(antilichamen) 18 immunisaties, die effectief zijn gebleken in diermodellen, een 
prioriteit in het translationeel onderzoek worden, met als toekomstig doel dergelijke 
benaderingen in de kliniek te kunnen gebruiken.
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DANkwOORD
Waarde lezer, wat fijn dat je zo volhardend bent, en na het lezen van dit proefschrift 
ook nog de moeite neemt om dit hoofdstuk te lezen. Hieruit blijkt niet alleen een 
diepgewortelde interesse voor wetenschappelijk onderzoek, maar het is tevens een 
blijk van respect voor de arbeid die de afgelopen 4,5 jaar door mijn collega’s en mij 
verricht is. Zelf ben ik tevreden met het resultaat, en kijk ik met veel plezier terug naar 
de periode waarin ik hieraan gewerkt heb. Graag wil ik iedereen die hieraan direct en/
of indirect heeft bijgedragen bedanken, en een aantal mensen wil ik hierbij expliciet 
noemen.
 Prof. M.G. Netea, beste Mihai, laten we beginnen met de drie fundamentele 
wetten van het promoveren…. We hebben: 1, een PhD student mag nooit een professor 
schaden, of, door nalatigheid, toestaan dat een Professor wordt geschaad. Ik geloof 
dat ik me daaraan heb kunnen houden (zo niet, dan hoor ik het graag). 2, een PhD 
student moet de bevelen van de professor opvolgen, tenzij dit conflicteert met de 
eerste wet. Eigenlijk is deze niet echt van toepassing, want van bevelen was niet echt 
sprake. Ik zou het meer een fijne samenwerking willen noemen, waarvan ik veel heb 
geleerd. Je optimisme en enthousiasme werken aanstekelijk, en na ieder overleg zat ik 
vol met nieuwe plannen en ideeën. En 3, een PhD student moet zijn/haar eigen bestaan 
beschermen zolang dit niet in strijd is met de eerste of tweede wet. Gelukkig heeft het 
nooit zo ver hoeven komen. Daarom heb niet alleen veel respect voor wie je bent als 
wetenschapper, maar ook als mens.
 Beste Leo, bedankt voor het vertrouwen dat je me afgelopen jaren gegeven 
hebt. Het was fijn dat je altijd ideeën en oplossingen had wanneer we overleg hadden. 
Jouw deur staat altijd open, en ik geloof dat jouw gezonde dosis humor bijdraagt aan de 
prettige sfeer in het lab.
 Frank, bedankt voor de begeleiding die je me tijdens mijn stage en de beginfase 
van mijn promotie gegeven hebt. Ik heb veel van je geleerd ook al blijven er ondanks 
de nodige discussies nog een aantal vraagstukken onopgelost. Zoals: “Waarom kan een 
macbook crashen terwijl Apple zo veel beter is dan Microsoft?” en “Waarom doet Prism 
stiekem een Sign-test in plaats van een Mann-Whitney U test, terwijl in feite Prism 
veel handiger is dan SPSS?”. Witte gij’t? Hopelijk kunnen we in de toekomst blijven 
samenwerken aan baanbrekende projecten.
 Prof. Dinarello, dear Charles, thank you for your hospitality when Thomas and 
I were in Denver. Many people know you as a great, widely-praised scientist, but I also 
got to know you as on of the most hospitable, sportive and best-cooking persons I have 
ever met. Your only flaw is that you sometimes forget to add sugar to your recipes. And 
butter. And real chocolate. It took me five months to regain my original weight after we 
came back from Denver. I would also like to thank Tania, Suzhao, ben, Jesper, Peleg, 
Stejara, Soo-hyun and Leonid for all the help and good times in- and outside of the lab.
 Prof. Scott, dear Bill, Monique, James and Athena, thank you for having me 
over at your lab, and taking the time to teach me, a complete newbie in the field of 
genetics, some basic programming skills. Although I was only there for a short time, the 
things I have learned turned out to be very useful throughout my whole PhD project.
 Uiteraard wil ik mijn co-auteurs bedanken: Adilia warris, Alexander Hoischen, 
Anca Riza, Andrew Gennery, Aylwin Ng, bart Jan kullberg, bas Heinhuis, Cisca 
wijmenga, Cleo van Diemen, Curtis Huttenhower, David williams, Desa Lilic, Dirk 
Gevers, Esther van de vosse, Eugène verwiel, John Perfect, Joost Schalkwijk, Joris 
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veltman, Jos van der Meer, karin Fransen, kathrin buffen, Melissa Johnson, Patrick 
Zeeuwen, Peer Arts, Peter Arkwright, Peter Hermans, R.k. Subbarao Malireddi, 
Ramnik Xavier, Stefanie Henriet, Suzanne van Sommeren, Thirumala-Devi kanneganti 
en vinod kumar. Thank you all for the fruitful collaboration.
 Natuurlijk wil ik ook mijn collega’s van Interne Geneeskunde bedanken. Ineke, 
bedankt voor je hulp met de fagocytose en killing experimenten. Cor, zonder jou zou het 
lab een stuk stiller zijn, en minder naar drop ruiken. Mensen weten je altijd te vinden 
als ze iets nodig hebben of willen weten. Bedankt voor je hulp bij het FACSen. Liesbeth 
en Trees, bedankt voor de stimulatie experimenten die jullie gedaan hebben. Bedankt 
Magda, voor de HPLC metingen die je hebt verricht.
 Marije, je bent een leuke en fijne collega en we hebben al veel samen 
meegemaakt. Samen met Martin is het 500FG team compleet en gaan we hier een 
heel succesvol project van maken. Monique, je was een fijne collega en buurvrouw. Ik 
wens je heel veel plezier en succes bij alle avonturen die je in Amerika gaat beleven. 
Theo, ook al ben je nu van de verkeerde kant van de buitenhoek, het is nog altijd leuk 
om immunologische en levensbeschouwelijke kwesties met je te bespreken. Mark G, je 
bent een hardwerkende, enthousiaste collega. Soms vraag ik me wel eens af of je niet 
beter had kunnen worden ingewerkt door een niet-neurotisch iemand.
 Verder wil ik alle andere (ex-)collega’s bedanken voor de aangename en 
gezellige werksfeer in de buitenhoek en in het lab: Ajeng, Anca, Anne, Anneke, Arjan, 
bart, bas b, Carolien, Cees, Daniela, Diana, Dorien, Edwin, Ekta, Erik, Gosia, Heidi, 
Helga, Hinta, Inge G, Inge vdM, Jaap, James, Janna, Jelle, Jenneke, Jessica, Johanna, 
Johanneke, karin, katharina, khutso, kiki, Louis, Maartje, Mario, Marius, Mark vb, 
Matthijs, Meta, Michelle, Mihai 2, Pleun, Reinout, Rinke, Rob, Siroon, Tania, Teske, 
Thijs, Tim, vesla, Xinhui en Zewen. Hierbij nog een speciale vermelding voor Mark S; 
onze absolute kampioen muurzitten.
 kim, Duby, Anniek, Piet, Peter, Mark; bedankt voor alle wetenschappelijke en 
niet zo wetenschappelijke discussies die we hadden tijdens onze lunches en in het lab. 
Ik hoop van harte dat al jullie dromen en wilde plannen werkelijkheid mogen worden. 
kim en Duby, ik ben vereerd dat jullie mijn paranimfen wilden zijn.
 Als laatste wil ik mijn familie bedanken. Hans en Truus, schoonouders kun je 
niet kiezen, maar ik heb het getroffen met jullie. Bedankt voor jullie steun en interesse 
die jullie de afgelopen jaren getoond hebben. Papenemmy, Mamenstef, dankzij jullie 
heb ik dit kunnen doen. Jullie gaven mij de mogelijkheid en het vertrouwen om te doen 
wat ik wilde, en daarvoor zal ik jullie altijd dankbaar zijn. Ik voel me een rijk mens omdat 
ik zoveel plekken thuis kan noemen.
 Thomas, onze onderzoeksonderwerpen hadden haast niet meer verschillend 
kunnen zijn. Jij weet niet wat een Th17 cel is, en ik heb geen verstand van ostheoarthrose. 
Toch begrijpen wij elkaar; binnen de wetenschappelijke wereld en in het leven kennen 
we allemaal dezelfde doelen, uitdagingen, frustraties en statistische vraagstukken. Het 
is fijn deze met je te kunnen bespreken en ik heb bewondering voor hoe gedreven je 
bent. Maar bovenal ben ik gelukkig dat we dit leven samen kunnen delen, vanaf nu 
samen met Robin. Het leven is een groot experiment, maar ik denk niet dat we bang 
hoeven te zijn voor regressie naar het gemiddelde. Ik hou van je!
